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CAse PresentAtIon
The resident internal medicine called from the Emergency Depart-
ment (ED). “Can you please come and see my patient, I think he is 
becoming septic and needs admission to the intensive care”. In the 
ED we found a confused older patient with an oxygen mask who 
was clearly dyspnoeic, the urinary catheter was filled with a dark 
brown fluid, the collecting bag was empty. The resident reported 
that he admitted the patient 4 hours earlier as he suspected pneu-
monia. On admission the patient was hypoxic but this clearly im-
proved with the supplemental oxygen. The resident was still waiting 
for all the laboratory results and the chest X-ray. However, now that 
the patient had developed hypotension he thought the patient was 
clearly at risk and intensive care admission was required. When we 
asked why he had not called us earlier, he replied that he intended 
to admit the patient to the general ward as he was haemodynami-
cally stable and oxygenation had improved on supplemental oxy-
gen so intensive care admission was not required. When reviewing 
the blood sample that was drawn 30 min following presentation, 
besides hypoxaemia, an increased lactate level of 4.6 mmol/l was 
present. The resident pointed out that hyperlactataemia in sepsis 
is not related to tissue hypoxia but rather is a marker of increased 
aerobic metabolism. Therefore he thought there was no need to 
react to this hyperlactataemia. 
In this case presentation the presence of hyperlactataemia did not 
result in treatment consequences. When having read this thesis the 
reader should be able to indicate whether the resident was right or 
wrong in this decision. 
AIM oF tHe tHesIs
The general aim of this thesis is to evaluate the clinical value of 
blood lactate monitoring by assessing various aspects of lactate 
monitoring, including aetiology, the prognostic value and the im-
pact on clinical outcome when incorporating lactate measurement 
in a treatment algorithm at the bedside. As the process of obtaining 
informed consent for participation in research is challenging in in-
tensive care patients due to the emergency nature of critical illness, 
the secondary aim of this thesis is to evaluate consent procedures in 
emergency critical care research.
oUtLIne oF tHe tHesIs
First, a summary of the history of lactate measurement is pre-
sented: although lactic acid was first found and described in sour 
milk by the Swedish chemist Karl Wilhelm Scheele (1742–1786) 
in 1780 (1), we aimed to honor the forgotten observations of the 
German physician–chemist Johann Joseph Scherer who first dem-
onstrated the presence of lactate in human blood in shock in 1843 
(chapter 2).
Since then, hyperlactataemia in intensive care medicine has been 
regarded mainly as a sign of tissue hypoxia (2). However, as lactate 
is a normal end product of carbohydrate metabolism, other proc-
esses, unrelated to tissue hypoxia, may also cause lactate levels to 
rise (3). Therefore, the exact aetiology of hyperlactataemia needs 
to be examined at the bedside to be able to properly interpret the 
results, which requires sufficient understanding of lactate metabo-
lism (figure 1). 
Despite our extensive knowledge on lactate metabolism, the use of 
blood lactate monitoring still remains controversial. This is reflected 
by its variable clinical use in different hospitals worldwide: some 
routinely measure it whereas others hardly do so. Because the clini-
cal benefit of blood lactate monitoring in critically ill patients has 
never been subjected to rigorous clinical evaluation, we performed 
a systematic health technology assessment (chapter 3). Using this 
format, we reviewed the technological aspects of lactate monitoring 
and the clinical impact on healthcare workers confidence, decision-
making, patient outcomes and the associated benefits and costs of 
its application in real clinical practice. 
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At least one thing is clear throughout the history of critical care: 
critically ill patients with increased blood lactate levels generally 
have significantly increased risk of morbidity and mortality, and the 
early identification and rapid treatment of these patients is widely 
acknowledged as a vital step towards improving survival (4). How-
ever, many issues remain to be elucidated. As in clinical practice 
treatment is frequently started before the first lactate level has been 
measured (e.g. oxygen, fluids), the prognostic value of lactate in 
the very early stage of critical illness, where no treatment has taken 
place (e.g. in pre-hospital care), is unknown. We therefore investi-
gated the value of lactate measurements when performed by para-
medic ambulance staff in the earliest possible stage (chapter 4). 
Another unresolved question is whether the predictive value of blood 
lactate levels equally applies to different groups of critically ill pa-
tients. Therefore, we investigated if the ICU admission diagnosis has 
any relevance for the prognostic value of lactate (chapter 5). 
Finally, although lactate is clearly related to mortality, it is not yet 
established why patients with hyperlactataemia have a worse out-
come. As multiple organ failure is the leading cause of death in 
ICU patients, we investigated the association between blood lactate 
levels and organ failure as expressed by the SOFA (sequential organ 
failure assessment) score and its various sub scores (chapter 6). 
Despite all these considerations the most important question still 
remains unanswered: will the use of lactate as an endpoint of resus-
citation in goal-directed therapy actually improve patient outcome? 
Therefore, we conducted a randomized controlled multi-centre trial, 
in which critically ill patients were randomly allocated to either lac-
tate monitoring (lactate group) or no lactate monitoring (control 
group) during the first eight hours of ICU stay (chapter 7). The 
results of this study should have important implications, not only for 
the use of lactate as a clinical monitor, but also for the initial goal-
directed therapy of ICU patients in general.
Furthermore, during the enrolment process of this clinical trial that 
used deferred consent, the situation arose that no deferred consent 
could be obtained from patients who died very early after start of 
the study. In chapter 8 we discuss whether data of these patients 
should be used or not? In chapter 9 we illustrate the impact of this 
ethical dilemma with data of our randomized controlled trial. Fi-
nally, in order to solve this matter for future research in an ethically 
valid and practically feasible way, we designed a flow chart for the 
conduct of emergency critical care research (chapter 10). 
Figure 1. Lactate metabolism
Lactate metabolism: the process of glycolysis, Krebs cycle, electron transport 
chain and gluconeogenesis. Dotted arrows depict the point of action of the vari-
ous mechanisms of hyperlactataemia: - inhibitory effect, + excitatory effect. 
Definitions of abbreviations: ATP= adenosin triphosphate, NADH= nicotinamide 
adenine dinucleotide, FADH2= flavin adenosine dinucleotide, PDH= pyruvate 
dehydrogenase, dysf = dysfunction, def = deficiency.
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BACkgroUnD InForMAtIon on oxygen 
trAnsPort
Before investigating goal-directed therapy (chapter 7), some basic 
principles related to oxygen transport require clarification. 
Global O2 transport can be described using the following formulas:
DO2 = CO x CaO2 
VO2 = CO x (CaO2 - CvO2) 
CvO2 = CaO2 - VO2/CO 
O2ER = VO2/ DO2= (SaO2 - SvO2)/ SaO2
DO2= oxygen delivery (ml/min)
VO2= oxygen consumption (ml/min)
CO= cardiac output
Hb= haemoglobin
SaO2= arterial oxygen saturation
SvO2= mixed venous oxygen saturation
CaO2= arterial oxygen content = (1.36 x Hb x SaO2) + (0.0031 x PaO2)
CvO2= mixed venous oxygen content = (1.36 X Hb X SvO2) + (0.0031 
X PvO2)
PaO2= arterial partial pressure of oxygen
PvO2= mixed venous partial pressure of oxygen
O2ER= oxygen extraction ratio
When haemoglobin levels and arterial oxygen saturation remain 
unchanged and given the fact that the freely dissolved oxygen can 
be neglected (multiplier of 0.0031), SvO2 is directly proportional to 
changes in the ratio of VO2 to CO. SvO2 thus reflects the relationship 
between whole-body O2 consumption and cardiac output. 
With help of the oxygen transport formulas, multiple causes of SvO2 
changes can be described. VO2 and the components of DO2 (CO, 
Hb and SaO2) interfere as is shown in figure 2. Note that drops 
in SvO2 are not only caused by decreases in DO2. Elevated oxy-
gen consumption due to fever (5), pain, agitation (6) and increased 
metabolic activity in sepsis (7), are very common in the ICU. In 
the first hours after major surgery, significant reductions in ScvO2 
were observed and these were not related to lower DO2, stressing 
the importance of post- operative increased oxygen consumption for 
ScvO2 (8).
The human body cannot spontaneously increase SaO2 or hemo-
globin level (at least not immediately). Increased VO2 is thus com-
pensated by increased CO or by elevated oxygen extraction in the 
peripheral tissues. An increase of CO would be the organism’s first 
choice to maintain VO2. When O2 need is not fulfilled by an adequate 
rise in CO, however, increased O2 extraction ensues, decreasing the 
SvO2 value. Importantly, also in healthy individuals, SvO2 decreases 
during heavy exercise despite a marked increase in CO. Adapta-
tion may play an important role, as healthy individuals may exhibit 
tissue hypoxia when ScvO2 values drop to 30 – 40% for a relatively 
short time, whereas patients with severe chronic heart failure may 
live constantly in this low range without developing tissue hypoxia 
(9). However, these patients can increase their VO2 only to a limited 
degree, as cardiac output cannot be raised and oxygen extraction 
is close to its limits. In hyperdynamic septic shock, patients seldom 
exhibit SvO2 levels less than 65%. However, it is a misperception 
that septic patients always have normal or high venous saturations. 
In the early (hypovolemic) course of severe sepsis and septic shock, 
venous saturations may well be below 50% (4). 
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A normal or high SvO2 or ScvO2 (>70%) may indicate a well- 
balanced oxygen supply for the body’s need. Unfortunately, normal 
or high values do not guarantee adequate tissue oxygenation. Only 
if tissue is still capable of extracting oxygen, S(c)vO2 can be re-
duced. In case of microcirculatory and mitochondrial dysfunction in 
sepsis (10) or local necrosis (e.g. limb or bowel ischaemia), venous 
return may have high O2 content despite persistent cellular hypoxia. 
Venous hyperoxia (>80%) was found to be indicative of a defect in 
systemic oxygen utilization after prolonged cardiac arrest (11).
svo2 versus scvo2
The use of central (ScvO2) rather than mixed (SvO2) venous satura-
tion has attracted attention of ICU clinicians. Central venous cathe-
ters are routinely inserted for central venous pressure recording and 
the infusion of vasoactive drugs or parenteral nutrition and conse-
quently, ScvO2 measurement does not involve extra risks. Moreover, 
it is less time-consuming compared with SvO2 measurement.
The central venous catheter sampling- site usually resides in the 
superior vena cava. Blood from the inferior vena cava (e.g. efflu-
ent from intra- abdominal organs) is therefore mainly neglected 
and ScvO2 thus represents upper body oxygen balance. Venous O2 
saturations differ among several organ systems since different or-
gans extract different amounts of O2 (12). In healthy conditions, 
SvO2 exceeds ScvO2 by about 2–3% (7). However, this difference 
changes under conditions of circulatory shock. In shock, ScvO2 ex-
ceeds SvO2 by about 5% (13, 14). During redistribution in low- flow 
shock states, splanchnic, mesenteric and renal blood flow decrease, 
resulting in an increase in O2 extraction in these regions and a sub-
sequent decrease in inferior vena cava saturation. In hyperdynamic 
septic shock, increased regional splanchnic metabolic rate rather 
than reduced perfusion, leads to lower SO2 in lower body venous 
return (7). Contrary to blood flow to the abdominal organs, cerebral 
flow is maintained over some period in shock, resulting in a delayed 
or absent drop of ScvO2 compared with SvO2. 
Another possible explanation of a lower level of SvO2 in comparison 
with ScvO2 is the mixing of atrial blood with blood emanating from 
the coronary sinus. Although coronary sinus flow may only be a 
fraction of total blood flow, the effluent from the coronary sinus has 
a very low SO2 (15). In shock, coronary blood flow is increased as a 
consequence of coronary vasodilatation while oxygen extraction of 
the myocardium remains high (16), thereby reducing SvO2 in com-
parison with ScvO2. 
The difference between ScvO2 and SvO2 is not equal in different 
ranges of cardiac output. A reversed correlation of the magnitude 
of the ScvO2 - SvO2 difference to CI and DO2 has been found (13, 
17). Again, distribution of blood flow in low- flow conditions away 
from renal, splanchnic and mesenteric areas towards the brain and 
myocardium is likely to explain this phenomenon.
Due to the lack of numerical equivalence, some authors have con-
cluded that ScvO2 cannot be used as a surrogate for SvO2 in the 
clinical setting (13, 14, 18, 19). Biases (mean of the differences) 
between the two sample sites ranged from 1% (17) to 7% (20) but 
Figure 2. Multiple factors influencing S(c)vO2
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more importantly, 95% confidence intervals of these biases were of-
ten clinically unacceptable (13, 14, 18, 21). In a study with a mean 
bias of -5% and a 95% confidence interval of 5% to -16% (14), a 
ScvO2 measurement of 74% would correspond to an SvO2 of 69% 
with an uncertainty of the estimate ranging from 58 to 79%. It thus 
demonstrates a great variability between individual absolute values 
and such variability would possibly urge the clinician to inappropri-
ate actions; especially when the ScvO2 value is around the normal 
limit of 70%.
Others stated that ScvO2 could indeed be used as a substitute for 
SvO2. They emphasized that from a clinical point of view, ScvO2 
needs to be interpreted over time and changes in ScvO2 would be 
able to parallel changes in SvO2 across a wide range of hemody-
namic conditions (20-22). In addition, the approximately 5% nu-
merical difference between SvO2 and ScvO2 values is found to be 
consistent, yet less important when addressing severe cases of oxy-
gen imbalance (23). A low ScvO2 – the range in which Rivers’ goal 
directed therapy was beneficial (4) - would result in even lower SvO2 
values. Thus, irrespective of whether ScvO2 equals SvO2, the pres-
ence of a low ScvO2 level is associated with adverse outcome, and 
correcting this value could improve this. Insertion of a pulmonary 
artery catheter can be time- consuming (24), whereas a central ve-
nous catheter can be introduced faster or is already inserted prior to 
ICU admission (in the operation theatre or emergency department). 
Therefore, the lack of accuracy of ScvO2- measurement could be 
compensated by positive outcome- effects of an earlier start of 
ScvO2- based therapy (25). 
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CHAPter 2
the first demonstration 
of lactic acid in human 
blood in shock by Johann 
Joseph scherer (1814-1869) 
in January 1843
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ABstrACt 
Lactic acid was first found and described in sour milk by Karl Wilhelm 
Scheele (1742–1786) in 1780. The German physician–chemist Jo-
hann Joseph Scherer (1841–1869) demonstrated the occurrence of 
lactic acid in human blood under pathological conditions in 1843 
and 1851. In this article we honour the forgotten observations by 
Scherer and describe the influence of Scherer’s finding on further 
research on lactic acid at the end of the 19th century. We conclude 
that Scherer’s 1843 case reports should be cited as the first descrip-
tion of lactic acid in human blood after death and also as the first 
demonstration of lactic acid as a pathological finding in septic and 
haemorrhagic shock. Carl Folwarczny was, in 1858, the first to dem-
onstrate lactic acid in blood in a living patient.
IntroDUCtIon
Lactic acid was first found and described in sour milk by the Swedish 
chemist Karl Wilhelm Scheele (1742–1786) in 1780 [1]. The Swedish 
chemist Jöns Jakob Berzelius (1779–1848) found lactic acid in fluid 
extracted from meat in 1808 [2, 3], and the German chemist Justus 
von Liebig (1803–1873), who established the world’s first school of 
chemistry at Giessen, proved that lactic acid was always present in 
muscular tissue of dead organisms [4]. In 1859, Emil Heinrich du 
Bois-Reymond (1818–1896) published several articles on the influ-
ence of lactic acid on muscle contraction [5–9]. Araki and Zillessen 
found that if they interrupted oxygen supply to muscles in mammals 
and birds, lactic acid was formed and increased [10–14]. This was 
the first demonstration of the relationship between tissue hypoxia 
and the formation of lactate. The occurrence of increased lactic 
acid in blood (hyperlactataemia) nowadays reflects severe illness, 
in which the increased blood lactate levels may result from both 
anaerobic and aerobic production or from a decreased clearance. 
It was the German physician–chemist Johann Joseph Scherer who 
first demonstrated the occurrence of lactic acid in human blood un-
der pathological conditions after death in 1843 and 1851 [15, 17], 
and Carl Folwarczny in 1858 who first demonstrated lactic acid in 
blood of a living patient. In this article we wish to honour Scherer’s 
forgotten observations and describe the influence of his finding on 
further research on lactic acid at the end of the 19th century. 
BIogrAPHy oF JoHAnn JosePH sCHerer
Born on 18 March 1814 in Aschaffenburg, Germany, Scherer stud-
ied medicine, chemistry, geology and mineralogy at the university of 
Würzburg between 1833 and 1836. He obtained his PhD in medi-
cine and surgery in 1838 with a thesis entitled “Versuche über die 
Wirkung einiger Gifte auf verscheidene Thierclassen” (Experiments 
on the action of some poisons on several classes of animals). He 
practiced medicine in Wipfeld, but inspired by the chemist Ernst 
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von Bibra (1806–1878) he completed his studies in chemistry at 
the University of Munich between 1838–1840 [18]. In 1840 he was 
employed at the laboratory of Justus Liebig at Giessen, and became 
professor at the medical faculty in 1842, professor of organic chem-
istry in 1847, and later professor of general, anorganic and phar-
maceutical chemistry. His work especially concerned quantitative 
research on blood and urine 
in pathological conditions. In 
1843 he published his book 
‘Chemische und Mikrosko-
pische Untersuchungen zur 
Pathologie angestellt an den 
Kliniken des Julius-Hospitales 
zu Würzburg’ (Chemical and 
microscopic investigations of 
pathology carried out at the 
Julius Clinic at Würzburg) [15] 
(Fig. 1), in which he described 
72 case reports, giving details 
on clinical course, diagnosis, 
and results obtained during 
autopsy and analysis of body 
fluids. Scherer died on 17 
February 1869 [18].
tHe 1843 CAses
In one chapter in his 1843 book entitled ’Untersuchungen von 
krankhaften Stoffen bei der im Winter 1842–1843 in Würzburg und 
der Umgegend herrschenden Puerperal- Fieber-Epidemie’ (Investi-
gations of pathological substances obtained during the epidemic 
of puerperal fever which occurred in the winter of 1842–1843 in 
and around Würzburg) Scherer described the cases of seven young 
women who all died peripartum. 
One of the women, the 23-year-old primipara Eva Rumpel, gave 
birth to a healthy child on 9 January 1843. The same night she 
developed a painfully swollen abdomen and became ill, fever-
ish, and sweaty, with rapid pulse and severe thirst. The initiated 
treatment was bloodletting and clystering. The next evening she de-
teriorated, became delirious, with anxious breathing, a tense abdo-
men, cold extremities and rapid pulse, finally losing consciousness. 
Again, bloodletting followed. At 4:30 a.m., 36 h after the onset 
of the first symptoms, she died. During autopsy, severe purulent 
endometritis, vaginal pus, pulmonary oedema, and shock liver and 
shock spleen were found. The blood that was obtained directly from 
the heart was chemically analyzed, in which lactic acid was found. 
Most likely this unfortunate woman had died from a fulminant septic 
shock caused by group A haemolytic streptococci (Streptococcus 
pyogenes). Scherer diagnosed this case as perimetritis with second-
ary peritonitis. 
Another patient, the 28-year-old, 7 months pregnant (second 
pregnancy) Margaretha Glück, was, after being icteric, nauseous, 
vomiting and complaining about epigastric pain for 8 days, admit-
ted to the lying-in birth clinic on 6 February 1843. Four days later 
she was transferred to the hospital with severe nosebleeds and gen-
eralized exanthema or purpura. In the evening she suffered from 
severe gastric bleeding and epistaxis, showing rapid pulse, cold 
extremities and dizziness. The next morning, she was transferred 
back to the birth clinic, where she gave birth to a premature child 
(30 weeks) and suffered from a severe post-partum fluxus. She was 
again transferred to the hospital with the following symptoms: cold 
clammy skin, tachycardia, severe lochia and persistent exanthema 
or purpura, but without signs of an acute abdomen. During the 
night of February 11, she became aphasic and restless, followed by 
chills and profound sweating. On the morning of February 13, she 
further deteriorated and bilirubinuria was detected. The next day 
she was comatose, finally developed rattling breathing and convul-
sions. Death occurred during the following night. Autopsy revealed 
a small intracerebral haematoma, normal lungs without pulmonary 
oedema, ascites and an anaemic, foul smelling uterus filled with pu-
rulent and decayed tissue and pus. Blood was also obtained directly 
Fig. 1 Title page of Scherer’s 1843 book
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from the heart during autopsy and lactic acid was found. In this case 
we could think of a haemorrhagic shock and cerebral haemorrhage 
due to clotting disorders possibly resulting from either acute fatty 
liver of pregnancy/ HELLP syndrome, idiopathic thrombocytopenic 
purpura, thrombotic microangiopathy (TTP/HUS) or DIC. The case 
was most likely complicated by a sepsis (endometritis). Scherer him-
self diagnosed this case as septic endometritis.
In the conclusions of his 1843 book, Scherer attached high impor-
tance to the fact that he found lactic acid in cases of puerperal 
fever, which he had not found before in healthy persons. He held 
the opinion that lactic acid was formed in blood during bodily dete-
rioration in severe diseases like puerperal fever. Lactic acid was thus 
described for the first time in human blood and was demonstrated 
for the first time as a symptom of septic and haemorrhagic shock.
In the same period a junior obstetrician in Vienna, Ignaz Philipp 
Semmelweis (1818–1865), discovered in 1847 that physicians car-
ried infectious particles on their hands from the mortuary to the 
obstetrical clinic, causing puerperal fever and puerperal sepsis, and 
he introduced a successful method for its prevention. Louis Pasteur 
(1822–1894) found in 1879 that infection with streptococci was the 
most important cause of puerperal fever [16].
tHe 1851 ArtICLe
Scherer worked closely with the famous pathologist Rudolf Virchow 
(1821–1902) on several projects (Fig. 2). In 1851 Virchow per-
formed an autopsy on a patient who had died from leukaemia and 
offered Scherer blood from this patient for analysis. The results of 
this analysis were published the same year in the ‘Verhandlungen 
der Physikalisch-Medicinischen Gesellschaft in Würzburg’ [17]. Vir-
chow and Scherer had previously studied the spleens of patients who 
died from leukaemia, and were curious if they could find the same 
results in the blood. Scherer reached the conclusion that: the blood 
of this patient contains: “Ameisensäure, Essigsäure und Milchsäure, 
die gleichfalls von mir schon 
früher als in der Milzflüssigkeit 
vorkommend bezeichnet wur-
den” (Formic acid, acetic acid, 
and lactic acid, as also found 
by me previously in fluids from 
the spleen).
FUrtHer reseArCH
Scherer’s observations in-
spired others to conduct fur-
ther research, primarily in 
patients with leukaemia [19–
22], but also in patients with 
other conditions and diseases 
and in animal experiments 
with dogs and rabbits [23]. 
While Scherer found lactic 
acid in blood obtained after 
death during autopsy, Mosler and Körner [19] mention an observa-
tion made by Carl Folwarczny, published in the Allgemeinen Wiener 
Medicinischen Zeitung in 1858, where blood was withdrawn from 
a leukaemia patient during life, analyzed according to Scherer’s 
method, and found positive for lactic acid. In addition, Carl Fol-
warczny described in 1863 in his ’Handbuch der Physiologischen 
Chemie’ [24] that lactic acid can be found in the blood of patients 
with leukaemia, septicaemia (pyaemia) and in conditions leading to 
septicaemia like puerperal fever, the latter probably after Scherer’s 
observations. In an extensive article, the Berliner physician Georg 
Salomon [25], who had serious doubts that the occurrence of lactic 
acid in blood was mostly related to leukaemia, proved in 1878 that 
lactic acid was also present in the blood of patients who were suf-
fering and died from other diseases. He studied blood obtained dur-
ing autopsy from cadavers, but also blood from patients obtained 
by bloodletting or cupping, and in some cases he compared the 
Fig. 2 Johann Joseph Scherer (left) and 
Rudolf Virchow (right) in 1849
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blood before and after death. He was able to demonstrate lactic 
acid in the blood of patients suffering from leukaemia, (pernicious) 
anaemia, congestive heart failure, chronic obstructive pulmonary 
disease, pleuritis, pericarditis, pneumonia and several solid malig-
nant tumours.
Gaglio [26] is often erroneously mentioned as the first author to find 
lactic acid in blood [27–29]. He was able to demonstrate lactic acid 
in fresh arterial blood withdrawn from dogs and rabbits after blood-
letting. Berlinerblau [30] confirmed these observations in mam-
malian and venous human blood. Both Gaglio and Berlinerblau, 
however, neglected previous research, as indignantly described by 
Salomon in 1888 [“Ich erlaube mir, den Inhalt meiner Arbeiten, die 
von Gaglio nur ganz flüchtig, von Berlinerblau gar nicht berührt sind, 
in Kürze zu reproduciren” (I take the liberty of summarizing the con-
tents of my work, which was mentioned only briefly by Gaglio and 
not at all by Berlinerblau)] [31].
The Japanese chemist Trasaburo Araki showed that the amount of 
lactic acid in exhausted muscle results from muscle activation [11]. 
Irisawa [32], inspired by the results obtained by Salomon and Gagl-
io, obtained fresh blood of 11 dying patients with serious conditions. 
In six cases he found hyperlactataemia, in four cases normal values. 
He speculated on the aetiology of hyperlactataemia, the most plau-
sible cause being the severe hypoxia during the dying process. In 
an experiment in which he made a dog anaemic for several days, 
he found a rise in lactic acid levels during the time leading up to 
death.
In Cambridge (UK), Walter Morley Fletcher (1873– 1933) and Fred-
erick Gowland Hopkins (1861–1947) worked together on the meta-
bolic changes occurring in muscular contractions and rigor mortis 
under anaerobic conditions, and found that lactate was the product 
of carbohydrate metabolism [33]. Their classic 1907 paper dem-
onstrated rigorously that muscle contraction is accompanied by the 
anaerobic formation of lactic acid, which is removed aerobically, 
at a rate depending on the level of exposure to oxygen [34]. Poul 
Astrup and John Severingshaus mentioned Scherer’s 1851 article 
as first demonstration of lactic acid in blood, but overlooked the 
1843 cases and Folwarczny’s work [35]. In conclusion, Scherer’s 
1843 case reports [15] should be cited as the first description of 
lactic acid in human blood and also as the first demonstration of 
lactic acid as a pathological finding in septic and haemorrhagic 
shock. Folwarczny, in 1858, was the first to demonstrate lactic acid 
in blood in a living patient.
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ABstrACt 
objective: Blood lactate monitoring has been implemented widely 
but its clinical value in critically ill patients has never been evalu-
ated properly. To decide whether the use of blood lactate monitoring 
in critical care practice is appropriate, we performed a systematic 
Health Technology Assessment. 
Data sources: Pubmed, other databases and citation review 
study selection: We searched for lactate combined with critically ill 
patients as the target patient population. Two reviewers independ-
ently selected studies based on relevance for the following ques-
tions: Does lactate measurement: I) perform well in a laboratory 
setting? II) provide information in a number of clinical situations? III) 
relate to metabolic acidosis? IV) increase workers confidence? V) al-
ter therapeutic decisions? VI) result in benefit to patients? VII) result 
in similar benefits in your own setting? VIII) result in benefits which 
are worth the extra costs?
Data synthesis: We concluded that blood lactate measurement in 
critically ill patients: I) is accurate in terms of measurement tech-
nique but adequate understanding of the (an)aerobic etiology is 
required for its correct interpretation, II) provides not only diagnos-
tic but also important prognostic information III) should be directly 
measured instead of estimated from other acid-base variables IV) 
has an unknown effect on healthcare workers confidence, V) can 
alter therapeutic decisions, VI) could potentially improve patient 
outcome when combined with a treatment algorithm to optimize 
oxygen delivery, but this has only indirectly been shown, VII) is likely 
to have similar benefits in critical care settings worldwide, VIII) has 
an unknown cost-effectiveness. 
Conclusions: the use of blood lactate monitoring certainly has a 
place in risk-stratification in critically ill patients, but it is unknown 
whether the routine use of lactate as a resuscitation endpoint im-
proves outcome. This warrants randomized controlled studies on 
the efficacy of lactate-directed therapy.
IntroDUCtIon 
Measurement of lactate in human blood was first described by 
Scherer in 1843 when he described a lethal case of fulminant septic 
shock due to puerperal fever in a young woman (1). Blood lactate 
monitoring is frequently performed in critically ill patients, usually 
aiming to detect tissue hypoxia (2). However, other processes not 
related to tissue hypoxia and subsequent anaerobic metabolism can 
also result in increased blood lactate levels (3), complicating clinical 
interpretation and therapy in cases of raised lactate levels. The use 
of blood lactate monitoring remains controversial which is reflected 
by its variable clinical use in different hospitals worldwide: some 
routinely measure it whereas others hardly do so. Because the clini-
cal benefit of blood lactate monitoring in critically ill patients has 
never been subjected to rigorous clinical evaluation, the question 
remains: should we routinely monitor lactate in the critically ill and 
if so, when should we measure it, what would be the therapeutic 
consequences and would this improve patient outcome? In order 
to address these controversies, we performed a systematic Health 
Technology Assessment (HTA) (4-6) which includes eight key ques-
tions (6) (table 1). 
I. Does lactate measurement perform well in a laboratory 
setting
II. Does lactate monitoring provide important information in a 
number of clinical situations?
III. Is there a relationship between lactate levels and metabolic 
acidosis?
IV. Does lactate monitoring increase workers confidence?
V. Does lactate measurement alter therapeutic decisions?
VI. Does lactate monitoring result in benefit to the patients?
VII. Can you expect a similar benefit in your own setting?
VIII. Are the expected benefits worth the extra costs?
Table 1. Eight-question format for performing a systematic Health Technology 
Assessment
Adapted from Keenan et al. (6).
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MetHoDs 
Data sources
Pubmed and other databases of English and non-English language 
literature (up to April 2008): the Cochrane CENTRAL Register of 
Controlled Trials, Cochrane Database of Systematic Reviews, Data-
base of Abstracts of Reviews of Effects, the Health Technology As-
sessment Database and NHS Economic Evaluation Database. Infor-
mation on ongoing clinical trials was derived from the US National 
Institutes of Health Web site (http://www.clinicaltrials.gov).
study selection 
We performed a systematic search for lactate (Medical Subject 
Heading (MeSH) terms lactic acid or lactic acidosis), in combination 
with critically ill patients as the target patient population (MeSH 
terms intensive care units, critical care, critical illness, hospital emer-
gency service, emergency medicine or postoperative care). Refer-
ences of retrieved literature were manually reviewed for additional 
relevant material. 
Out of the retrieved information, two reviewers (TJ and JvB) inde-
pendently selected studies to be included in this health technology 
assessment on the basis of relevance for answering the eight key 
questions. Disagreements were resolved by consensus. General ex-
clusion criteria were: no original research, case reports and articles 
describing D-lactate or lactate concentration in other fluids than 
whole blood or plasma. 
For each key question (table 1), separate inclusion criteria were 
defined: 
Question I 
To evaluate how accurate lactate measurement is in ideal controlled 
conditions, we first included studies that evaluated the accuracy of 
the measurement itself by comparison with a gold standard (arterial 
blood as reference site and central hospital laboratory as reference 
technique) and that used the Bland-Altman method for assessing 
agreement (7). 
To evaluate the diagnostic performance of lactate measurement we 
subsequently included studies that investigated the anaerobic and/
or aerobic etiology of hyperlactatemia. Because the etiology is com-
plex and we could not find consensus definitions of gold standards 
for comparison we didn’t define specific methodological or statisti-
cal requirements.
Question II
In this step we focussed on the use of lactate as a prognostic tool. 
Because mortality is the most important and least subjective end-
point, we restricted inclusion to studies that used mortality as the 
primary endpoint and that provided sufficient information to con-
struct 2x2 contingency tables or area under the receiver operating 
characteristic curve (AUROC). 
Question III
We included studies on the association between blood lactate lev-
els and other acid-base variables. Due to space limitations we did 
not include studies on the prognostic value of these acid-base vari-
ables.
Question IV
We included studies evaluating the effect of blood lactate monitor-
ing on healthcare workers confidence. 
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Question V
We included studies that evaluated alterations in treatment follow-
ing implementation of blood lactate monitoring protocols. We also 
included professional guidelines providing recommendations on 
blood lactate monitoring in critically ill patients. 
Question VI
We included studies that combined the measurement of lactate lev-
els with a treatment algorithm in order to provide benefit to the pa-
tient. Most studies focused on oxygen delivery (DO2) therapy, which 
we classified in increasing order of importance:
1. Observational cohort studies following implementation of a 
lactate-guided DO2 therapy algorithm. 
2. Randomized controlled studies evaluating goal-directed DO2 
therapy that were not specifically lactate-guided, but that used 
lactate levels as a primary or secondary endpoint
3. Randomized controlled studies evaluating goal-directed DO2 
therapy that included a lactate-guided group and a non lactate-
guided group.
For question VI, studies evaluating pre- and intra-operative inter-
ventions were excluded to increase homogeneity.
Question VII
In order to estimate whether you could experience the same benefits 
in your own ED or ICU, you need to know whether the demograph-
ics of your patient population are comparable, whether you have 
an equally educated and organized team and whether you have 
similar access to facilities and equipment. For this question we were 
not able to define specific criteria. Instead, we subjectively assessed 
external validity of the studies selected in step I to VI. 
Question VIII
We included studies evaluating costs or cost-effectiveness of blood 
lactate monitoring. 
resULts
The results of the search and selection process are described in 
figure 1.
I. Does it perform well in the laboratory?
Accuracy of lactate measurement:
Device: Using the hospital’s standard laboratory as the reference 
method, the selected studies generally reported small biases with 
clinically acceptable limits of agreement for point-of-care blood 
gas analyzers (Nova Stat Profile 7,10, ultra®, Nova Biomedical, 
Waltham, Mass., USA (8-10), Chiron Diagnostics®, 865 series, Fern-
wald, Germany/ Medfield, USA (11-14) and Radiometer ABL 725, 
Radiometer Medical A/S, Bronshoj, Denmark (15)) and hand-held 
devices (Accusport/trend®, Roche Diagnostics, Mannheim, Germany 
(9-11, 16), i-STAT CG4+, East Windsor, NJ, USA (15) and Lactate 
Pro, ARKRAY, Kyoto, Japan (17)). Lactate plus (Nova Biomedical, 
Waltham, MA, USA) produced higher lactate values than the refer-
ence method (15, 17).
Compartment: Although some described slightly higher peripheral 
venous (18) or capillary levels (11), most investigators found satis-
factory agreement comparing capillary (16, 19, 20), venous (21) or 
central/ mixed venous (22-24) levels with arterial levels as reference. 
Sample handling: Ongoing in-vitro glycolyis was reported to occur 
after blood sampling, resulting in erroneous elevation of lactate 
levels (25), particularly in case of leucocytosis or high hematocrit 
(26). Analysis within 15 minutes or storage <4°C were suggested 
for avoiding this. 
Exogenous factors: Infusion of Ringer’s lactate didn’t hamper accu-
racy (27), provided that blood was drawn from a catheter that was 
adequately cleared from Ringer’s lactate (28). Another study showed 
that the most commonly used critical care drugs neither affected the 
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accuracy (29). Finally, renal replacement therapy eliminated only 
negligible amounts of lactate and consequently did not interfere with 
lactate monitoring (30). However, lactate-containing buffer solutions 
were able to induce transient hyperlactatemia (31-33).
etiology of hyperlactatemia: 
Anaerobic hyperlactatemia
Systemic oxygen imbalance: Traditionally, hyperlactatemia is associ-
ated with tissue hypoxia. The causal relationship has been confirmed 
by experimental (34-36) and clinical (2) studies: when reducing the 
components of systemic DO2 until oxygen demand could no longer 
be met, and oxygen consumption was limited by DO2, this coincided 
with a sharp increase in lactate levels. 
Several other observations also pointed to an anaerobic origin of 
hyperlactatemia in critically ill patients. Hemodynamically unstable 
patients with septic or cardiogenic shock had increased lactate/pyru-
vate ratio’s (37) and decreased arterial ketone body ratio’s (i.e. ra-
tio between acetoacetate to ß-hydroxybutyrate: proposed to reflect 
mitochondrial redox state), suggesting anaerobic production (37, 
38). In the early phase of septic shock, hyperlactatemia was accom-
panied by oxygen supply dependency (39). Rivers and colleagues 
demonstrated that hyperlactatemia in severe sepsis or septic shock 
prior to resuscitation coincided with a low central venous oxygen 
saturation (ScvO2) and that increases in DO2 were associated with 
reductions in lactate (40). Similarly, low skin temperature, cardiac 
output and mixed venous oxygen saturation (SvO2) were associated 
with higher lactate levels (41). 
Regional/microcirculatory oxygen imbalance: No critical level of DO2 
or SvO2 could be associated with hyperlactatemia which could repre-
sent regional differences in oxygen delivery and demand (42). Further-
more, improving capillary perfusion was correlated with a reduction 
in lactate levels in patients with septic shock, independent of changes 
in systemic haemodynamic variables (43). The latter observation illus-
trates the hypothesis that, in the absence of low systemic DO2 relative 
to systemic metabolic demand, microcirculatory processes hampering 
oxygen utilization at the tissue level may raise lactate levels.
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Aerobic hyperlactatemia
Selected studies demonstrated that other mechanisms than tissue 
hypoxia can also account for hyperlactatemia. We found the follow-
ing aerobic mechanisms:
- Increased aerobic glycolysis, resulting in amounts of pyruvate that 
exceed the pyruvate dehydrogenase capacity. Such enhanced gly-
colysis can be triggered by cytokine-mediated uptake of glucose 
(44, 45) or catecholamine-stimulated increased Na-K-pump ac-
tivity (46-51), which was supported by a study of Levy et al. in sep-
tic shock patients, where antagonizing the Na-K-pump completely 
stopped muscle lactate overproduction (3). 
- Mitochondrial dysfunction (52-54). 
- Impaired activity of pyruvate dehydrogenase (PDH), essential for 
the conversion of pyruvate into acetyl co-enzyme A. This enzyme 
is inhibited in septic conditions (55, 56) and increasing its activ-
ity with dichloroacetate significantly reduces blood lactate levels 
(57). Thiamin deficiency (beri-beri’s disease) inhibits PDH activity 
and can cause hyperlactatemia (58). 
- Liver dysfunction (59-62) and liver surgery (63). Reduced lactate 
clearance was also reported following cardiac surgery (64) and 
in sepsis (65, 66), where it was shown to predict poor outcome 
(67). 
- Not the splanchnic area (68), but the lung can be an important 
source of lactate, both in pulmonary (61, 69) and extra-pulmo-
nary (70) disease, probably reflecting metabolic adaptations in 
response to inflammatory mediators rather than tissue hypoxia 
(71). 
- Alkalosis (72), because an H+-linked carrier mechanism is in-
volved in the transport of lactate across the cell membrane that 
increases cellular lactate efflux during alkalosis. 
- Several drugs and intoxications: Nucleosidic reverse transcriptase 
inhibitors used for the treatment of HIV (by inducing mitochondri-
al cytopathy) (73-75), epinephrine (by increased glycogenolysis, 
glycolysis and stimulation of the Na-K-pump) (76, 77), metformin 
(particularly in the presence of renal insufficiency), although a 
Cochrane review found no evidence that metformin is associated 
with increased lactate levels if prescribed under study conditions 
(78). Intoxications with methanol, cyanide (by inhibition of oxida-
tive phosphorylation) (79) or ethylene-glycol (by artifactual reac-
tion of lactate electrodes) (80) also significantly elevated lactate 
levels. 
II. Does it provide important information in a 
number of clinical situations?
We selected studies on the prognostic value of hyperlactatemia in 
many different critical care conditions (table 2 (ED) and 3 (ICU)). In 
the ED setting, AUROC for mortality varied from 0.67 (81) to 0.98 
(82), which indicates moderate to excellent prognostic accuracy. 
In the ICU setting, AUROC varied from 0.53 (83) and 0.58 (84) to 
0.86 (85), which indicates poor to good prognostic performance. 
To answer the question whether a hyperlactatemic patient will die, 
which is what clinicians want to know when individually assessing 
patients, the positive predictive value or post-test probability is im-
portant. In some of our selected studies, positive predictive values 
for death in case of abnormal lactate levels (>2.0-2.5 mmol/l) were 
very low (4-15% (81, 86, 87)). However, comparison of the pre-test 
probability (which is the study population mortality rate) with the 
post-test probability determines the value that lactate can add in 
risk-stratification: from our selected studies it becomes clear that 
lactate generally increased the ability to predict non-survival, both 
in the ED and in ICU setting.
None of the studies took into account that the real pre-test probabil-
ity not only depends on the mortality rate, but also on the clinicians’ 
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ability to estimate risk using all other available clinical parameters. 
Some authors therefore called for a future study that captures clini-
cians’ estimates for probability of death prior to lactate measure-
ment, in order to evaluate the capacity to influence clinical practice 
decisions (88). 
III. Is there a relationship between lactate levels 
and metabolic acidosis?
The level of lactate may be estimated from other acid base vari-
ables. However, there was no clinically important relationship be-
tween lactate and pH or base excess (89-94), although one study 
showed that base excess could predict hyperlactatemia (95). Accu-
racy of the anion gap for screening for hyperlactatemia was gener-
ally poor (96-99), but this varied to reasonably accurate (95). Other 
studies showed that lactate was only responsible for a minor per-
centage of metabolic acidosis in critically ill patients (93, 100-103). 
Furthermore, lactate or non-lactate etiologies of metabolic acidosis 
are associated with different mortality rates (89, 104). Therefore, 
although hyperlactatemia has often been associated with the pres-
ence of a metabolic acidosis (lactic acidosis), this relationship ap-
peared not straightforward at all. Because the conversion of pyru-
vate to lactate does not directly result in production of H+ ions, 
it was hypothesized that only if the H+ ions generated during the 
hydrolysis of adenosine triphosphate cannot be recycled in the mi-
tochondria, i.e. in anaerobic conditions, acidosis coincides with hy-
perlactatemia (105). Following this hypothesis, it has been argued 
that the presence of metabolic acidosis can be used to distinguish 
aerobic from anaerobic hyperlactatemia (106). 
The weak correlation between hyperlactatemia and metabolic aci-
dosis has also been explained from another point of view. In Stew-
art’s acid-base classification three independent variables control 
pH: strong ion difference (SID), pCO2 and the sum of the weak 
acids and proteins in plasma (107). An increased lactate level 
reduces SID, which has an acidifying effect. However, in the Stew-
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art’s model, this does not necessarily result in acidosis because oth-
er simultaneous alterations in SID, changes in the amount of weak 
acids and proteins, or changes in pCO2 can all influence pH (93, 
100). 
IV. Does it increase healthcare worker confidence?
Information provided by a parameter may lead to increased con-
fidence among health care providers. Although questionable if no 
other clinical endpoint (mortality, morbidity, costs) is improved, in-
creased confidence might be an important goal when decisions are 
made in conditions of uncertainty in critical care. For instance, in 
a trial on peri-operative pulse oximetry, the rate of complications 
was not reduced, but 80% of the anesthesiologists felt more secure 
when using a pulse oximeter (108). It seems likely that lactate deter-
minations could increase worker confidence because rapidly avail-
able and definite endpoints of resuscitation are scarce. An obser-
vation that the nursing team expressed a positive attitude towards 
implementation of a hemodynamic protocol that included frequent 
lactate measurements, indirectly supports this (109). However, we 
were not able to find a study that specifically evaluated the effect on 
healthcare workers confidence. 
V. Are therapeutic decisions altered as a result of 
blood lactate levels?
In studies on treatment alterations following implementation of 
lactate monitoring, hyperlactatemia was interpreted as a result of 
anaerobic conditions due to systemic oxygen imbalance and this 
was a trigger to increase oxygen delivery or decrease oxygen de-
mand (110-113). This included administration of fluids, inotropic 
agents, red blood cell transfusion, mechanical ventilation, paralytic 
agents, sedatives and analgetics. In the only randomized control-
led study in which measurement of lactate was compared with not 
measuring lactate, more fluids and inotropes were administered in 
the lactate group (114). 
We also selected professional guidelines: the Surviving Sepsis Cam-
paign recommends the use of lactate as a trigger for early goal-
directed therapy (≥4 mmol/l) (115). The Clinical Practice Guideline 
concerning trauma resuscitation recommends lactate as a resuscita-
tion endpoint but acknowledged that evidence of improved survival 
of such strategy has not been shown (116). Finally, the International 
Consensus Conference (ICC) 2006 on hemodynamic monitoring 
and management of patients in shock also stresses the lack of clini-
cal trials investigating the clinical value of incorporating lactate in a 
treatment protocol (117).
VI. Does application of blood lactate monitoring 
result in benefit to patients?
As monitoring itself will not change outcome, an integrated treat-
ment algorithm has to provide the benefit to patients. This has to 
be aimed at the conditions leading to hyperlactatemia rather than 
at reduction of lactate levels alone. For instance, improving pyru-
vate metabolism by administration of dichloroacetate decreased 
lactate levels (57) but this was not associated with a clinical benefit. 
Another study showed that bicarbonate therapy didn’t improve he-
modynamic variables in patients with lactic acidosis (118). These 
observations indicate that the detrimental outcome associated with 
hyperlactatemia is more likely to be determined by the underlying 
cause than by the hyperlactatemia itself. 
We selected four observational studies evaluating implementation 
of a lactate-guided DO2 therapy algorithm (table 4A). Lactate lev-
els decreased significantly during lactate-guided therapy (110, 111, 
113), which coincided with an increase in ScvO2 in one study (110). 
Patients who responded with normalization of lactate had lower 
mortality than those who remained hyperlactatemic (111, 113). 
One observational study made a comparison with an historical 
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control group and found lower mortality following implementation 
of a lactate-guided DO2 therapy algorithm (112).
We selected nine randomized controlled studies that evaluated goal-
directed DO2 therapy, which was not specifically lactate-guided, but 
that used lactate levels as a primary or secondary endpoint (table 
4B). Out of the five studies that showed a positive outcome (40, 
119-122), three studies reported a decrease of lactate in the inter-
vention group compared with the control group (40, 120, 122).
However, we found only one completed randomized controlled study 
evaluating goal-directed DO2 therapy that included a lactate-guided 
and a non lactate-guided group (table 4C). This study in a post 
cardiac-surgery population showed a reduction in length of stay in 
the lactate-guided group (114). Two studies are currently ongoing.
VII. Can you expect a similar benefit in your own 
setting?
To answer this question the external validity of the previously select-
ed studies needs to be determined. Given that lactate measurement 
is generally considered as easy and accurate, that it is commonly 
available worldwide and given that evidence on the prognostic value 
of hyperlactatemia has been very consistent and applies to many 
different populations, it is clear that lactate can be used as a prog-
nostic marker in your own setting. However, the value of lactate as 
a therapeutic tool remains unclear. 
VIII. Are the expected benefits worth the costs?
A hand-held lactate device, such as accutrend®, costs around € 
200 and a test strip costs € 2. The price of a blood gas analyzer is 
around € 30 000 and total costs per sample are € 2 (10). In a Ger-
man study, total costs were lowest with €1 per measurement using 
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the hand-held device, followed by € 2 using the blood gas analyzer 
(Chiron 865 series®) and € 5 when using the central hospital’s labo-
ratory (11). In the Netherlands, external budget costs per measure-
ment are € 12. We didn’t find a study on the cost-effectiveness of 
lactate monitoring. Although costs of lactate measurement itself are 
relatively low, costs of subsequent therapeutic consequences and 
use of health care resources are unknown.
DIsCUssIon
We found that lactate performs well in the laboratory: the measure-
ment itself is accuarate and clinicians at the bedside can trust the 
numerical value of lactate levels they collect. However, sufficient 
understanding of anaerobic and aerobic mechanisms of production 
and clearance is essential for the correct interpretation of hyper-
lactemia. Although the prognostic accuracy of lactate varied consid-
erably, lactate generally increased the ability to predict non-survival, 
both in the ED and ICU. The consistency of this finding means that 
lactate certainly has a place in the risk-stratification of critically ill 
patients. Because of the weak correlation between hyperlactatemia 
and metabolic acidosis, lactate should be directly measured instead 
of estimated from other acid-base variables. Furthermore, lactic or 
non-lactic metabolic acidoses are associated with different mortal-
ity. 
Concerning the clinical impact of lactate monitoring, it seems likely 
that it can increase healthcare workers confidence, although we 
were not able to find studies on this topic. Lactate monitoring has 
the potential to alter therapeutic decisions as hyperlactatemia in 
critically ill patients is often interpreted as a result of systemic oxy-
gen imbalance, triggering goal-directed DO2 therapy. Indirect evi-
dence supports the therapeutic benefit of lactate monitoring. How-
ever, there is a lack of clinical trials investigating the clinical value of 
lactate-directed therapy; the only single-center clinical trial advocat-
ing its efficacy was performed in post-cardiac surgery patients and 
this cannot easily be extrapolated to other critical care populations. 
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In addition, although costs of lactate measurement itself are rela-
tively low, cost-effectiveness of lactate measurements is unknown. 
Strengths of our study include the systematic search and selection 
strategy and the eight-question format that provides a complete and 
clinically relevant assessment of the real value of lactate monitoring. 
Our study also has limitations. We didn’t perform a methodological 
quality assessment of the selected studies. The variety of study de-
signs was too large for a single methodological quality score. We 
neither performed a meta-analysis, which would have been valuable 
when evaluating prognostic accuracy or efficacy of lactate-directed 
therapy. However, the studies were far too heterogeneous (large 
variations in patient categories, mortality rates, lactate cutoff values 
and timing of measurements or interventions). Last, the results of 
this study obviously need to be interpreted in the light of the search 
and selection criteria, and we might have missed information.
ConCLUsIon
Based on the results of this systematic health technology assess-
ment, blood lactate monitoring is recommended in critical care set-
tings as the ED and ICU because it clearly has a place in the risk-
stratification of critically ill patients. However, it is unknown whether 
the routine use of lactate as a resuscitation endpoint improves out-
come. This warrants randomized controlled studies on the efficacy 
of lactate-directed therapy.
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ABstrACt
Introduction: A limitation of pre-hospital monitoring is that vital 
signs often do not change until a patient is in a critical stage. Blood 
lactate levels are suggested as a more sensitive parameter to evalu-
ate a patient’s condition. The aim of this pilot study was to find pre-
sumptive evidence for a relation between pre-hospital lactate levels 
and in-hospital mortality, corrected for vital sign abnormalities.
Methods: In this prospective observational study (n = 124), pa-
tients who required urgent ambulance dispatching and had a systo-
lic blood pressure below 100 mmHg, a respiratory rate less than 10 
or more than 29 breaths/minute, or a Glasgow Coma Scale (GCS) 
below 14 were enrolled. Nurses from Emergency Medical Services 
measured capillary or venous lactate levels using a hand-held de-
vice on arrival at the scene (T1) and just before or on arrival at the 
emergency department (T2). The primary outcome measured was 
in-hospital mortality. 
results: The average (standard deviation) time from T1 to T2 was 
27 (10) minutes. Non-survivors (n = 32, 26%) had significantly 
higher lactate levels than survivors at T1 (5.3 vs 3.7 mmol/L) and at 
T2 (5.4 vs 3.2 mmol/L). Mortality was significantly higher in patients 
with lactate levels of 3.5 mmol/L or higher compared with those with 
lactate levels below 3.5 mmol/L (T1: 41 vs 12% and T2: 47 vs 15%). 
Also in the absence of hypotension, mortality was higher in those 
with higher lactate levels. In a multivariable Cox proportional hazard 
analysis including systolic blood pressure, heart rate, GCS (all at 
T1) and delta lactate level (from T1 to T2), only delta lactate level 
(hazard ratio (HR) = 0.20, 95% confidence interval (CI) = 0.05 to 
0.76, p = 0.018) and GCS (HR = 0.93, 95% CI = 0.88 to 0.99, 
p = 0.022) were significant independent predictors of in-hospital 
mortality. 
Conclusions: In a cohort of patients that required urgent ambulance 
dispatching, pre-hospital blood lactate levels were associated with 
in-hospital mortality and provided prognostic information superior 
to that provided by the patient’s vital signs. There is potential for 
early detection of occult shock and pre-hospital resuscitation guided 
by lactate measurement. However, external validation is required 
before widespread implementation of lactate measurement in the 
out-of-hospital setting.
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IntroDUCtIon
An important limitation of patient monitoring in the pre-hospital 
phase is that the standard vital signs such as heart rate and blood 
pressure often do not change until a patient reaches a critical stage 
[1-3]. Pain and anxiety, contributing to increased sympathetic tone, 
influence these vital signs and render them insensitive for monitor-
ing the adequacy of tissue perfusion [4]. Many patients who appear 
to be haemodynamically stable based on normal vital signs have 
increased blood lactate levels (‘occult hypoperfusion’ or ‘compen-
sated shock’) [1, 5]; as a result, lactate levels are often considered 
to be better resuscitation endpoints than standard vital signs [6]. 
Lactate levels are commonly used to stratify risk and to assess ad-
equacy of resuscitation in the intensive care unit (ICU) [7, 8] and in 
the emergency department (ED) [9-11], but are not currently used 
in the pre-hospital setting [12]. As it is possible to measure blood 
lactate levels on-site using a fast and accurate hand-held analyser 
on capillary or venous blood [13, 14], lactate monitoring can be 
transferred from the hospital to the pre-hospital setting. The aim 
of this pilot study was to find presumptive evidence for a relation 
between pre-hospital lactate levels and patient outcome. We hy-
pothesised that pre-hospital blood lactate measurements would en-
able the prediction of in-hospital mortality and that this prognostic 
value would be independent of commonly available standard vital 
parameters.
MAterIALs AnD MetHoDs
study design
This was a prospective observational cohort study. 
setting
A Dutch Emergency Medical Service (EMS), referring to three uni-
versity-affiliated hospitals, dispatched ambulances that were staffed 
by certified EMS nurses with two years of postgraduate training in a 
critical care setting (ICU, cardiac care unit, anaesthesiology or ED) 
and one year of training in EMS-specific procedures. 
selection of participants
A convenience sample of patients were enrolled who required ur-
gent ambulance dispatching and had a systolic blood pressure be-
low 100 mmHg, respiratory rate of less than 10 or more than 29 
breaths/minute or a Glasgow Coma Scale (GCS) of less than 14 on 
arrival of the ambulance. Exclusion criteria were the unavailability 
of a first lactate measurement or epileptic seizures, in which case 
hyperlactataemia is prognostically less sensitive [15]. The study was 
approved by the Medical Ethics Committee, which waived the need 
for obtaining informed consent.
Interventions
Pre-hospital treatment was provided by EMS nurses according to 
Dutch national ambulance protocols (Landelijk Protocol Ambulanc-
ezorg (LPA)). These protocols are in accordance with the pre-hospital 
and advanced trauma life support guidelines of the National Asso-
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ciation of Emergency Medical Technicians, based on the Advanced 
Trauma Life Support standard of the American College of Surgeons. 
During the study period from June 1997 to November 1998, LPA 
version 4 (1996 to 1999) was used. When compared with the cur-
rent version 7 (2007 to 2010), most protocols were similar.
Methods of measurements and data collection
The first lactate measurement (T1) was performed by EMS nurses 
as soon as possible after arrival at the scene (before any pre-hos-
pital treatment); the second measurement (T2) was obtained just 
before or on arrival at the ED (after pre-hospital treatment). The 
lactate level was measured in venous or capillary blood immediately 
after blood was drawn (at T1 or T2) using a point-of-care hand-
held lactate analyser (Accutrend, Roche Diagnostics, Mannheim, 
Germany). This is a small, battery-powered, reflectance photometer 
with a turnaround time of 60 seconds that uses chemistry test strips 
on which a drop of blood is applied. Hospital physicians were not in-
formed about the lactate levels collected by the EMS nurses. Other 
obtained data at both T1 and T2 included heart rate, diastolic and 
systolic blood pressures, peripheral oxygen saturation obtained by 
pulse oxymeter (SpO2) and GCS. SpO2 was regarded as a binary 
variable, which was defined as abnormal if it was lower than 92% 
or if the pulse oxymeter signal could not be retrieved because of 
inadequate peripheral perfusion (n = 25). If heart rate and blood 
pressure readings could not be obtained because of cardiac arrest 
at T1 (asystole or ventricular fibrillation, n = 11), we considered 
these values as 0 (this was only done at T1, not at T2). 
outcome measures
The primary outcome measured was in-hospital mortality. 
Primary data analysis
Because lactate levels were not normally distributed, they were log-
arithmically transformed before analysis. To evaluate the prognos-
tic accuracy of the lactate levels, receiver operating characteristic 
(ROC) curves for in-hospital mortality were constructed and area 
under the ROC curves (AUROC) were calculated. Using ROC-curve 
analysis, we defined appropriate cut-off values (which are not avail-
able for the pre-hospital setting) and calculated sensitivity, specifi-
city, positive predictive values (PPV) and negative predictive values 
(NPV). In order to identify patients who were likely to die, the test 
had to be sensitive while remaining specific [16] and had to have 
an acceptable PPV [17]. Mortality rates of patients with high or low 
lactate levels were compared using a chi squared test or Fisher’s 
exact test if necessary, based on sample size.
In order to identify independent predictors of in-hospital death, ad-
justed for standard variables available in the pre-hospital setting, a 
multivariable Cox proportional hazards (PH) model was construct-
ed. The variables systolic blood pressure, heart rate, GCS and the 
change in lactate level from T1 to T2 were simultaneously entered 
in this model (the number of variables was restricted to four to re-
duce the possibility of overfitting). A backward elimination method 
was used, in which each step removed the variable with the highest 
p-value above 0.10 according to the likelihood ratio test. Interaction 
between all variables was not tested because of the risk of overfit-
ting. The PH assumption was confirmed by entering variable-by-
time interaction terms one by one, with time on the log scale. By 
choosing Cox PH instead of logistic regression analysis, we took 
account of the time of death, rather than just dead (yes or no) in 
the analysis. Statistical analyses were performed using SPSS version 
11.0.1/12.0.1 (SPSS, Inc., Chicago, IL, USA).
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resULts
Characteristics of study subjects
We enrolled 135 patients. Three patients were excluded because of 
a missing first lactate measurement and eight patients had epileptic 
seizures. The baseline characteristics of the remaining 124 patients 
are described in Table 1. The mean (standard deviation) time at the 
scene from arrival to departure of the ambulance was 16 (8) min-
utes. Mean duration of the subsequent transfer to the ED was 11 (6) 
minutes. The total time from arrival at the scene to arrival in the ED 
was 27 (10) minutes.
Before pre-hospital treatment (t1)
Of the 124 patients who were included in the study on arrival of the 
ambulance at the scene, 92 survived and 32 died. Compared with 
the survivors, the non-survivors had a lower systolic blood pressure, 
lower GCS, more often an abnormal SpO2 and an older age (Table 
2). Heart rates were not significantly different. Lactate levels were 
higher in the non-survivors (Figure 1).
At T1, the AUROC of lactate for in-hospital death was 0.69 (95% 
confidence interval (CI) = 0.58 to 0.80, p = 0.001). We established 
a lactate level of 3.5 mmol/L as the best cut-off point for T1. A lac-
tate level of 3.5 mmol/L or more was 75% sensitive (95% CI = 60 
to 90%) and 63% specific 95% CI = 53 to 73%) for prediction of 
death, with a PPV of 41% (95% CI = 29 to 54%) and a NPV of 88% 
Total:  
n = 124
Non-survivors: 
n = 32
Survivors: 
n = 92
Age (years, ±SD) 62 ± 19 68 ± 14 * 59 ± 20 *
Sex (n, % male) 73 (59%) 22 (69%) 51 (55%)
Intensive care unit admission  
(n, %)
57 (46%) 15 (47%) 42 (46%)
Length of stay in hospital  
(days, ±SD)
13 ± 21 3 ± 6 * 17 ± 23 *
Time arrival ambulance to ED 
(minutes, ±SD)
27 ± 9 29 ± 10 26 ± 10
Ambulance diagnosis (n, %):
 - cardiac arrest 12 (10%) 8 (25%) * 4 (4%) *
 - myocardial infarction 17 (14%) 2 (6%) 15 (16%)
 - other cardiological disorders 8 (6%) 1 (3%) 7 (8%)
 - sepsis 8 (6%) 4 (13%) 4 (4%)
 - haemorrhage 10 (8%) 3 (9%) 7 (8%)
 - neurological disorder 19 (15%) 9 (28%) * 10 (11%) *
 - trauma without severe  
  traumatic brain injury
18 (15%) 2 (6%) 16 (17%)
 - trauma with severe traumatic  
  brain injury
2(2%) 1 (3%) 1 (1%)
 - attempted suicide 4 (3%) 0 (0%) 4 (4%)
 - others 26 (21%) 2 (6%) * 24 (26%) *
Table 1. Baseline characteristics
Continuous data are presented as mean ± standard deviation (SD). Binary data 
are presented as n (percentage of total, non-survivors or survivors). * p< 0.05. ED 
= emergency department.
T1 T2
NS S NS S
Heart rate (beats/
minute, ±SD)
75 ± 51 89 ± 30 90 ± 40 90 ± 22
Systolic arterial pressure 
(mmHg,±SD)
101 ± 66 * 126 ± 41 * 132 ± 43 136 ± 28
Mean arterial pressure 
(mmHg,±SD)
86 ± 56 * 108 ± 35 * 113 ± 36 117 ± 23
SpO2 < 92% or no 
signal (n, %)
23 (72%) * 34 (37%) * 12 (43%) 22 (28%) 
GCS (±SD) 8 ± 6 * 13 ± 4 * 9 ± 6 * 13 ± 4 *
Table 2. Vital signs in survivors (S) and non-survivors (NS) on arrival of the ambu-
lance on the scene (T1) and just before or on arrival at the emergency department 
(T2)
Continuous data are presented as mean ± standard deviation (SD). Binary data 
are presented as n (percentage non-survivors or survivors). Number of patients: 
T1 n = 124 (32 NS and 92 S), T2 n = 106 (28 NS and 88 S). * p< 0.05. SpO2= 
peripheral oxygen saturation, GCS= Glasgow Coma Scale.
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(95% CI = 80 to 96%). Mortality in patients with a high lactate level 
was 41% (95% CI = 29 to 54%), compared with 12% (95% CI = 4 
to 20%) for those with a lower level (Figure 2). Patients with high 
lactate levels also had lower systolic blood pressures (100 vs 137 
mmHg, p< 0.001), lower GCS (10 vs 14, p< 0.001), more often an 
abnormal SpO2 (74 vs 21%, p< 0.001) and were more often admit-
ted to the ICU (57 vs 36%, p = 0.022). 
At T1, 33 patients had a systolic blood pressure below 100 mmHg. 
To adjust for the presence of a systolic blood pressure below 100 
mmHg [18], a stratified analysis was performed, which showed that 
lactate was still significantly associated with mortality (Figure 3).
After pre-hospital treatment (t2)
Follow-up lactate measurements were available for 106 patients. Of 
these patients, 78 survived and 28 died in the hospital. Compared 
with the survivors, the non-survivors had a lower GCS (9 vs 13, 
Figure 2. Patient survival according to lactate levels below or above the cut-off 
threshold of 3.5 mmol/L
Figure 1. Mean lactate levels in survivors (S) and non-survivors (NS) upon arrival 
of the ambulance at the scene (T1) and just before/on arrival at the emergency 
department (T2)
Arrow bar represents standard error. Number of patients at T1: n = 124 and at 
T2: n = 106.
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lsp< 0.001) and a higher lactate level (Figure 2). Systolic blood pres-
sure, heart rate and SpO2 did not significantly differ between the 
two groups. 
At T2, the AUROC was 0.72 (95% CI = 0.60 to 0.84, p = 0.001). 
Here, 3.5 mmol/L was again considered as the most appropriate 
cut-off point with a sensitivity for death of 64% (95% CI = 47 to 
82%), specificity of 74% 95% CI = 65 to 84%), PPV of 47% (95% 
CI = 31 to 63%) and a NPV of 85% (95% CI = 77 to 94%). In the 
high lactate group, 47% (95% CI = 31 to 63%) of the patients died, 
while only 15% (95% CI = 6 to 23%) of those with a lower lactate 
level died (Figure 2). Additionally, patients in the high lactate group 
had a lower systolic blood pressure (125 vs 140 mmHg, p = 0.017), 
lower GCS (10 vs 13, p = 0.002), more often an abnormal SpO2 
(50 vs 22%, p = 0.003) and were more often admitted to the ICU 
(71 vs 35%, p< 0.001). 
Eleven patients had a systolic blood pressure below 100 mmHg at 
T2. In the other patients with a systolic blood pressure of 100 mmHg 
or above (n = 95), mortality rates remained significantly higher in 
those with high (47%, 14 out of 30) versus low lactate levels (15%, 
10 out of 65, p = 0.001).
When examining the evolution of lactate during the pre-hospital 
phase, the lactate level, on average, increased 0.1 mmol/L in non-
survivors, whereas in survivors it decreased 0.6 mmol/L (p = 0.044). 
This evolution of lactate from T1 to T2 had prognostic significance 
even after the effect of the other parameters (systolic blood pres-
sure, heart rate and GCS) had been taken into account in the multi-
variable Cox PH model. Of the variables, only the change in lactate 
level and the GCS were independently associated with in-hospital 
mortality (Table 3). The hazard of death decreased by 80% (95% 
CI = 24 to 95%) for every 63% decrease of the lactate level at T2 
relative to the level at T1 (i.e. a larger decrease in lactate during 
pre-hospital treatment was associated with decreased mortality). 
Although a model with six instead of four entered variables is a pos-
sible overfit, adding age and SpO2 to the start model resulted in a 
final model in which delta lactate remained independently associ-
Figure 3. In-hospital mortality stratified by systolic blood pressure and blood  
lactate level measured at arrival of the ambulance at the scene (T1).
*p = 0.046 #p = 0.032 Number of patients per group: low systolic blood  
pressure (SBP)/low lactate n = 8, low SBP/high lactate n = 25, high SBP/low  
lactate n = 58, high SBP/high lactate n = 33.
Variable Start model Final model
HR 95% CI p value HR 95% CI p value
Δ ln(lactate)  
T1 to T2* 
0.20 0.05 to 0.79 0.022 0.20 0.05 to 0.76 0.018
SBP T1 per 
mmHg
1.00 0.99 to 1.01 0.56 Not in 
model
0.87
Heart rate T1 
per beat/minute
1.01 0.99 to 1.02 0.47 Not in 
model
0.66
GCS T1 per unit 0.93 0.87 to 0.99 0.034 0.93 0.88 to 0.99 0.022
Table 3. Multivariable Cox proportional hazards model for the identification of 
independent variables associated with in-hospital death
The variables were simultaneously entered in the model (start model). A backward 
elimination method was used to construct the final model. 
* Δ ln(lactate) T1 to T2: for every 63% decrease (100*(1-(1/e)) = 63%) of the 
lactate level at T2 relative to the level at T1, the hazard of death decreased by 
80% (100 (1-HR)) in the final model (95% CI = 24 to 95%). e = 2.71828, GCS = 
Glasgow Coma Scale, HR = hazard ratio, ln = natural logarithm, SBP = systolic 
blood pressure, T1 = on arrival of the ambulance on the scene, T2 = just before 
or on arrival at the emergency department.
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ated with in-hospital mortality (with equal hazard ratio, 95% CI and 
p value, data not shown).
subgroup of patients without cardiac arrest
To test the hypothesis that blood lactate levels remained predic-
tive for outcome in a population that is not obviously in circulatory 
shock, we repeated the analyses in the subgroup of patients without 
cardiac arrest. In addition, this would correct for possible negation 
of the association of tachycardia with mortality because of the cod-
ing of heart rate as 0 in cases of cardiac arrest.
Twelve patients had cardiac arrest at T1. Four patients died out-of-
hospital (before T2). Of the eight patients with return of spontane-
ous circulation at T2, four died during hospital admission and four 
survived. In the subgroup excluding the 12 patients with cardiac 
arrest (n = 112, in-hospital mortality 21%), lactate level remained 
a prognostic marker for in-hospital death. The AUROC was 0.66 
(95% CI = 0.52 to 0.80, p = 0.015) at T1 and 0.69 (95% CI = 0.55 
to 0.82, p = 0.007) at T2. A lactate level of 3.5 mmol/L remained 
the most appropriate cut-off value at both time points. Using this 
value at T1, mortality was 35% (95% CI = 21 to 49%) in the group 
with high lactate levels compared with 12% (95% CI = 4 to 20%) in 
the group with low lactate levels (p = 0.005). At T2, this was 43% 
(95% CI = 26 to 61%) compared with 15% (95% CI = 11 to 19%)(p 
= 0.002). In the final model of multivariable Cox PH analysis per-
formed in the non-cardiac arrest patients, the effect of the change 
in lactate levels from T1 to T2 remained equally strong with a haz-
ard ratio of 0.22 (95% CI = 0.04 to 1.11), but it was not statistically 
significant (p = 0.067).
DIsCUssIon
Our results show that in a cohort of patients that required urgent 
ambulance dispatching, pre-hospital blood lactate levels were asso-
ciated with in-hospital mortality. In addition, lactate was more sensi-
tive in identifying patients at risk of death than the conventional vital 
parameters such as systolic blood pressure and heart rate. 
The mortality rate of 41% for patients with a first lactate level of 3.5 
mmol/L or more indicates that a high-risk population could be iden-
tified immediately on arrival of the ambulance at the scene. This 
was clinically relevant because a simple procedure such as meas-
urement of lactate levels increased the ability to predict death from 
26% (pre-test probability or study population mortality) to 41% at 
T1 and 47% at T2 (post-test probability or PPV). Furthermore, the 
NPV of 88% demonstrated that low lactate levels identified patients 
with a low risk of dying. Our study found that a cut-off value of 3.5 
mmol/L for the out-of-hospital setting is close to 4.0 mmol/L, which 
was found to have prognostic significance in the ED [7, 9, 19]. The 
prognostic accuracy of pre-hospital lactate levels for predicting in-
hospital death, as expressed by AUROC, sensitivity and specificity, 
was comparable with values found in the ED and ICU setting [5, 7, 
9, 19]. Aside from the prognostic information obtained from single 
lactate measurements, our data also emphasised the value of serial 
measurements in which the response to administered pre-hospital 
therapy could be monitored [10, 20]. 
Importantly, the prognostic value of lactate was independent of vi-
tal signs. In particular, the association between hyperlactataemia 
and mortality was not confounded by simultaneous hypotension. 
Our observation that lactate was a more sensitive marker is in line 
with earlier studies in the ED or ICU describing the phenomenon of 
occult hypoperfusion [1, 5, 11, 20-23]. Apparently, compensated 
shock in which there are signs of tissue hypoperfusion despite the 
presence of stable vital signs is equally important in the pre-hospital 
setting. Insufficient oxygen delivery might have been an important 
cause of hyperlactataemia in our patients, particularly in the earli-
est phase of disease presentation as was the case in our study [24-
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26]. In addition, increased aerobic metabolism [27] and reduced 
clearance [28] might have also contributed to the increased blood 
lactate levels early in critical illness when blood pressure and heart 
rate were not yet affected [12].
The use of blood lactate measurement in EMS might have clinical 
potential: as a triage tool and as a trigger for optimisation of oxygen 
delivery [29-33] where the pre-hospital setting provides the earliest 
possible timing, which is regarded as crucial to avoid irreversible 
damage [34-36]. 
This study has several limitations. First, an important limitation is 
that the data were collected in 1997 and 1998. Due to practical 
reasons, these data have not been analysed and published until 
now. Although substantial time has elapsed, we believe that our 
data are still useful as differences between ambulance protocols 
of the study period (LPA version 4) in comparison with the current 
guidelines (LPA version 7) are minimal. Also, even if changes in 
pre-hospital treatment over the past few years would have affected 
the pre-hospital evolution of lactate, we still assume that the in-
trinsic association between a certain lactate course and its related 
impact on outcome remains unaltered. Furthermore, the impact of 
in-hospital care on mortality was limited because the average time 
to in-hospital death was only three days. Nonetheless, progress over 
the years in in-hospital care in the fields of emergency medicine and 
critical care medicine may affect the rate of in-hospital mortality.
Second, in this pilot study, we chose to include patients based on 
abnormal vital signs rather than including all patients for whom am-
bulances were dispatched. This allowed establishing associations 
between lactate levels, abnormalities in vital signs and outcome 
without needing to enroll a very large cohort of patients. However, 
this resulted in a relatively high mortality rate (26%), limiting the 
ability of the result to be generalised to other out-of-hospital set-
tings. Also, stratified analyses of more homogeneous groups, such 
as trauma or medical patients, were not possible. 
Last, the chosen entry criteria are compensatory mechanisms for 
hypoperfusion and may have confounded the potential to discover 
hyperlactataemia in haemodynamically stable patients. By adjusting 
for vital parameters in multivariable analysis and by excluding car-
diac arrest patients, who are in apparent shock, we tried to correct 
for this. 
ConCLUsIons
The present data show that pre-hospital blood lactate levels pre-
dicted in-hospital mortality in a population that required urgent am-
bulance dispatching, and that these measurements provided prog-
nostic information over and above common vital signs. In the early 
pre-hospital phase, measuring lactate level was a more sensitive 
way of identifying a population at risk than measuring systolic blood 
pressure and heart rate. Its use in EMS has the potential for ear-
lier detection of occult shock, optimisation of triage decisions and 
earlier start of goal-directed therapy. However, external validation 
in larger cohorts of consecutive patients for which ambulances are 
dispatched is required before widespread implementation of lactate 
level measurement in the out-of-hospital setting.
key messages
• Pre-hospital blood lactate levels were associated with in-
hospital mortality.
• A blood lactate level of 3.5 mmol/L was the best cut-off value 
in the pre-hospital phase to discriminate survivors from non-
survivors.
• The prognostic value of pre-hospital blood lactate level was 
superior to that of heart rate and systolic blood pressure.
• The use of blood lactate measurement in EMS might have 
potential for triage decisions, earlier detection of occult shock 
and earlier start of goal-directed therapy.
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AUROC = area under the ROC curve, CI = confidence interval, 
ED = emergency department, EMS = Emergency Medical Services, 
GCS = Glasgow Coma Scale, ICU = intensive care unit, LPA = Lan-
delijk Protocol Ambulancezorg (Dutch ambulance protocols), NPV 
= negative predictive value, PH = proportional hazards, PPV = pos-
itive predictive value, ROC = receiver operating characteristic,SD = 
standard deviation, SpO2 = peripheral oxygen saturation obtained 
by pulseoxymeter, T1 = on arrival of the ambulance at the scene, 
T2 = just before or on arrival at the emergency department.
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ABstrACt
Background: Hyperlactatemia and its reduction following admission 
in the ICU have been related to survival. Because it is unknown 
whether this equally applies to different groups of critically ill pa-
tients, we compared the prognostic value of repeated lactate levels 
(a) in septic patients versus patients with hemorrhage or other con-
ditions generally associated with low-oxygen-transport (LT) (b) in 
hemodynamically stable versus unstable patients. 
Methods: In this prospective observational two-center study (n= 
394 patients), blood lactate levels at admission to the ICU (Lac T0) 
and the reduction of lactate levels from T=0 to T=12 hours (ΔLac 
T0-12) and from T=12 to T=24 hours (ΔLac T12-24), were related 
to in-hospital mortality. 
Results: Reduction of lactate was associated with a lower mortal-
ity only in the sepsis group (ΔLac T0-12: hazard ratio (HR) 0.34, 
p=0.004 and ΔLac T12-24: HR 0.24, p=0.003), but not in the 
LT group (ΔLac T0-12; HR 0.78, p=0.52 and ΔLac T12-24; HR 
1.30, p=0.61). The prognostic values of Lac T0, ΔLac T0-12 and 
ΔLac T12-24 were similar in hemodynamically stable and unstable 
patients (p=0.43).
Conclusions: Regardless of the hemodynamic status, lactate reduc-
tion during the first 24 hours of ICU stay is associated with improved 
outcome only in septic patients, but not in patients with hemorrhage 
or other conditions generally associated with low-oxygen-transport. 
We hypothesize that in this particular group a reduction in lactate is 
not associated with improved outcome due to irreversible damage 
at ICU admission.
IntroDUCtIon
Blood lactate levels are often determined in critically ill patients, 
because repeated measurements identify those patients who are 
at risk for multiple organ failure and death [1-3]. In these patients, 
hyperlactatemia is thought to be predominantly caused by impaired 
organ perfusion. Although this condition is often associated with 
hemodynamic instability, hyperlactatemia can also occur during sta-
ble hemodynamic conditions, in which case it is considered to be 
due to occult hypoperfusion [4-6]. Treatment aims at correction of 
tissue perfusion, resulting in decreased lactate levels and improved 
patient outcome [7]. 
With this purpose, monitoring of lactate levels is used in a very 
broad range of patients, including trauma as well as sepsis patients 
[8, 9]. The generalized use of lactate in critically ill patients has 
given rise to a universal concept that a high lactate level is bad 
and that a decrease in lactate levels is good, despite considerable 
differences in underlying disease (e.g. hemorrhage versus sepsis) 
and hemodynamic status within the patient population. In fact, it is 
unknown whether these factors, which can be clinically evaluated at 
admission, influence the risk of death associated with initial lactate 
levels and their course during therapy. Therefore it was our objective 
to compare the prognostic value of repeated lactate levels follow-
ing ICU admission in different categories of patients: (a) in septic 
patients versus patients with hemorrhage and other conditions gen-
erally associated with low-oxygen-transport and (b) in hemodynami-
cally stable versus unstable patients. 
MAterIALs AnD MetHoDs
study design and patients
In this prospective observational two-center study we enrolled all 
consecutive unscheduled patients admitted to the general ICU of 
two Dutch university-affiliated hospitals from May 2000 to April 
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2002. In patients who were readmitted during the study period only 
data of the first admission were used. This study was approved by 
the Medical Ethical Committees of both hospitals and informed con-
sent was waived.
Patient classification
In order to categorize patients according to their disease on admis-
sion to the ICU, we used pre-specified admission diagnoses derived 
from the APACHE III scoring system [10]. In this way, patients were 
classified as SEPSIS (all conditions associated with infectious dis-
ease), LT (hemorrhage and other conditions generally associated 
with low-oxygen-transport: low cardiac output, hemoglobin level or 
oxygen saturation) or OTHERS. The SEPSIS group comprised the 
following admission diagnoses: bacterial/viral pneumonia, aspira-
tion pneumonia, meningitis/encephalitis, sepsis, septic shock, intes-
tinal perforation and cholecystitis/cholangitis. The LT group com-
prised the following admission diagnoses: trauma with or without 
traumatic brain injury, gastro-intestinal bleeding, ruptured aortic 
aneurysm, cardiogenic shock, congestive heart failure, arrhythmia, 
acute myocardial infarction, pulmonary embolism with circulatory 
failure and cardiac arrest. Patients who could not be classified as 
either SEPSIS or LT, were classified as OTHERS because we were 
not able to determine whether these patients should be regarded 
as either SEPSIS or LT according to their disease on admission. As 
a result, the OTHERS group of admission diagnoses became very 
heterogeneous, including patients with completely different mecha-
nisms of hyperlactatemia (e.g. liver failure). Therefore, we focused 
on the SEPSIS and LT groups in the first analysis.
In a second analysis, patients were classified as hemodynamically 
stable (HD stable) or hemodynamically instable (HD instable), which 
was defined as a mean arterial pressure (MAP) < 60 mmHg and/
or the requirement of catecholamines (dopamine ≥ 3 mcg/kg/min, 
dobutamine any dose, norepinephrine any dose or epinephrine any 
dose) during the first 24 hours following ICU admission.
Data collection
For each patient base-line characteristics were recorded, including 
APACHE III [10] (for admission diagnosis), APACHE II [11] (for dis-
ease severity) and hospital and ICU length of stay and mortality. 
Predicted hospital death rate was calculated as e-3.517+(APACHE II)*0.146/
(1+e-3.517+(APACHE II)*0.146)[11]. Blood lactate levels were collected at 
the time of ICU admission (Lac T0) and after 12 and 24 hours follow-
ing admission. The reduction in lactate was calculated from 0 to 12 
hours (ΔLac T0-12) and from 12 to 24 hours (ΔLac T12-24). For lactate 
measurement, arterial blood samples were drawn from an arterial 
catheter and analyzed in the central hospital laboratory. Renal, res-
piratory and circulatory organ function were assessed on the basis 
of serum creatinine levels (creat), requirement of mechanical venti-
lation (MV) and a MAP<60 mmHg/ requirement of catecholamines 
(MAP/catechol).
treatment
Normalization of blood lactate levels was a treatment target in both 
hospitals. This was primarily done by increasing DO2 (fluids guided 
by fluid challenges, dobutamine or other inotropic agents, red blood 
cell transfusion, mechanical ventilation/ optimization of oxygena-
tion) and/or decreasing VO2 (e.g. analgosedation).
statistical analysis
Since blood lactate levels were not normally distributed, they were 
logarithmically transformed before analysis. To compare lactate lev-
els of survivors and non-survivors, the Student’s t-test was used. 
Mortality rates of patients with hyperlactatemia (≥ 2.5 mmol/l [5, 
7, 12]) were compared with those of patients with normal levels by 
using Â2 testing or Fisher’s exact test if necessary, based on sample 
size. To evaluate the prognostic values of lactate levels at T=0, 
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T=12 and T=24, receiver-operating-characteristic (ROC)-curves 
for in-hospital death (primary outcome measure) were constructed 
with corresponding area-under-the-ROC values (AUROC).  
In order to evaluate whether the prognostic values of lactate at ad-
mission (Lac T0) and of the reduction over time (ΔLac T0-12 and ΔLac 
T12-24) were dependent of admission diagnosis (SEPSIS or LT) or he-
modynamic status (HD stable or HD instable), multivariable Cox propor-
tional hazards models were constructed. These models excluded 
patients who died within 24 hours and those with missing lactate 
levels. Two multivariable analyses were constructed: (a) for the com-
parison between SEPSIS and LT and (b) for the comparison between 
HD stable and HD instable patients: 
(a) The following variables were entered in the model: Lac T0, 
ΔLac T0-12, ΔLac T12-24 and diagnosis (SEPSIS or LT) and 
subsequently, interaction terms were added (diagnosis∙Lac T0, 
diagnosis∙ΔLac T0-12 and diagnosis∙ΔLac T12-24). For this analysis, 
patients classified as OTHERS were excluded.
(b) The following variables were entered in the model: Lac T0, 
ΔLac T0-12, ΔLac T12-24 and HD status (HD stable or HD instable) and 
again, interaction terms were added (HD status∙Lac T0, HD 
status∙ΔLac T0-12 and HD status∙ΔLac T12-24).
To correct for the hemodynamic status within the SEPSIS vs. LT 
comparison, an additional subgroup analysis was performed: 
(c) The following variables were entered in this model: Lac T0, 
ΔLac T0-12, ΔLac T12-24, diagnosis, HD status, diagnosis∙Lac T0, 
diagnosis∙ΔLac T0-12 and diagnosis∙ΔLac T12-24. Subsequently, 
additional interaction terms were added: HD status∙diagnosis, 
HD status∙Lac T0, HD status∙ΔLac T0-12, HD status∙ΔLac T12-24, 
diagnosis∙Lac T0∙HD status, diagnosis∙ΔLac T0-12∙HD status and 
diagnosis∙ΔLac T12-24∙HD status. 
Values are provided as mean ± standard error of the mean (SE) 
(with exception of the baseline characteristics where the values 
represent mean ± standard deviation (SD)). Statistical analyses 
were performed using SPSS version 11.0.1/12.0.1 (SPSS, Inc., Chi-
cago, IL, USA).
resULts
Patient characteristics
421 patients were enrolled during the study period, of which 27 
patients were excluded because data were recorded during re-ad-
missions. The flow chart of patient enrollment is shown in figure 1. 
Table 1 provides an overview of the distribution of admission diag-
noses in the SEPSIS, LT and OTHERS groups. Table 2 describes the 
baseline characteristics and clinical variables of the total population 
and more specifically for the SEPSIS and LT groups and the HD stable 
and HD instable groups.
Figure 1. Flow-chart of enrolled patients.
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sePsIs vs. Lt
Sepsis compared with LT patients had a higher APACHE II score, 
longer length of ICU stay but an equal length of hospital stay and 
mortality (table 2). The proportion of patients with hyperlactatemia 
at admission was equal.
In the SEPSIS group, the mean lactate level was significantly higher 
in non-survivors than in survivors at T=12 and T=24, but not at 
admission (figure 2). In contrast, in the LT group, it was higher in 
non-survivors at admission and T=12, but not at T=24. When look-
ing at patients with normal or elevated levels, a similar difference 
between the SEPSIS 
and LT groups was 
found (figure 3a 
and 3b). In the SEP-
SIS group, mortality 
was not significantly 
higher in those with 
elevated levels at ad-
mission, but those 
with normalized levels after 24 hours did have a lower risk of dying. 
In the LT group, outcome was worse in patients with abnormal lev-
els directly at admission, whereas after 24 hours, mortality in those 
with abnormal levels was not higher anymore than in those with 
levels in the normal range. In the subgroup of LT patients with initial 
Group Admission diagnosis N Percentage 
of subtotal 
SEPSIS group Sepsis respiratory tract 64 46%
Sepsis urinary tract 9 6%
Abdominal sepsis 35 25%
Cholecystitis/ cholangitis 8 6%
Meningitis/ encephalitis 3 2%
Others 21 15%
Subtotal group
140 100%
LT group Trauma without traumatic brain injury 15 12%
Trauma with traumatic brain injury 13 11%
Ruptured abdominal aortic aneurysm 28 23%
Gastro-intestinal bleeding 35 29%
Arrhythmia 5 4%
Acute myocardial infarction 3 2%
Pulmonary embolism with circulatory failure 2 2%
Congestive heart failure 9 7%
Cardiogenic shock 4 3%
Cardiac arrest 9 7%
Subtotal group
123 100%
OTHERS group Non-infectious respiratory disease (e.g. COPD) 19 15%
Liver failure 1 1%
Pancreatitis 4 3%
Intestinal obstruction (non-surgical) 2 2%
GI surgery: obstruction 19 15%
GI surgery: Inflammatory bowel disease 4 3%
GI surgery: intestinal ischemia 3 2%
SAH/ intracerebral hemorrhage/ CVA 9 7%
Epileptic seizure 5 4%
Metabolic disease (e.g. diabetic ketoacidosis) 8 6%
Autointoxication 8 6%
Hematological disorder 7 5%
Renal insufficiency 13 10%
Others 29 22%
Subtotal group
131 100%
Total 394
Table 1. The groups classified on the basis of APACHE III admission diagnoses. 
Figure 2. Mean lactate 
levels in survivors (S) and 
non-survivors (NS) in 
SEPSIS and LT groups. 
Error bars represent ±1 
standard error of the 
mean. *p<0.05, ** 
p<0.01 for comparison 
between survivors and 
non-survivors at the dif-
ferent time points (T=0, 
T=12 and T=24 hours).
GI surgery = gastro-intestinal surgery, SAH = subarachnoid hemorrhage
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hyperlactatemia who succeeded to normalize lactate during 24 
hours of treatment, still 45% died compared to 36% in those who 
did not.
The accuracy to predict mortality also differed when focusing on the 
ROC curves. AUROC values increased from T=0 to T=24 in the 
SEPSIS group whereas they decreased in the LT group (figure 4). 
Multivariable analysis confirmed the impact of admission diagnosis 
on the ability of lactate levels to predict outcome: the prognostic 
values of Lac T0, ΔLac 0-12 and ΔLac 12-24 were significantly differ-
ent between SEPSIS and LT (p=0.043 for the interaction term). In 
the SEPSIS-group reductions in lactate level were associated with 
significantly lower mortali-
ty, whereas in the LT-group 
this was not the case (table 
3). 
To evaluate whether the 
LT group would be a val-
id comparison group for 
trauma patients only, we 
have separated out the 
23% trauma patients and 
compared these to the en-
tire LT group. Although the results are not significant, as expected 
due to the low number of patients (n=28), they trended towards 
the same direction as in the LT group. Similar to the LT group, 
mortality seemed to be higher in trauma patients with an abnormal 
(27%, 4/15) versus a normal lactate on admission (15%, 2/13). Also 
in agreement with the LT group, mortality in trauma patients who 
normalized their lactate within 24 hours (35%, 6/17) didn’t seem to 
be lower compared with those who failed to normalize lactate (0%, 
0/5).
Administered catecholamines could possibly confound lactate levels 
and their prognostic values. However, epinephrine, mostly associat-
ed with increased production of lactate, was hardly used (n=2) and 
Figure 3. A) Mortality rates of SEPSIS patients with high (≥ 2.5 mmol/l) or normal 
(<2.5 mmol/l) blood lactate levels at admission or after 24 hours of ICU therapy. 
B) Mortality rates of LT patients with high (≥ 2.5 mmol/l) or normal (<2.5 mmol/l) 
blood lactate levels at admission or after 24 hours of ICU therapy.
A B
Figure 4. Receiver operating 
characteristic (ROC) curves of 
lactate levels at the different 
time points to predict in-hospital 
death. The arrows depict the 
progression of the prognostic 
value of lactate during the first 
24 hours of ICU admission. 
The area-under-the-ROC value 
increased from T=0 to T=24 
in the SEPSIS group (T=0 0.52, 
p=0.73; T=12 0.62, p=0.049; 
T= 24 0.68, p=0.004) whereas 
it decreased in the LT group 
(T=0 0.71, p=0.002; T=12 
0.69, p=0.004; T=24 0.59, 
p=0.15).
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additional correction for catecholamine use in general (any infusion 
of norepinephrine, dopamine, dobutamine or epinephrine) did not 
affect the difference in prognostic value between the SEPSIS and LT 
groups (p=0.13 for the interaction term). 
When looking at organ function, we found that in the LT group re-
nal, respiratory and circulatory organ function were similar in non-
survivors and survivors at T=0 (creat 122 vs 106, p=0.26; MV 71% 
vs 59%, p=0.22; MAP/catechol 28% vs 37%, p=0.39). However, 
at T=24 LT non-survivors on average had more severe organ dys-
function (creat 141 vs 94, p<0.001; MV 70% vs 46%, p=0.030; 
MAP/catechol 49% vs 25%, p=0.017). 
On the other hand, in the SEPSIS group non-survivors had more 
severe renal and circulatory organ dysfunction at T=0 (creat 245 
vs 154, p=0.009; MV 39% vs 50%, p=0.27; MAP/catechol 55% vs 
29%, p=0.004), whereas at T=24 organ function was comparable 
(creat 172 vs 140, p=0.24, MV 75.8% vs 62.2%, p=0.200, MAP/
catechol 55% vs 42%, p=0.20). The use of renal replacement ther-
apy was similar at all times, both in the LT (T=0: 0 vs 0%, T=24: 3 
vs 0%, p=0.30) and in the SEPSIS groups (T=0: 5 vs 1%, p=0.21, 
T=24: 9 vs 8%, p=0.73).
Hemodynamic status
Patients in the HD instable group (n=204) had a higher APACHE II 
score, longer length of stay and a higher mortality than patients in 
the HD stable group (n=190)(table 2). The proportion of patients with 
hyperlactatemia at admission was higher in HD instable patients. Nev-
ertheless, multivariable analysis showed that the prognostic value of 
Lac T0, ΔLac 0-12 and ΔLac 12-24 was similar in HD instable and HD stable 
patients (p=0.43 for the interaction term). 
sepsis vs Lt according to hemodynamic status
The effect of SEPSIS or LT on the relationship between serial lactate 
levels and outcome persisted after subdivision by hemodynamic sta-
tus (Figure 5). This can be illustrated by the dichotomous analyses 
(table 4): both in the hemodynamically instable and stable patients 
of the SEPSIS group, mortality was equal in those with abnormal 
Table 3. Cox proportional hazard model: hazard ratios (95% CI) for in-hospital 
death for the lactate level at ICU admission (Lac T0) and the reduction from 0 to 
12 hours (ΔLac T0-12) and 12 to 24 hours (ΔLac T12-24).
Sepsis Low-TO2
Lac T0 2.72 (1.42-5.20) p=0.003 2.43 (1.14-5.16) p=0.021
ΔLac T0-12 0.34 (0.16-0.71) p=0.004 0.78 (0.36-1.67) p=0.52
ΔLac T12-24 0.24 (0.10-0.61) p=0.003 1.30 (0.48-3.49) p=0.61
Figure 5. Mean lactate levels in survivors (S) and non-survivors (NS) of the SEPSIS 
and LT groups according to hemodynamic status.
Because of logarithmic transformation, interpretation of the hazard ratios is as 
follows: in the SEPSIS group, each decrement specified as a 10% increase of the 
0 to 12 hours lactate ratio (ΔLac T0-12) causes a -10% (-16 to -3%) change of the 
mortality hazard. Each 10% increase of ΔLac T12-24 causes a -13% (-20 to -5%) 
change. In the LT group, the corresponding (non-significant) changes in mortality 
are -2% (-9 to +5%) for ΔLac T0-12 and +3% (-7 to +13%) for ΔLac T12-24. Each 10 
% reduction in Lac T0 causes a -10% (-16 to -4%) change of the mortality hazard 
in SEPSIS and -9% (-16 to -1%) in LT.
Error bars represent ±1 standard error of the mean. *p<0.05, **p<0.01 for 
comparison between survivors and non-survivors at the different time points (T=0, 
T=12 and T=24). Solid line = non-survivors. Dashed line = survivors.
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and normal levels at admission, but after 24 hours, mortality be-
came higher in patients with elevated levels. In the LT group, pa-
tients with high and normal levels after 24 hours had equal mortality 
rates, also irrespective of their hemodynamic status.
This could be confirmed in the Cox PH model, in which additional 
correction for hemodynamic status within the Sepsis-LT model did 
not change the found differences in prognostic value between SEP-
SIS and LT (p=0.16 for the interaction term). Similarly, when looking 
at ROC curve analysis, both in the hemodynamically instable and 
stable patients of the SEPSIS group, AUROC was lowest at admis-
sion and highest after 24 hours. In both hemodynamic subgroups 
of the LT group, AUROC was highest at admission and decreased 
over time (data not shown). Thus, the impact of admission diagno-
sis (SEPSIS or LT) on the prognostic value was really independent of 
the hemodynamic status.
DIsCUssIon
This study shows that a reduction in lactate concentration during 
the first 24 hours following ICU admission is associated with im-
proved outcome in septic patients, but not in patients presenting 
with hemorrhage or other conditions frequently associated with low-
oxygen-transport. 
Surprisingly, the lactate levels at admission, but not the reduction 
over time, predicted mortality in the LT group. This is illustrated by 
the high mortality (45%) in LT patients with initial hyperlactatemia 
despite the normalization of lactate levels during the first 24 hours. 
We hypothesize that the non-survivors, who had significantly higher 
admission lactate levels, experienced a more severe insult in the 
time before ICU admission that could have led to irreversible organ 
damage. During the first 24 hours in the ICU the conditions leading 
to increased lactate levels (e.g. tissue oxygen delivery-demand mis-
match) could have been resolved, leading to a reduction in lactate 
levels, but not to a recovery of tissue damage [13]. As a result, only 
the lactate levels at admission and not after 24 hours were related 
to patient survival.
 Such a phenomenon is probably best illustrated by the recovery 
from cardiac arrest, in which the extent of (neurological) organ 
damage determines prognosis [14], rather than the ability to re-
duce lactate levels in 24 hours following return of spontaneous cir-
culation [15, 16]. Possibly a likewise mechanism is present in other 
low-oxygen-transport conditions such as trauma and hemorrhage. 
Following hemorrhage control and restoration of circulation, severe 
and irreversible organ damage might already have occurred despite 
a normalization of lactate levels at a later stage. This explanation 
is supported by our observation that the LT non-survivors developed 
more severe organ dysfunction after 24 hours, while the mean lac-
tate concentration was equal to survivors at that time-point. 
In the SEPSIS group we found opposite results. Lactate levels in the 
SEPSIS non-survivors remained elevated over 24 hours, which is in 
agreement with previous studies [3, 17]. Several explanations exist 
for the hyperlactatemia in this group of patients other than impaired 
tissue oxygen delivery [18, 19]. First, cytokine-mediated uptake of 
glucose [20] or catecholamine-stimulated increased Na-K-pump 
activity [21] might have increased aerobic glycolysis. Second, pyru-
vate dehydrogenase dysfunction may have limited the conversion of 
pyruvate to acetyl co-enzyme A [22, 23] and last, microcirculatory 
derangement [24, 25] or mitochondrial dysfunction [26] may have 
hampered oxygen utilization at the tissue level. Based on our re-
Hemodynamically instable Hemodynamically stable
Lactate  
< 2.5
Lactate  
≥ 2.5
p- 
value
Lactate  
< 2.5
Lactate  
≥ 2.5
p- 
value
Sepsis T=0 31% (13/42) 35% (16/46) 0.70 28% (10/36) 14% (2/14) 0.32
T=24 24% (12/50) 46% (12/26) 0.049 18% (6/34) 75% (3/4) 0.035
LT T=0 14% (3/22) 48% (18/38) 0.008 17% (6/36) 30% (8/27) 0.22
T=24 38% (15/40) 39% (5/13) 0.95 21% (8/39) 40% (2/5) 0.32
Table 4. Mortality rates of SEPSIS and LT patients with normal and high blood 
lactate levels according to hemodynamic status.
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sults we can only conclude that if these processes can somehow be 
resolved within the first 24 hours of ICU admission, thereby lead-
ing to decreased lactate levels, patient survival in this group is im-
proved.
The different time course of lactate levels in the SEPSIS and LT non-
survivors could possibly be explained by differences in the etiology 
of hyperlactatemia, although mechanisms such as catecholamine 
stimulated Na-K-ATP-ase activation have been described in hemor-
rhage as well [27-29]. Another hypothesis could be that the SEPSIS 
patients suffered a less severe and more continuous insult from their 
disease compared to the LT patients. As a result organ damage and 
dysfunction might be more reversible and less related to patient 
survival. This is supported by our observation that the extent of or-
gan dysfunction in SEPSIS survivors and non-survivors became simi-
lar after 24 hours (i.e. survivors had similar organ dysfunction but 
somehow this was reversible), whereas the exact opposite happened 
in LT patients. Reversal of organ dysfunction in septic patients has 
been suggested to be part of a protective regulatory process, which 
induces a temporary hypometabolic state resembling hibernation 
that may protect the cells from dying and allow the possibility of 
functional recovery [30].
With regard to the patients’ hemodynamic status, we found that the 
prognostic value of hyperlactatemia was similar in hemodynami-
cally stable and instable patients, also within the SEPSIS and LT 
groups. This means that, regardless of hemodynamics, reduction or 
normalization of lactate was not associated with improved outcome 
in LT patients. This finding might be in contradiction with previous 
studies in trauma patients with occult hypoperfusion [5, 7], in which 
a long time to normalization was associated with a higher mortality. 
Besides potential variation in time prior to ICU admission, this dis-
crepancy could perhaps be explained by the higher mortality in our 
LT patients (29% versus 3-11% [5, 7]), possibly corresponding with 
more irreversible organ damage at admission. 
Our study has several limitations. First, the group classification 
might have changed during the 24 hours. For instance, a trauma 
patient with a hemorrhagic shock at admission could have devel-
oped ischemia-reperfusion damage or sepsis within 24 hours. How-
ever, for clinical relevance we were interested in the course of lac-
tate concentration in different categories of patients who can be 
easily identified immediately at admission. Although this classifica-
tion might have introduced some inaccuracy, it does resemble daily 
clinical practice where the prognosis needs to be estimated at the 
bedside as soon as patients are admitted. Second, we did not collect 
indices to examine anaerobic or aerobic etiology of hyperlactatemia 
(e.g. lactate to pyruvate ratio, liver function test, serum catecho-
lamine concentration or microcirculation imaging). We felt that it 
was beyond the scope of this study to speculate on the exact causes 
of hyperlactatemia in our patients. Third, we did not register any 
form of advanced hemodynamic monitoring, such as cardiac output 
or SvO2, nor measured oxygen transport. This might be considered 
a disadvantage because septic patients can be hypodynamic in the 
early phase [19] and trauma or aortic aneurysm surgery patients 
can be hyperdynamic in a later phase due to sepsis or ischaemia-
reperfusion. However, as mentioned before we categorized our pa-
tients according to their admission diagnosis, prior to invasive moni-
toring. In this way we tried to make an early classification based 
on underlying disease rather than on hemodynamic profile. Last, 
although treating clinicians generally aimed at normalization of lac-
tate levels by increasing DO2 and reducing VO2, we did not collect 
data on actual provided treatment. Different clinicians might have 
responded differently to patients with increased lactate levels, in 
ways we did not capture in our documentation. We don’t know in 
which way this might have influenced the study results. However, 
because the same trained intensivists were primarily responsible for 
the treatment of both SEPSIS and LT patients, it seems unlikely that 
the difference between SEPSIS and LT is systematically biased by a 
difference in compliance with resuscitation protocols. 
In conclusion, we found that lactate reduction during the first 24 
hours of ICU stay is associated with improved outcome only in septic 
patients, but not in patients with hemorrhage or other conditions 
generally associated with low-oxygen-transport, regardless of the 
hemodynamic status. Therefore, lactate-directed therapy might not 
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be as beneficial in this particular group of patients, or should be 
started in an earlier phase in the emergency department. 
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ABstrACt
objective: To evaluate whether the level and duration of increased 
blood lactate levels is associated with daily SOFA scores and organ 
subscores and to evaluate these associations during the early and 
late phase of ICU stay. 
Design: Retrospective observational study 
setting: Mixed ICU of a university hospital 
Patients: 134 heterogeneous ICU patients
Interventions: None
Measurements and main results: We calculated the area under the 
lactate-curve above 2.0 mmol/l (lactateAUC>2). Daily SOFA scores 
were collected during the first 28 days of ICU stay to calculate initial 
(day 1), maximal, total and mean scores. Daily lactateAUC>2 were 
related to both daily SOFA scores and organ subscores using mixed 
model ANOVA. This was also done separately during the early 
(<2.75 days) and late (>2.75 days) phase of ICU stay. 
Compared to normolactatemic patients (n=78), all median SOFA 
variables were higher in patients with hyperlactatemia (n=56)(initial 
SOFA: 9 (inter quartile range 4-12) vs 4 (2-7); max SOFA: 10 (5-13) 
vs 5 (2-9); total SOFA: 28 (10-70) vs 9 (3-41); mean SOFA: 7 (4-
10) vs 4 (2-6), all p<0.001). The overall relationship between daily 
lactateAUC>2 and daily SOFA was an increase of 0.62 SOFA-points 
per 1 day∙mmol/l of lactateAUC>2 (95% CI: 0.41-0.81, p<0.00001). 
During early ICU stay, the relationship between lactateAUC>2 and 
SOFA was 1.01 (95% CI: 0.53-1.50, p<0.0005), and during late 
ICU stay, this was reduced to 0.50 (95% CI: 0.28-0.72, p<0.0005). 
Respiratory (0.30, 0.22-0.38, p<0.001) and coagulation (0.13, 
0.09-0.18, p<0.001) subscores were most strongly associated with 
lactateAUC>2. 
Conclusion: Blood lactate levels were strongly related to the SOFA 
score. This relationship was stronger during the early phase of ICU 
stay, which provides additional indirect support for early resuscitation 
to prevent organ failure. The results confirm that hyperlactatemia 
can be considered as a warning signal for organ failure 
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IntroDUCtIon
Multiple organ failure (MOF), which can occur in many severe con-
ditions including trauma (1), sepsis(2), burns (3) and severe acute 
pancreatitis (4), is an important cause of morbidity and mortality. 
Blood lactate levels have been associated with the occurrence of 
organ failure using lesser-known organ failure scales (1, 5, 6). How-
ever, the relationship between lactate levels and the well validated 
Sequential Organ Failure Assessment (SOFA) score (7-11) has not 
yet been studied. Although lactate as a biomarker and SOFA as 
an organ dysfunction scale have different functions, an associa-
tion between the two might have clinical implications. Blood lac-
tate measurement may act as a real-time marker for the severity of 
organ failure, whereas calculating the SOFA score takes 24 hours. 
Potentially, this might improve therapy by adapting resuscitation to 
serial lactate measurements, which might prevent organ failure and 
eventually improve clinical outcome.
Because the SOFA score comprises scores from six different organ 
systems, it is also possible to evaluate the association of lactate with 
separate organ systems. It is unknown to which extent the cardio-
vascular and other SOFA subscores are related to lactate levels. 
The aim of our study was to evaluate whether the level and duration 
of increased blood lactate levels (represented by the area under the 
lactate-curve) is associated with daily SOFA scores and its sepa-
rate organ subscores and to evaluate whether these associations 
are time-dependent (early versus late phase of ICU stay). We hy-
pothesize that increased lactate levels will be associated with higher 
SOFA scores and that this association will be stronger in the early 
phase than in the late phase.
PAtIents AnD MetHoDs
Design
Retrospective observational study in the mixed ICU of a tertiary care 
university hospital.
Patients
Consecutive ICU patients with available lactate measurements who 
were admitted in January and February 2005 were eligible for study 
participation. Patients admitted with acute or chronic liver failure, 
defined as the presence of any kind of liver disease and a pro-
thrombin time >15 seconds, were excluded. The study was exempt 
from review and approval of the Local Ethics Committee by the 
Dutch Central Committee on research involving Human Subjects 
(CCMO), which waived the need for informed consent. 
Data collection
Data from the first 28 days spent in the ICU were collected retro-
spectively from the electronic patient data monitoring system and 
hospital administration database. We collected demographic infor-
mation, serial blood lactate levels and relevant variables for calcu-
lation of daily SOFA scores. The Glasgow Coma Scale collected in 
sedated patients was the assumed score without sedation. Mortality 
and length of stay were recorded. 28-day mortality was the primary 
outcome measure to evaluate survival.
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soFA sCores
SOFA scores were calculated every day that a patient was staying in 
the ICU during the observation period of maximal 28 days. To cal-
culate the SOFA score, the worst value for each parameter in each 
24-hour period was used. If variables that were required to calculate 
the SOFA score were missing, they were regarded as normal until 
the first real variable was available. For any missing value thereaf-
ter, the last known real value was used. The following SOFA-derived 
variables were used (8):
1.) Initial SOFA: the SOFA score on the first day of ICU 
admission (from time of admission to 24 hours following 
admission, e.g., from 16:00 to 16:00 hours the next day). 
2.) Max SOFA: the highest daily SOFA score during the 
observation period (maximal 28 days following ICU 
admission).
3.) Total SOFA: the sum of all daily SOFA scores during the 
observation period
4.) Mean SOFA: the total SOFA score divided by the number of 
days spent on the ICU during the observation period 
MOF was defined as a score of at least 3 on two or more different 
individual organs of the SOFA score on any day during the observa-
tion period (12). 
Lactate
Lactate levels were measured in arterial blood using point-of-care 
blood gas analyzers (ABL 700, Radiometer Copenhagen, Denmark, 
upper normal limit 2.0 mmol/l). Lactate buffer solutions for renal 
replacement therapy and continuous epinephrine infusion were not 
used during the study period. 
The area under the curve of lactate levels above the threshold of 2.0 
mmol/l was calculated daily using the following formula:
lactateAUC>2 = (§ ((time 2 – time 1) ∙ 0.5 ∙ (lactate level time 1 + 
lactate level time 2))) – (§ ((time 2 – time 1) · 2.0 mmol/l)).
Time 1= time of lactate level > 2.0 mmol/l or calculated time that 
the lactate-time curve between two subsequent lactate measure-
ments crosses the threshold of 2.0 mmol/l
Time 2= time of next lactate level > 2.0 mmol/l or next calculated 
time that the lactate-time curve crosses the threshold of 2.0 mmol/l
(Time periods between lactate measurements were calculated in 
minutes. Subsequently, lactateAUC>2 was converted into days∙mmol/l)
Figure 1 clarifies the formula. LactateAUC>2 was zero if lactate levels 
did not exceed the threshold of 2.0 mmol/l. LactateAUC>2 was ex-
pressed as the value on the day of admission (initial lactateAUC>2), 
the maximum of daily calculations of lactateAUC>2 (max lactateAUC>2), 
the sum of all daily calculations (total lactateAUC>2) and the mean of 
all daily calculations (mean lactateAUC>2).
Figure 1. Example of calculation of the daily area under the curve of lactate levels 
above 2.0 mmol/l (lactateAUC>2)
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statistics
Values are described as 
medians with interquartile 
ranges (IQR). Kruskal-Wal-
lis tests were performed 
to compare survivors and 
non-survivors and those 
with and without hyper-
lactatemia. To evaluate 
the prognostic value of 
SOFA and lactateAUC>2, 
univariate Cox propor-
tional hazards models 
were performed. Daily 
SOFA scores were related 
to daily lactateAUC>2 using 
mixed model ANOVA. In 
this way, between-patient 
and within-patient varia-
tions (e.g., within a single 
patient, the score on day 
4 is correlated to the score 
on day 5, on day 6, etc.) 
of daily SOFA scores were 
taken into account. The 
day-to-day correlation 
of within-patients SOFA 
scores was assumed to 
have a first-order autore-
gressive structure. The effects of daily values of lactateAUC>2 on daily 
SOFA were also estimated separately during the early and late phase 
of ICU stay; because consensus time definitions are unavailable, we 
arbitrarily defined the early phase of ICU stay as before the median 
length of ICU stay (= 2.75 days). Finally, the daily individual SOFA 
organ scores were related to daily lactateAUC>2. P < 0.05 was con-
sidered statistically significant. Data were analysed using the SPSS/
PC program (version 10.1.0/12.0.1, SPSS, Chicago, Ill, USA).
resULts 
During the study period 205 patients were admitted to the ICU. 
11 patients were excluded due to liver failure, and lactate was not 
measured within the first 24 hours of ICU admission in another 60 
patients. The baseline and clinical characteristics of the remain-
ing 134 patients are displayed in table 1. In total, 2627 lactate 
levels were available, which corresponded to an average of 3 
measurements per patient per day. Median lactate at admission 
was 1.3 mmol/l (IQR 0.8-2.3), with a range between 0.5 and 19.0 
mmol/l. Twenty-nine percent of the patients had hyperlactatemia 
Characteristic Value: 
median (IQR)
Number of patients 134
Age (years) 61 (46-69)
Sex (male:female) 65%:35%
APACHE II 19 (14-25)
28-day mortality 22%
ICU mortality 16%
In-hospital mortality 31%
ICU LOS (days) 3 (1-8)
Hospital LOS (days) 14 (6-28)
Referring ward:
- ED 34%
- Surgical ward/OT 34%
- Medical ward 15%
- Neurological ward 5%
- Other 13%
Admission diagnosis:
- Sepsis/ severe 
sepsis/ septic shock*
36%
- Trauma 16%
- SAH/ intracerebral 
hemorrhage/ stroke/ 
neurosurgery
13%
- Ruptured aortic 
aneurysm
8%
- Oesophagectomy 7%
- Heart failure 4%
- Pulmonary embolus 3%
- Intoxication 3%
- Cardiac surgery 0%
- Others 10%
Vasopressor/ inotropic 
support day 1
34%
Lactate at admission 
(mmol/l)
1.3 (0.8-2.3)
Table 1. Baseline and clinical 
characteristics
LOS=length of stay, 
ED=emergency depart-
ment, OT=operation theatre. 
IQR=interquartile range. 
*Sepsis, severe sepsis and septic 
shock classification as defined 
by (31).
Survivors (n=105) Non-survivors (n=29)
Initial SOFA 5 (2-8) 9 (7-12)*
Max SOFA 5 (3-9) 9 (7-13)*
Total SOFA 13 (4-52) 26 (9-67)#
Mean SOFA 4 (2-6) 8 (6-11)*
Initial lactateauc>2 0 (0-0.4) 0 (0-2.0)*
Max lactateauc>2 0 (0-0.7) 0.5 (0-2.2)*
Total lactateauc>2 0 (0-0.8) 0.5 (0-2.7)*
Mean lactateauc>2 0 (0-0.2) 0.2 (0-1.0)*
Table 2. SOFA and lactate in 28-day survivors and non-survivors
Median values (interquartile range) of SOFA and area under the lactate-curve 
above 2.0 mmol/l (lactateAUC>2) in 28-day survivors and non-survivors. Values are 
provided for the initial (day 1), maximal, total and mean variables of SOFA and 
lactateAUC>2. *p<0.05, #p=0.07
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(>2.0 mmol/l) at admission, 34% had hyperlactatemia within the 
first 24 hours and 42% at any time during their ICU stay. 
soFA and lactate in survivors and non-survivors
Generally, SOFA and lactateAUC>2 were higher in 28-day non- 
survivors than in survivors (table 2). Initial, max and mean (but not 
total) values of SOFA and lactateAUC>2 significantly predicted 28-day 
mortality (table 3). 
Hyperlactatemia and soFA
Generally, the risk of MOF or death increased when lactate levels 
were higher for a longer period (figure 2). In patients with hyperlac-
tatemia (lactateAUC>2 >0, n=56) compared with normolactatemic 
patients (lactateAUC>2 =0, n=78), all SOFA-derived variables were 
significantly higher (figure 3). 
The daily lactateAUC>2 was significantly associated with the daily 
SOFA score. 
The overall relationship between the two variables was an increase 
of 0.62 SOFA-points per 1 day∙mmol/l of lactateAUC>2 (95% CI: 0.41-
Variable Hazard ratio 95% CI P-value
Initial SOFA 1.14 1.05-1.24 0.002
Max SOFA 1.10 1.02-1.18 0.011
Total SOFA 1.00 0.99-1.00 0.70
Mean SOFA 1.24 1.13-1.24 <0.001
Initial lactateAUC>2 1.39 1.19-1.63 0.001
Max lactateAUC>2 1.33 1.14-1.55 0.002
Total lactateAUC>2 1.07 0.99-1.17 0.14
Mean lactateAUC>2 1.57 1.33-1.84 <0.001
Table 3. Hazard ratios of SOFA and lactate for prediction of 28-day mortality
Figure 2. Multiple organ failure (MOF) and 28-day mortality according to the ini-
tial (A and B), the maximal (C and D) and the total (E and F) daily area under the 
curve of lactate levels above 2.0 mmol/l. 
A B
C D
E F
Results of univariate Cox proportional hazard models. The hazard ratios of initial 
(day 1), maximal, total and mean SOFA and lactateAUC>2 for 28-day mortality are 
shown. For instance, this can be interpreted as a 57% increased hazard of death 
for every increase of 1 day∙mmol/l in mean lactateAUC>2.
Number of patients: initial lactateAUC>2 (A and B) 0: n=88, 0-1: n=22, 1-2: n=10, 
2-3: n=5, >3: n=9. Max lactateAUC>2 (C and D) 0: n=78, 0-1: n=22, 1-2: n=13, 
2-3: n=11, >3: n=10. Total lactateAUC>2 (E and F) 0: n=78, 0-1: n=21, 1-2: 
n=9, 2-3: n=8, >3: n=18.
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0.81, p<0.00001). During the early phase of ICU stay (before a 
median of 2.75 days), the relationship between lactateAUC>2 and 
SOFA was 1.01 SOFA points per 1 day∙mmol/l of lactateAUC>2. (95% 
CI: 0.53-1.50, p<0.0005). During the later ICU stay (>2.75 days), 
this was 0.50 SOFA points per 1 day∙mmol/l of lactateAUC>2 (95% CI: 
0.28-0.72, p<0.0005). 
Hyperlactatemia and individual soFA organ scores
Comparing patients with and without hyperlactatemia, the initial, 
max, total and mean scores of almost all individual organ systems 
were higher in patients with hyperlactatemia (table 4). However, 
lactate was only significantly associated with respiratory and coagu-
A B
C D
Figure 3. Initial (A), maximal (B), total (C) and mean (D) SOFA for patients with 
hyperlactatemia (lactateAUC>2 >0, n=56) compared to the patients without 
(lactateAUC>2 =0, n=78). 
Table 4. SOFA organ subscores in normo- and hyperlactatemic patients
Max subscores lactateAUC>2 =0 lactateAUC>2 >0
Max SOFA respiratory 2 (0-3) 3 (2-4)*
Max SOFA coagulation 0 (0-1) 1 (0-2)*
Max SOFA cardiovascular 1 (0-3) 2 (1-4)*
Max SOFA CNS 1 (0-3) 3 (0-4)*
Max SOFA renal 0 (0-0) 0 (0-2)*
Max SOFA liver 0 (0-0) 0 (0-1)*
Total subscores lactateAUC>2 =0 lactateAUC>2 >0
Total SOFA respiratory 3.5 (0-17) 9.5 (3-23)*
Total SOFA coagulation 0 (0-1) 2 (0-5)*
Total SOFA cardiovascular 1.5 (0-6) 4 (1-13)*
Total SOFA CNS 1 (0-8) 7.5 (0-28)*
Total SOFA renal 0 (0-0) 0 (0-8)*
Total SOFA liver 0 (0-0) 0 (0-2)*
Mean subscores lactateAUC>2 =0 lactateAUC>2 >0
Mean SOFA respiratory 1.9 (0-2.3) 2.0 (1.3-2.6)*
Mean SOFA coagulation 0 (0-0.5) 0.5 (0-1.1)*
Mean SOFA cardiovascular 0.8 (0-1.1) 1.0 (0.5-2)*
Mean SOFA CNS 0.5 (0-2) 1.1 (0-2.8)
Mean SOFA renal 0 (0-0) 0 (0-2)*
Mean SOFA liver 0 (0-0) 0 (0-0.3)*
Initial subscores lactateAUC>2 =0 lactateAUC>2 >0
Initial SOFA respiratory 2 (0-3) 2 (1-4)*
Initial SOFA coagulation 0 (0-1) 1 (0-2)*
Initial SOFA cardiovascular 1 (0-2) 1 (1-4)*
Initial SOFA CNS 0 (0-2) 1 (0-4)
Initial SOFA renal 0 (0-0) 0 (0-2)*
Initial SOFA liver 0 (0-0) 0 (0-0)
A
B
C
D
Arrow bar represents the interquartile range.
Initial (A), maximal (B), total (C) and mean (D) values of the individual SOFA 
organ subscores for patients with hyperlactatemia (lactateAUC>2 >0, n=56) 
compared to the patients without (lactateAUC>2 >0, n=78), * = p<0.05
- 146 -
Chapter 6
6
- 147 -
O
bs
er
va
tio
na
l s
tu
di
es
 o
n 
th
e 
pr
og
no
st
ic
 v
al
ue
 o
f b
lo
od
 la
ct
at
e 
le
ve
ls
lation systems during overall ICU admission when specifically look-
ing at the effect of increases in lactateAUC>2 on different organs in 
mixed model analysis (table 5). In the early phase of ICU admission, 
increases in lactate levels were also associated with cardiovascular 
and renal dysfunction, but this association disappeared during the 
late phase.
DIsCUssIon
We found a clear association between lactate and SOFA, which was 
stronger in the early phase of ICU admission as compared to the 
late phase. This provides additional indirect support for the impor-
tance of early resuscitation in the prevention of organ failure (13-
17). Possibly, serial lactate measurements may guide the process of 
optimizing oxygen delivery in this early phase (http://www.clinicaltri-
als.gov/ct/show/NCT00270673?order=1).
When looking at the individual organ systems, the cardiovascu-
lar subscore was not strongly associated with lactate levels (table 
5). This emphasizes the phenomenon of occult hypoperfusion in 
which hypotension is not a necessary characteristic for the presence 
of raised blood lactate levels (18-20). In addition, many aerobic 
mechanisms of hyperlactatemia, not related to tissue hypoxia, have 
been described in critically ill patients (21). However, despite the 
weak overall association of the cardiovascular system with lactate, 
there was a significant and clinically relevant association in the early 
phase, but this later disappeared (table 5). Apparently, the link be-
tween the severity of the initial insult, cardiovascular collapse and a 
rise in lactate levels is stronger in the early phase.
Respiratory and coagulation subscores were most strongly associat-
ed with lactate (table 5). An increased SOFArespiratory score often 
indicates the presence of acute lung injury or ARDS, which directly 
influences severity of disease and outcome (22). The lung has been 
described as an important source of lactate (23), probably reflect-
ing metabolic adaptations in response to inflammatory mediators 
rather than actual tissue hypoxia (24). SOFAcoagulation is a more 
indirect marker of critical illness: a link exists from thrombocytope-
nia via disseminated intravascular coagulation to hyperlactatemia 
and unfavourable outcomes (25). Similar to the platelet count, lac-
tate might possibly act as a general biomarker of critical illness (21, 
26). Because liver dysfunction can lead to hyperlactatemia (27, 28), 
it was remarkable that the liver subscore was not related to lac-
tate. Probably, the number of patients with liver dysfunction was too 
small for a statistically significant association because we excluded 
patients with acute or chronic liver failure and because liver failure 
is less prevalent compared to other organ failure in critically ill pa-
tients (1). 
Finally, our data reconfirm the prognostic value of SOFA and lactate 
for mortality (18, 29, 30). Only total SOFA and total lactateAUC>2 
did not predict 28-day mortality (table 3): it is difficult to establish a 
relationship between total values and survival in patients who died 
early because they could not accumulate many SOFA points or a 
high lactateAUC>2, whereas they were the most severely ill (8). 
Our study has limitations. First, although we focussed on individu-
al organs by evaluating SOFA subscores, this observational study 
effect 
overall
p-value 
overall
effect 
early 
p-value 
early 
effect 
late 
p-value 
late 
SOFA respiratory 0.30 <0.001 0.27 0.001 0.34 <0.001
SOFA coagulation 0.13 <0.001 0.08 0.12 0.12 <0.001
SOFA cardiovascular 0.09 0.053 0.22 0.033 0.03 0.60
SOFA CNS 0.07 0.14 0.20 0.065 0.03 0.54
SOFA renal 0.04 0.29 0.20 0.017 -0.03 0.95
SOFA liver 0.02 0.21 0.02 0.61 0.04 0.80
Table 5. Relationship between lactate and SOFA organ subscores
Effects of an increase of 1 day∙mmol/l in daily lactateAUC>2 on the daily differ-
ent SOFA organ subscores. The effects are shown for overall ICU stay and then 
separated for the early (<2.75 days) and late (>2.75 days) phase of ICU stay. For 
instance, an increase in lactate concentration from 2.0 mmol/l to 3.0 mmol/l dur-
ing a time period of a day was associated with a 0.30 increase in the respiratory 
SOFA score per day. This was 0.27 early in the ICU stay and 0.34 late in the ICU 
stay. Statistics: mixed model ANOVA.
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does not allow speculation on the cause of the link between hyper-
lactatemia and organ dysfunction. Second, this was a retrospec-
tive observational study, which does not allow drawing of defini-
tive conclusions; prospective validation of our findings is required. 
We did not conduct a prospective trial because this would inter-
fere with an ongoing randomized controlled trial on the efficacy of 
early lactate-directed therapy (http://www.clinicaltrials.gov/ct/show/
NCT00270673?order=1). Third, 60 patients were excluded due to 
unavailability of lactate within the first 24 hours. 
The ICU consisted of three different units to which patients were 
randomly admitted. In 2 of 3 units, lactate measurement was au-
tomatically incorporated in routine blood gas analysis. In the other 
unit, lactate measurement was performed on clinical indication. 55 
of 60 excluded patients without available lactate levels were admit-
ted to the unit where lactate was measured on clinical indication. 
However, the random admission of patients to one of the units guar-
anteed that exclusion because of missing lactate levels took place in 
unselected patients. This prevented selection bias. 
ConCLUsIon
The present study shows that both the duration and level of hyper-
lactatemia estimate the risk of organ failure. This risk was greater 
early in the ICU stay, which provides additional indirect support for 
the concept of early-goal directed therapy. Of all individual SOFA 
organ systems, respiratory and coagulation subscores were most 
strongly associated with lactate. Further research is warranted to 
elucidate the contribution of individual organs in the etiology of hy-
perlactatemia and to study whether early blood lactate level-guided 
resuscitation can actually prevent organ dysfunction.
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ABstrACt
rationale: It is unknown whether lactate monitoring aimed to de-
crease levels during initial treatment in critically ill patients improves 
outcome. 
objective: To assess the effect of lactate monitoring and resuscita-
tion directed at decreasing lactate levels in ICU patients admitted 
with a lactate level of ≥ 3.0 mEq/l.
Methods: Patients were randomly allocated to two groups. In the 
lactate group, treatment was guided by lactate levels with the objec-
tive to decrease lactate by ≥ 20% per two hours for the initial eight 
hours of ICU stay. In the control group, the treatment team had no 
knowledge of lactate levels (except for the admission value) during 
this period. The primary outcome measure was hospital mortality. 
Measurements and main results: The lactate group received more 
fluids and vasodilators. However, there were no significant differ-
ences in lactate levels between the groups. In the intention-to-treat 
population (348 patients), hospital mortality in the control group 
was 43.5% (77/177) compared with 33.9% (58/171) in the lactate 
group (p=0.067). When adjusted for predefined risk factors, hos-
pital mortality was lower in the lactate group (hazard ratio 0.61, 
95%CI 0.43-0.87, p=0.006). In the lactate group, SOFA scores 
were lower between 9 and 72 hours, inotropes could be stopped 
earlier, patients could be weaned from mechanical ventilation and 
discharged from the ICU earlier.
Conclusions: In patients with hyperlactatemia on ICU admission, 
lactate monitoring significantly reduced hospital mortality when ad-
justing for predefined risk factors. As this was consistent with im-
portant secondary endpoints, this study suggests that initial lactate 
monitoring has clinical benefit.
trial registration: ClinicalTrials.gov NCT00270673
IntroDUCtIon 
Increased blood lactate levels have been associated with significant 
morbidity and mortality ever since its first description in 1843 by 
Scherer (1). Many studies have emphasized the prognostic impor-
tance of either a single lactate level (2), or limited lactate reduction 
during treatment (3-5). Interestingly the prognostic value of lactate 
levels seems to be independent from the underlying critical illness 
(6) or the presence of shock or organ failure (7). 
Despite this strong and already long lasting predictive power of lac-
tate levels, little evidence exists on what interventions would benefit 
patients with increased lactate levels or a failure to reduce lactate 
(8). Earlier studies have shown that improving lactate metabolism 
by the administration of dichloroacetate decreases lactate levels but 
does not result in improved outcome in critically ill patients (9, 10). 
This could indicate that the detrimental outcome associated with 
increased lactate levels or delayed reduction is more likely related to 
the underlying cause than to the hyperlactatemia itself. 
Both experimental (11) and clinical studies (12, 13) have empha-
sized tissue hypoxia, characterized by supply dependent oxygen con-
sumption, as a cause of increased lactate levels. These findings 
would support therapy aimed at improving the balance between the 
demand for oxygen by the tissues and the delivery of oxygen to the 
tissues, by increasing oxygen delivery and/or decreasing oxygen de-
mand, in patients with increased lactate levels or a failure to reduce 
lactate. However, as other processes, not related to anaerobic me-
tabolism, can also result in increased blood lactate levels (14, 15), 
the efficacy of the latter approach could be limited. In the literature 
the efficacy of therapy aimed at decreasing lactate levels is only 
indirectly supported by observational studies (16-18) and studies 
evaluating goal-directed therapy aimed at optimizing oxygen de-
livery (19, 20). The landmark study in the latter respect by Rivers 
et al. showed that early goal-directed therapy, aimed at improving 
hemodynamics and oxygen delivery, improved outcome in patients 
with severe sepsis and increased lactate levels (19). Only one ran-
domized controlled single-center study has specifically studied the 
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effects of a resuscitation strategy aimed at normalizing lactate levels 
(21). Although this study showed a decrease in morbidity associ-
ated with this therapeutic approach, the findings cannot easily be 
extrapolated to the general intensive care population, as only post-
cardiac surgery patients were included. 
Therefore, the primary objective of this multicenter study was to test 
whether patients with elevated lactate levels (≥ 3.0 mEq/l) on ICU 
admission would benefit from serial lactate monitoring, aimed to re-
duce these levels by 20% per two hours, when compared to patients 
in whom serial lactate monitoring was not available. Secondary ob-
jectives were the effects of lactate monitoring on the development 
of organ failure, the duration of mechanical ventilation, the use of 
inotropes, vasopressors and renal replacement therapy and finally 
the length of ICU stay.
Some of the results of this study have been previously reported in 
the form of an abstract (22).
MetHoDs
study population
Patients were recruited from four Dutch mixed ICUs (one university 
hospital and three university-affiliated hospitals) between February 
2006 and March 2008. All consecutive patients with a blood lac-
tate level at or above 3.0 mEq/l upon ICU admission were eligible 
for inclusion. We excluded patients with liver failure (prothrombin 
time >15 seconds or INR equal or higher than 1.5 and any he-
patic encephalopathy (23)), following liver surgery, age < 18 years, 
a contraindication for central venous catheterization, epileptic sei-
zures (“grand-mal”, shortly before or during admission), an evident 
aerobic cause of hyperlactatemia (at the discretion of the treating 
physician) or a do-not-resuscitate status.
 
study design
This was a multi-center, open-label randomized controlled study, 
conducted under supervision of an independent Data Safety Moni-
toring Board (DSMB). The Ethics Committees of all participating 
centers approved the study protocol. Because of the emergency na-
ture and severity of disease in the target population, patients were 
enrolled under deferred consent: study procedures were temporarily 
allowed without consent and, as soon as possible, written consent 
from the patient or legal representative was obtained. The Dutch 
central committee on research involving human subjects approved 
the use of all data if the research procedures were finished or if the 
patient had died before consent could be obtained (24).
The start of the study was defined as the time of the first avail-
able lactate level immediately following ICU admission. For the next 
eight hours (treatment period), patients were randomly allocated to 
either treatment aimed to decrease lactate levels by at least 20% 
per two hours or to standard therapy where the treatment team 
was blinded for the results of lactate level measurements (except 
for the admission value). Thereafter patients were followed-up until 
discharge from the hospital or death whichever came first (obser-
vation period). The randomization, using a block size of eight, was 
stratified according to participating center and the presence or ab-
sence of sepsis as defined by standard criteria (25). Randomization 
was done with the use of opaque, sealed envelopes. The statistician 
of the DSMB generated the random allocation sequence with the 
use of a computer program. Physicians enrolled the patients and 
opened the envelope with the lowest available registration number 
within the appropriate stratum. By immediately filling out name and 
date on the randomization form the connection between the patient 
and the outcome of the randomization was safeguarded. Physicians 
were unaware of the randomization block size.
Treatment assignment was not recorded in the medical chart or 
electronic patient data monitoring system and clinicians on general 
wards, who cared for the patients following ICU discharge, were not 
aware of the treatment assignment.
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treatment
Patients were treated according to their randomization group by 
qualified intensivists available 7x24h in a closed format setting. 
In both groups the treating clinicians, and not the (principle) 
investigator(s), were primarily responsible for the treatment of the 
included patients. Duration of the eight-hours treatment period was 
Figure 1A. Treatment algorithm control group and lactate group
Figure 1B. Additional treatment algorithm lactate group
The goal for CVP was 12-15 mmHg in mechanically ventilated patients. Besides 
the static CVP goals, CVP was used as a dynamic safety limit during fluid chal-
lenges (27). Both crystalloids and colloids could be used at the discretion of 
the clinician. Albumin was not a standard resuscitation fluid in the participating 
centers. The goal for hemoglobin was 10 g/dl in patients with cardiac ischemia. 
(Hemoglobin 7.0 g/dL = 4.3 mmol/L, 10 g/dL = 6.2 mmol/L)
If the lactate level became ≤ 2,0 mEq/l, a further decrease was no longer re-
quired.
Fluid responsiveness was assessed by a fluid challenge of 200 mL crystalloids or 
colloids. The goal was an increase in blood pressure, ScvO2 or stroke volume, or 
a decrease in heart rate. CVP was used as a dynamic safety limit (27): if CVP in-
creased ≤ 2 mmHg, fluid administration was continued, if CVP increased > 2 and 
≤ 5 mmHg, the fluid challenge was repeated after waiting for 10 minutes, if CVP 
increased ≥ 5 mmHg, fluid administration was stopped. Before administration of 
vasodilators, fluid responsiveness was assessed and fluids were infused if neces-
sary. The recommended dose for nitroglycerin was 2 mg in ½ hour followed by 2 
mg per hour. Hemoglobin 7.0 g/dL = 4.3 mmol/L , 10 g/dl = 6.2 mmol/L,
NTG=nitroglycerine, RBCs= red blood cell transfusions
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based on the study of Polonen et al (21). Thereafter both groups 
received standard treatment during which lactate levels could be 
obtained in all patients at the discretion of the treating physician. 
In the control group, hemodynamic support was aimed at standard 
resuscitation endpoints, adapted from recently published guidelines 
(26) (figure 1a): heart rate less than 100 b/min, mean arterial pres-
sure (MAP) at or above 60 mmHg, central venous pressure (CVP) 
8-12 mmHg  (12-15 in mechanically ventilated patients) with the 
use of CVP as a dynamic safety limit during fluid challenges (27), 
urinary output more than 0.5 ml/kg.hr, arterial oxygen saturation 
(SaO2) at or above 92% and hemoglobin level at or above 7.0 g/dL 
(at or above 10.0 g/dL in case of cardiac ischemia) (28). The use of 
central venous oxygen saturation (ScvO2) and clinical assessment of 
peripheral perfusion (e.g. by touching the skin or measuring capil-
lary refill time (29)) was allowed at the discretion of the attending 
clinician. Most important, in the control group lactate levels were 
not available for the treatment team and patient during the treat-
ment period. 
In the lactate group, blood lactate levels were measured every two 
hours. The therapeutic endpoints were identical to those in the con-
trol group (Figure 1a). However, in addition, the therapeutic inter-
ventions had to result in a decrease in the lactate level of at least 
20% every two hours (cut-off level based on findings of two studies 
(3, 30)). This endpoint was to be achieved by a resuscitation strat-
egy as outlined in figure 1b. Central venous hemoglobin oxygen sat-
uration (ScvO2) was measured continuously with a fiberoptic probe 
(CeVOX ®, Pulsion Medical Systems AG, Munich, Germany), which 
was inserted through a lumen of the central venous catheter. The 
central venous oxygenation parameter was used to balance oxygen 
delivery with demand as suggested by Pinsky and Vincent (31). This 
probe was removed at the end of the treatment period. When ScvO2 
was at or above 70%, but lactate levels did not decrease by at least 
20% during a two-hour time interval, vasodilator therapy was started 
with the goal to improve microvascular perfusion (32)(Figure 1b). 
Before the start of a vasodilator, fluid responsiveness was assessed 
and fluids were administered when needed. 
Data collection
Biochemical and clinical variables required for calculation of 
APACHE II and SOFA scores were collected at 0, 8, 24, 48, and 72 
hours after the start of the study. APACHE II and SOFA scores were 
calculated in a way to record baseline information and to assess 
outcome following an eight-hour intervention (19).  Blood lactate 
levels, CVP, heart rate, MAP and urine output were recorded at 0, 
2, 4, 6, 8, 24, 48, and 72 hours. ScvO2 levels were only recorded 
during the treatment period. Lactate levels were measured in arte-
rial blood (but capillary or venous blood was also allowed) using 
the hospital’s central laboratory, a blood gas analyzer (ABL 700, 
Radiometer Copenhagen, Denmark) or a hand-held lactate ana-
lyzer (Accutrend ®, Roche Diagnostics, Mannheim, Germany) (33). 
In the lactate group, lactate levels were measured on-site to fa-
cilitate immediate lactate-guided treatment. In the control group, 
blood samples for lactate measurements were sent to the laboratory 
where it was coded and measured but not reported to the treat-
ment team and not recorded in the patient records. All samples 
where transported and analyzed immediately to prevent erroneous 
lactate elevation by in-vitro glycolysis. The use of fluids, inotropes, 
vasopressors, vasodilators and blood products was recorded every 
two-hours during the treatment period and subsequently from 9 to 
24, 25 to 48 and 49 to 72 hours. The use of additional therapy and 
therapeutic interventions (e.g. antibiotics, corticosteroids, surgery) 
was recorded from 0 to 8, 9 to 24, 25 to 48 and 49 to 72 hours. 
When patients were discharged before 72 hours, vital signs, labo-
ratory values and administered therapy were no longer recorded. 
The duration of mechanical ventilation (invasive and non-invasive), 
renal replacement therapy (all techniques) and use of vasopressors 
and inotropes use was registered until 28 days following start of the 
study. Survival was captured until hospital discharge. 
All sites were monitored for data quality by a team consisting of the 
principal investigator (TJ) and three research nurses (WM, WintV, 
CB). 
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statistical analysis
In-hospital mortality was the primary endpoint. Secondary prede-
fined endpoints were ICU and day-28 mortality, resuscitation end-
points, administered treatment, APACHE II and SOFA scores, dura-
tion of mechanical ventilation, use of renal replacement therapy, 
use of vasopressors and inotropes and length of ICU stay. 
Based on a retrospective observational pilot study (n= 931, unpub-
lished data) that we performed prior to this study, we estimated an 
in-hospital mortality rate for the control group of 42%. In order to 
detect a 15% absolute reduction in hospital mortality, similar to the 
study by Rivers et al. (19), with a two-sided alpha of 0.05, a power 
of 80%, and to allow for a 20 patient dropout, we calculated that a 
sample-size of 350 patients was required. 
An interim analysis was performed by the DSMB following the enrol-
ment of 175 patients. Based on an alpha-spending function halfway 
between the O’Brien & Fleming and the Pocock boundary shapes, 
the alpha used in the interim analysis was set at 0.013, resulting in 
an alpha of 0.043 to be used at the end of the study. Based on the 
results of the interim-analysis, the DSMB recommended the con-
tinuation of the study, as the pre-defined criteria for superiority or 
futility were not met.
The results were analyzed according to an intention-to-treat prin-
ciple. Differences in hospital mortality and in ICU-mortality were 
tested using the Log rank and Chi-square test. Day-28 mortality 
was estimated by the Kaplan-Meier method. Differences in mortal-
ity rates were also tested using multivariate Cox’s proportional haz-
ards analysis, stratified by center and presence or absence of sepsis. 
Adjustments were made for the following pre-defined co-variables: 
age, sex, baseline APACHE II and baseline SOFA-score. Mixed mod-
els were estimated to quantify differences in vital signs, laboratory 
variables, APACHE II and SOFA scores during the treatment period, 
at 8 hours following start of the study and during the observation 
period. The effect on time to ICU discharge, time to weaning from 
mechanical ventilation, time to cessation of vasopressors and ino-
tropes and duration of renal replacement therapy, was assessed by 
cumulative hazard estimates and adjusted Cox’s proportional haz-
ard analysis, censoring for early deaths (34).
Because of possible heterogeneity between septic and non-septic 
hyperlactatemia and its subsequent treatment, pre-specified sub-
group analyses were performed in these two groups of patients and 
in further subsets of severe sepsis, septic shock, neurologic, cardiac 
arrest and other non-sepsis patients.
results
Patient enrolment is shown in figure E1 of the Online Data Supple-
ment*. The intention-to-treat population consisted of 348 patients; 
177 patients were randomized to the control group and 171 to lac-
tate group. In 18 patients a major protocol violation occurred (table 
E1 Online Data Supplement). These patients remained in the inten-
tion-to-treat population. Table 1 shows the baseline characteristics 
of the patients in the intention-to-treat population. Sixteen patients 
died during the eight-hour treatment period (10 control patients 
Variable Control group 
(N=177)
Lactate group 
(N=171)
Age – yr 62 ±18 62 ±15
Male sex – n (%) 109 (62%) 112 (66%)
Median time from arrival at hospital 
to randomization – hours (interquartile 
range)
8 (1-79) 5 (1-65)
ICU admission within 6 hours from 
hospital admission - n (%)
87 (49%) 90 (53%)
Median time from ICU admission to 
randomization – hours (interquartile 
range)
0.5 (0.1-1.0) 0.6 (0.2-1.3)
APACHE II score 22.7 ±9.1 23.6 ±8.6
SOFA score 8.8 ±4.3 9.1 ±3.7
Table 1. Baseline characteristics of the patients
*The Online Data Supplement can be found at the end of this chapter
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vs. 6 patients in the lactate group). From eight to 72 hours follow-
ing study entry another 52 patients died (27 control patients vs. 
25 patients in the lactate group) and 79 patients were discharged 
from the ICU to the ward (38 control patients vs. 41 patients in the 
lactate group). At 72 hours following study entry, 201 patients were 
still admitted to the ICU (102 control patients and 99 patients in the 
lactate group). 
therapeutic endpoints
The proportion of patients that reached the conventional resuscita-
tion goals that were applicable to both randomization groups was 
equal in both groups at any time point (except for heart rate at 6 
hours, which was more often met in the control group)(table E2 
Online Data Supplement). However, despite that the goal of a de-
crease in lactate level of ≥ 20% per 2 hours was only used in the 
lactate group, this goal was also equally met in both randomization 
groups.
During the treatment period and the subsequent observation pe-
riod, mean values of lactate were similar (table 2). pH, base excess, 
bicarbonate, MAP, heart rate, CVP and hemoglobin were similar in 
both groups as well (table E3 Online Data Supplement**).
Administered therapy
During the treatment period, patients in the lactate group received 
significantly more fluids than control group patients (table 3). In 
addition, more patients in the lactate group received vasodilator 
therapy (table 3, table E4 Online Data Supplement). Patients in 
both groups received similar quantities of red blood cell transfusion. 
Similar proportions of patients in both groups required the use of 
vasopressors and inotropes. 
Diagnostic category – n (% of patients in the randomization group)
      - Sepsis category: 67 (38%) 68 (40%)
            - Severe sepsis     - 39 (22%)     - 30 (18%)
            - Septic shock     - 28 (16%)     - 38 (22%)
      - Non-sepsis category: 110 (62%) 103 (60%)
            - Neurologic     - 19 (11%)     - 18 (11%)
            - Cardiac arrest     - 24 (14%)     - 24 (14%)
            - Other non-sepsis     - 67 (38%)     - 61 (36%)
Hospital – n (% of patients in the randomization group)
      - Hospital I 98 (55%) 98 (57%)
      - Hospital II 27 (15%) 25 (15%)
      - Hospital III 15 (8%) 14 (8%)
      - Hospital IV 37 (21%) 34 (20%)
Referring department – n (% of patients in the randomization group)
      - Operation theatre (acute surgery) 55 (31%) 38 (22%)
      - Operation theatre (elective 
surgery)
21 (12%) 21 (12%)
      - Ward or emergency department 95 (54%) 103 (60%)
      - Other ICU 6 (3%) 9 (5%)
Treated with metformin 7 (4%) 8 (5%)
Treated with anti-retroviral therapy 0 (0%) 2 (1%)
Median blood lactate level – mEq/l 
(interquartile range) 4.5 (3.5-6.2) 4.5 (3.6-6.1)
Central venous oxygen saturation - % - 73 ±11
Values are means ±SD unless otherwise specified.
Hours after start of therapy Control group Lactate group P value
Lactate level – mEq/l*
Baseline (0 hours) 4.7 (3.9-5.5) 4.6 (3.9-5.4) 0.75
8 2.7 (2.3-3.2) 2.6 (2.2-3.1) 0.59
0-8 3.3 (2.8-3.9) 3.2 (2.7-3.8) 0.80
9-72 1.7 (1.4-2.0) 1.6 (1.3-1.9) 0.17
Table 2. Blood lactate levels
The adjusted mean values (95% CI) were obtained from mixed model analysis. 
*Lactate levels are expressed as geometric means. P-values were calculated fol-
lowing logarithmic transformation of lactate levels.
**The Online Data Supplement can be found at the end of this chapter
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Similar proportions of patients in the control and lactate group re-
ceived mechanical ventilation (86% vs. 84% p=0.76, including 2% 
vs. 2% non-invasive ventilation), antibiotics (67% vs. 61% p=0.27), 
corticosteroids (45% vs. 40% p=0.38), additional surgery follow-
ing ICU admission (9 vs. 6% p=0.36), analgesics (fentanyl or mor-
fine; 58% vs. 50%, p=0.13), sedatives (midazolam, lorazepam or 
propofol; 71% vs. 71%, p=0.91), therapeutic hypothermia (10% vs 
6%, p=0.20) and a percutaneous coronary intervention (1% vs. 1%, 
p=0.96).
During the observation period, more patients assigned to the lactate 
group received vasodilators when compared to the control group 
(table 3). During the observation period a trend towards less use of 
fluids was observed in the lactate group when compared to control 
group.
MortALIty
In the control group 43.5% (77/177) of the patients did not survive 
to hospital discharge whereas in the lactate group 33.9% (58/171) 
died during their hospital stay (P=0.067, table 4, figure 2). When 
adjusted for the predefined risk factors at baseline, the treatment 
protocol to decrease lactate levels resulted in a significant reduction 
in the risk of hospital death (hazard ratio 0.61; CI 0.43-0.87, table 
4, table E5 Online Data Supplement). 
Treatment Control group Lactate group P value
Fluids, ml^
    0-8 hours# 2194 ±1669 2697 ±1965 0.011
    9-72 hours§ 10043 ±6141 8515 ±4987 0.055
Red blood cell transfusion, ml
    0-8 hours# 196 ±495 322 ±1037 0.15
    9-72 hours§ 345 ±667 423 ±1300 0.59
Any inotropic agent, %& 
    0-8 hours# 32.9 40.1 0.17
    9-72 hours± 44.2 35.2 0.12
Any vasodilator, %$
    0-8 hours# 20.2 42.5 <0.001
    9-72 hours± 27.1 43.2 0.005
Any vasopressor (%)@
    0-8 hours# 63.6 69.5 0.25
    9-72 hours± 63.7 71.4 0.16
Table 3. Fluids and vasoactive medication use during the initial treatment phase 
and up to 72 hours
P-values as calculated by two-sample Student’s t-test or the chi-square test, as 
appropriate.
# Values are shown for all patients 
§ Cumulative values (±SD) are shown for patients who were still admitted to the 
ICU after 72 hours
± Proportions are shown for patients who stayed for more than 8 hours in the ICU
^ sum of crystalloid and colloid fluids
& dobutamine, enoximone or epinephrine
$ nitroglycerine or ketanserin
@ norepinephrine, dopamine or fenylephrine
Variable Control group 
(n=177)
Lactate group 
(n=171)
Relative risk 
(95%CI)
P Value
Unadjusted analysis - % (n)*
In-hospital 
mortality
43.5%  
(77/177)
33.9%  
(58/171)
0.78  
(0.60-1.02)
0.067
28-day 
mortality
35.6%  
(63/177)
30.4%  
(52/171)
0.85  
(0.63-1.16)
0.30
ICU-mortality 34.5%  
(61/177)
28.7%  
(49/171)
0.83  
(0.61-1.14)
0.24
Adjusted analysis - hazard ratio (95% CI)§
In-hospital 
mortality
 0.61  
(0.43-0.87)
0.006
28-day 
mortality
0.75  
(0.52-1.09)
0.134
ICU-mortality 0.66  
(0.45-0.98)
0.037
Table 4. Mortality
*Chi-square test. § Cox proportional hazard analysis with adjustment for age, sex, 
APACHE II score (modified; at baseline) and SOFA SCORE (modified; at baseline), 
and stratified for centre and sepsis group, as predefined in the study protocol.
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organ failure, inotropes, vasopressors, renal 
replacement therapy and length of stay
Patients assigned to the lactate group had reduced organ failure 
(SOFA score) in the observation period (table 5). Patients in the 
lactate group were faster weaned from mechanical ventilation (haz-
ard ratio 0.72; 95% CI 0.54-0.98; figure 3a) and inotropes (hazard 
ratio 0.65; 95% CI 0.42-1.00; figure 3b) than patients in the control 
group. More importantly, patients in the lactate group could be dis-
charged from the ICU earlier (hazard ratio 0.65; 95% CI 0.50-0.85; 
figure 4). 
There were no significant differences in the time to stop vasopres-
sors (hazard ratio 0.84; 95% CI 0.61-1.15; figure 3c) or renal re-
placement therapy (hazard ratio 0.56; 95% CI 0.22-1.43; figure 3d) 
between both groups.
subgroup and exploratory analyses
Pre-specified and post-hoc specified subgroup analyses are shown 
in figure 5. In addition, two post-hoc exploratory analyses were per-
formed to investigate the difference in statistical significance be-
tween the unadjusted and the adjusted primary outcome. First, 
when adding interaction terms for age and APACHE II score to 
the pre-defined multivariable model for hospital mortality, effect 
modification could not be demonstrated (age*randomization group 
(p=0.74) and APACHE II score*randomization group (p=0.85)). 
Second, when excluding six patients with missing data on covariates 
(APACHE II and SOFA scores at T=0 hrs), effect size and p-value 
remained similar (data not shown).
Number at risk:
Control 177 118 110 105 102 101 101 101 101 101 100
Lactate 171 122 115 114 114 114 113 113 113 113 113
Figure 2. Kaplan Meier survival curve
Hours after start of 
therapy
Control group Lactate group P value
APACHE II score#
Baseline (0 hours) 15.6 (14.4-16.8) 16.3 (15.1-17.5) 0.28
8 13.4 (12.2-14.7) 13.0 (11.8-14.3) 0.52
0-8 14.5 (13.4-15.7) 14.7 (13.5-15.8) 0.78
9-72 10.5 (9.3-11.6) 9.9 (8.7-11.0) 0.17
SOFA score#
Baseline (0 hours) 6.4 (5.6-7.1) 6.4 (5.6-7.1) 0.89
8 7.2 (6.5-7.9) 6.9 (6.2-7.6) 0.27
0-8 6.8 (6.0-7.5) 6.8 (6.0-7.5) 0.58
9-72 7.0 (6.3-7.7) 6.4 (5.7-7.2) 0.009
Table 5. Disease severity and organ failure
The adjusted mean values (95% CI) were obtained from mixed model analysis. # 
APACHE II and SOFA scores were calculated at the various time points (0, 8, 24, 
48, and 72 hours following study entry).
Survival was followed-up until hospital discharge. The longest duration of hospital 
stay was 196 days.
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Figure 3B. Time to stop inotropes
Figure 3C. Time to stop vasopressors
Figure 3D. Time to stop renal replacement therapy
Figure 3A. Time to weaning from mechanical ventilation
Assessed by cumulative hazard estimates and Cox’s proportional hazard analysis, 
with censoring for early deaths.
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DIsCUssIon
In this multi-center, open-label randomized controlled study, lactate 
monitoring during the first eight hours of ICU admission, aimed at 
reducing lactate levels by at least 20% per two hours, significantly 
reduced ICU length of stay and also ICU and hospital mortality when 
adjusting for predefined and commonly accepted risk factors. 
There was a discrepancy in statistical significance between the 
adjusted and unadjusted analysis of the study’s primary outcome 
measure. This could not be explained by different data sets being 
used due to missing data or by a heterogeneous effect of the rand-
omization therapy in some end of the spectrum of age or APACHE 
II score. Instead, this difference might probably be explained by a 
clearer estimation of the actual effect when adjusting for risk fac-
tors that are well-known predictors of mortality: such predefined 
covariate adjustment makes treatment effect estimation more indi-
vidualized and reduces noise in the analysis. In our study, which was 
originally powered to detect a 15% mortality difference, it thereby 
improved the statistical power (i.e. the ability to identify a smaller 
treatment effect when it really exists) (35). In addition, the observed 
9.6% absolute reduction in hospital mortality was consistent with 
substantial improvement in important clinical outcomes, including 
reduced short-term organ failure, earlier weaning from the ventila-
tor and subsequent earlier discharge from the ICU.
Monitoring itself cannot improve outcome, therefore the therapeu-
tic plan associated with the monitor is equally important. As for all 
studies investigating efficacy of a treatment algorithm, the effect in 
this study is the result of the combination of all individual treatment 
goals and therapy components. The main differences in therapy be-
tween the two groups in the treatment period were the administra-
tion of more fluids and the increased use of vasodilators in patients 
assigned to the lactate group. While goal-directed fluid resuscitation 
is widely recommended (36-38), the use of vasodilators in critically ill 
patients is controversial (39). Nevertheless, some studies have sug-
gested beneficial effects of vasodilator therapy in critically ill patients. 
For instance in fluid resuscitated patients with septic shock, adminis-
Figure 5. Pre-specified and post-hoc subgroup analyses.
Figure 4. Time to discharge from the ICU
Assessed by cumulative hazard estimates and Cox’s proportional hazard analysis, 
with censoring for early deaths.
Early ICU admission = < 6 hours following hospital admission. Late ICU admis-
sion = > 6 hours following ICU admission. P-value for interaction according to 
Breslow-Day test of homogeneity. *= p-value between neurologic and other non-
sepsis.
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tration of nitroglycerin reversed microcirculatory shutdown and shunt-
ing (40). In severe heart failure and cardiogenic shock nitroglycerine 
has been shown to improve microcirculatory perfusion (41, 42). Fi-
nally, Buwalda et al. described positive effects on tissue perfusion and 
oxygen extraction in addition to microcirculatory recruitment (43).
Surprisingly, the treatment algorithm of the lactate group did not 
result in faster reduction of lactate when compared to control group 
therapy, despite a more aggressive resuscitation in the lactate group. 
In fact, this observation might actually argue against lactate as a 
target of hemodynamic therapy. It suggests that hyperlactatemia 
does not sufficiently reflect tissue hypoperfusion and emphasizes its 
complicated etiology in critical illness (14, 15). On the other hand, 
our study underscored the function of lactate as a warning signal. 
In the control group the treating clinicians might not have been 
sufficiently warned that their patients did not improve or even de-
teriorated in the presence of stable hemodynamic parameters and 
conventional resuscitation. Also, in the lactate group the availability 
of lactate levels might have resulted in restricted treatment in select-
ed patients when lactate levels had already decreased sufficiently. 
In this way, lactate-guided resuscitation potentially made treatment 
tailor-made to the individual patient.
The early goal-directed therapy study by Rivers et al. reported re-
duced mortality in the treatment group (19). However, as their study 
was exclusively done in the Emergency Department of a single hos-
pital, growing concerns arose on the applicability of this strategy in 
other settings and other patient groups (44, 45). The Rivers’ study 
was situated in the Emergency Department where resuscitation was 
initiated earlier in a population with generally higher lactate levels 
and lower CVP and ScvO2 values (46). This probably explains the 
difference in resuscitation intensity (i.e. difference in fluid adminis-
tration) between the two studies. Nevertheless, similar to the Rivers’ 
study, therapy guided by repeated lactate measurements in our study 
resulted in an increased use of fluids during the treatment period 
whereas during the subsequent observation period a trend towards 
decreased use of fluids was found when compared to the control 
group. Our study therefore confirms the early goal-directed therapy 
study results (19) underscoring the importance of adequate resusci-
tation as long as lactate levels remain elevated, even following ICU 
admission after early stabilization in the Emergency Department. In 
addition our study extends the concept of early goal-directed therapy 
to other patient groups, as only about 40% of the patients enrolled 
in the current study had severe sepsis or septic shock. 
The treatment effect seemed consistent throughout almost all pre-
defined subgroups, although it might arguably be more pronounced 
in septic than in non-septic patients and in severe septic than in sep-
tic shock patients. The only pre-defined subgroup in which mortality 
did not seem to be lower in the lactate group was the neurological 
subgroup (i.e. patients with traumatic brain injury, neurovascular 
conditions or neuro-oncological conditions). In this particular group 
of patients, vasodilatation therapy might possibly interfere with op-
timal targeting of cerebral perfusion. Finally, analogous to previous 
studies on hemodynamic optimization in high-risk patients (47), the 
treatment effect seemed larger when patients were admitted to the 
ICU early before the development of organ failure. However, al-
though subgroup analysis might provide valuable exploratory infor-
mation and facilitate hypothesis generation, care has to be taken in 
the interpretation given its well-known limitations, including limited 
statistical power (48). 
Some methodological aspects are important, particularly regarding 
the open-label protocol design of this study (49, 50). First, as blind-
ing of the treatment team in a study like this is impossible, this 
imposes a risk of bias. However, none of the monitored co-interven-
tions were significantly different between the two groups. Also, the 
treatment team was practically blinded to treatment-assignment fol-
lowing the initial eight-hours period and at discharge to the general 
ward. Second, the therapy endpoints in the control group have been 
acknowledged by international guidelines. These endpoints were as 
often met in the control group as in the lactate group, suggesting 
no under-treatment in the control group. Additionally, the control 
group mortality was comparable with the mortality in the pilot study, 
conducted immediately prior to start of the study. However, given 
that ScvO2 monitoring was mandatory in the lactate group and fac-
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ultative in the control group, we cannot exclude the possibility that 
this had an impact on the observed outcome difference. Third, an 
important limitation of the study design is that the observed differ-
ences in treatment between the two groups provide only suggestive, 
and not conclusive support for a mechanism that is responsible for 
the clinical outcome benefit. In addition, as the treatment mecha-
nism is determined by the sum of its multiple resuscitation endpoints 
and treatments, this limits the interpretation of the individual inter-
ventions used in the algorithm. For instance, given the debate on 
the best method to assess fluid responsiveness and adequate end 
points of fluid resuscitation (51, 52), we have chosen a dynamic ap-
proach using central venous pressure (27) as it was practically most 
suitable in a multi-center environment within the earliest hours of 
ICU admission. In addition, this would probably resemble usual care 
in many ICUs worldwide (53) enlarging external generalizability of 
the results. 
In summary, in ICU patients with a lactate level at or above 3.0 
mEq/l upon admission, early monitoring of lactate levels with the 
added target to reduce levels by 20% per two hours on top of cur-
rently recommended resuscitation guidelines, significantly reduced 
ICU length of stay. ICU and hospital mortality were significantly re-
duced when adjusting for predefined risk factors and as this was 
consistent with important secondary endpoints, the results of this 
study suggest that initial lactate monitoring has clinical benefit.
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onLIne DAtA sUPPLeMent
Patient Group Protocol violation
1 Control Treated as lactate group
2 Lactate Failure placement central venous catheter
3 Control Wrong timing of measurements
4 Lactate Treated as control group
5 Control No measurements due to emergency surgery
6 Control Missing study equipment (study forms)
7 Lactate Missing study equipment (ScvO2 monitor)
8 Lactate Missing study equipment (ScvO2 probe)
9 Lactate Failure placement central venous catheter
10 Lactate Failure protocol implementation (ward too busy) 
11 Lactate Failure protocol implementation (ward too busy) 
12 Lactate Missing study equipment (ScvO2 monitor)
13 Lactate Failure protocol implementation (clinician unaware of 
study protocol) 
14 Lactate Failure placement central venous catheter
15 Lactate Technical problems study equipment (ScvO2 probe)
16 Lactate Failure placement central venous catheter
17 Lactate Failure protocol implementation (refusal clinician to 
participate) 
18 Lactate Missing study equipment (reason unknown)
Table E1. Major protocol violations per patient
Control group 
(N=177)
Lactate group 
(N=171)
P value
Mean arterial pressure ≥ 60 
mmHg
      - 0 hours 88% 87% 0.77
      - 2 hours 93% 90% 0.36
      - 4 hours 91% 93% 0.57
      - 6 hours 95% 92% 0.27
      - 8 hours 93% 91% 0.66
Table E2. Resuscitation endpoints during the treatment period (0-8 hours)
- 186 -
Chapter 7
7
- 187 -
Ef
fic
ac
y 
of
 g
oa
l-d
ir
ec
te
d 
th
er
ap
y 
in
 t
he
 IC
U
Heart rate ≤ 100 beats/min
      - 0 hours 51% 46% 0.32
      - 2 hours 51% 47% 0.47
      - 4 hours 54% 50% 0.45
      - 6 hours 60% 49% 0.045
      - 8 hours 56% 51% 0.32
Central venous pressure ≥ 8 
mmHg
      - 0 hours 83% 80% 0.63
      - 2 hours 82% 84% 0.65
      - 4 hours 85% 88% 0.57
      - 6 hours 86% 81% 0.30
      - 8 hours 82% 83% 0.83
Urinary production  
≥ 0.5 ml/kg/hr
      - 0-8 hours 72% 76% 0.36
Hemoglobin level ≥ 4.3 mEq/l
      - 0 hours 96% 95% 0.51
      - 2 hours 94% 91% 0.55
      - 4 hours 98% 92% 0.078
      - 6 hours 94% 96% 0.57
      - 8 hours 99% 98% 0.70
Δ lactate ≥ 20% decrease
      - 0-2 hours 55% 53% 0.74
      - 2-4 hours 38% 39% 0.86
      - 4-6 hours 48% 40% 0.19
      - 6-8 hours 47% 45% 0.71
Central venous oxygen 
saturation ≥ 70%
      - 0 hours 60%
      - 2 hours 62%
      - 4 hours 65%
      - 6 hours 67%
      - 8 hours 74%
Hours after start of 
therapy
Control group Lactate group P value
pH
Baseline (0 hours) 7.32 (7.27-7.36) 7.31 (7.26-7.36) 0.58
8 7.36 (7.31-7.41) 7.37 (7.32-7.41) 0.61
0-8 7.34 (7.29-7.39) 7.34 (7.29-7.39) 0.99
9-72 7.38 (7.33-7.43) 7.39 (7.34-7.43) 0.37
Base excess – mEq/l
Baseline (0 hours) -4.9 (-7.7- -2.8) -5.5 (-8.3- -2.8) 0.27
8 -3.0 (-5.8- -0.2) -3.5 (-6.3- -0.7) 0.40
0-8 -4.0 (-6.8- -1.1) -4.5 (-7.3- -1.7) 0.27
9-72 -1.7 (-4.5-1.1) -1.6 (-4.4-1.2) 0.79
Bicarbonate – mEq/l
Baseline (0 hours) 20.1 (17.6-22.6) 19.8 (17.3-22.3) 0.57
8 21.4 (18.9-23.9) 21.3 (18.8-23.8) 0.79
0-8 20.8 (18.2-23.3) 20.5 (18.0-23.1) 0.63
9-72 22.9 (20.3-25.4) 22.9 (20.4-25.5) 0.90
Mean arterial pressure – mmHg
Baseline (0 hours) 81 (76-87) 81 (75-86) 0.71
8 78 (73-84) 79 (74-84) 0.66
0-8 80 (75-86) 80 (74-86) 0.69
9-72 84 (79-90) 85 (79-90) 0.68
Heart rate – beats/minute
Baseline (0 hours) 100 (95-104) 103 (98-108) 0.17
8 97 (92-102) 99 (94-104) 0.40
0-8 98 (94-103) 100 (95-105) 0.30
9-72 96 (91-100) 93 (89-98) 0.25
Central venous pressure&– mmHg
Baseline (0 hours) 13 (7-19) 13 (7-18) 0.72
8 12 (7-18) 12 (6-18) 0.71
0-8 12 (7-18) 13 (7-18) 0.90
9-72 12 (6-18) 11 (6-17) 0.30
Table E3. Metabolic parameters and hemodynamics
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Hemoglobin level – g/dl*
Baseline (0 hours) 11.0 (10.2-11.6) 10.8 (10.2-11.4) 0.63
8 10.6 (10.0-11.4) 10.6 (10.0-11.4) 0.87
0-8 10.6 (10.0-11.4) 10.6 (9.8-11.4) 0.69
9-72 10.0 (9.3-10.8) 10.2 (9.3-10.8) 0.69
The adjusted mean values (95% CI) were obtained from mixed model analysis. 
&80% of the control group patients and 78% of the lactate group patients were 
mechanically ventilated at baseline. * to convert from g/dl to mmol/l: multiply by 
0.6206
Treatment Control  
group
Lactate  
group
P value
Inotropic agents 
  - Dobutamine,  
   % (mean dose)
 0-8 hours# 25.4%  
(6.7 µg/kg/min)
33.5%  
(5.6 µg/kg/min)
0.10 
 9-72 hours§ 27.8% 37.7% 0.076
  - Enoximone,  
   % (mean dose)
 0-8 hours# 8.1%  
(4.8 mg/hr)
9.0%  
(3.8 mg/hr)
0.77
 9-72 hours§ 9.0% 11.6% 0.47
  - Epinephrine,  
   % (mean dose)
 0-8 hours# 1.7%  
(0.41 µg/kg/min)
0.6%  
(0.12 µg/kg/min)
0.62
 9-72 hours± 2.0% 0.0% 0.25
Vasodilators
  - Nitroglycerine,  
   % (mean dose)
 0-8 hours# 14.5%  
(2.5 mg/hr)
31.7%  
(2.0 mg/hr)
<0.001
 9-72 hours± 18.1% 33.1% 0.004
  - Ketanserin,  
   % (mean dose) 
 0-8 hours# 6.4%  
(2.5 mg/hr)
12.0%  
(3.3 mg/hr)
0.072
 9-72 hours± 11.1% 13.7% 0.51
Vasopressors 
  - 
Norepinephrine,  
   % (mean dose)
 0-8 hours# 50.3%  
(0.40 µg/kg/min)
62.3%  
(0.34 µg/kg/min)
0.026
 9-72 hours± 60.3% 67.6% 0.20
  - Dopamine,  
   % (mean dose)
 0-8 hours# 14.5%  
(5.4 µg/kg/min)*
10.8%  
(9.8 µg/kg/min)*
0.31
 9-72 hours± 15.9% 11.6% 0.30
  - Fenylephrine,  
   % (mean dose)
 0-8 hours# 7.5%  
(1.9 µg/kg/min)
4.8%  
(2.3 µg/kg/min)
0.30
 9-72 hours± 2.4% 1.4% 0.66
Table E4. Specified vasoactive medication use during the initial treatment phase 
and up to 72 hours
P-values as calculated by two-sample Student’s t-test or the chi-square test, as 
appropriate.
# Values are shown for all patients 
± Proportions are shown for patients who stayed for more than 8 hours in the ICU
*= p<0.05 for dose
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Figure E1 Online Data Supplement.
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IntroDUCtIon
Respect for individual autonomy, expressed in the concept of in-
formed consent, is the basic ethical principle in research with hu-
mans. 
Many ICU patients are unable to give consent as a consequence 
of mental incapacity, and this can be further complicated in emer-
gency situations, in which treatment needs to be initiated without 
delay. Various approaches are used as surrogate to subject consent: 
waiver of consent, consent by an independent physician and de-
ferred consent (DC). DC involves randomization at the investigator's 
discretion according to criteria that have been explicit during ethical 
review of the protocol, followed by the request for patient's (de-
ferred subject consent) or representative's (deferred proxy consent) 
informed consent in a later phase. Several emergency trials have 
used DC [1-4]. 
During the enrolment process in an ongoing Dutch multi-center 
randomized controlled trial using DC, the situation arose that no 
deferred (subject or proxy) consent was obtained from patients who 
died early after start of the study. Should data of these patients be 
used or not? In this article we analyze this practical and ethical 
problem.
tHe “eArLy LACtAte-DIreCteD tHerAPy on 
tHe ICU”- stUDy As An exAMPLe 
To evaluate the efficacy of early lactate-directed therapy, two of the 
authors (TCJ, JB) are currently conducting a multi-center trial. Pa-
tients eligible for inclusion are randomly allocated to either 8 hours 
of early lactate-directed therapy or control group therapy. Since 
early timing of goal-directed therapy is essential [7, 8], patients are 
randomized immediately after the first available lactate level, result-
ing in a very short inclusion time-window. The Ethics Committee 
approved the use of DC, referring to the Dutch revised “Medical 
Research in Human Subjects Act” [6]. Study procedures are tempo-
rarily undertaken without consent and, as soon as possible, written 
consent from the patient or legal representative is sought.  
Figure 1. Flow-chart of the process of deferred consent in enrolled patients in the 
“Early Lactate-Directed Therapy on the ICU”-study (February-December 2006)
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Until December 2006, we collected data from 115 patients (figure 
1). In 11.7% (13/111), consent could not be obtained due to early 
death (< 72 hrs, before relatives could be approached). Given the 
predicted sample size of 350 patients, not using data of these pa-
tients would result in an additional requirement of 41 patients. In 
2.7% (3/111), relatives could not be identified or contact was lost. 
In 2.7% (3/111), relatives refused consent and these patients were 
withdrawn from analysis. Median randomization-to-consent time 
was 1 day (n=92, IQR 0-3 days). 
The Ethics Committee of the coordinating center was asked for a 
judgement on the use of already obtained data of patients who died 
before consent could be sought. Our proposal to use the data was 
rejected. 
PreVIoUs exPerIenCes on PAtIents WHo 
DIeD BeFore oBtAIneD DC
Some emergency studies using DC have reported on the use of data 
from patients who died early. In the PAC-man trial using DC [2], 
consent was sought from patients who regained consciousness (de-
ferred subject consent), whether or not relative’s assent was ob-
tained earlier. It was stated that “if the patient’s died without re-
gaining mental competency, the patient’s data were included in the 
trial analysis” [9]. Fifty percent (249/500) of the patients died with 
obtained relative’s assent (not consent) but without obtained sub-
ject DC. Nine percent (45/500) died with neither relative’s assent 
nor subject DC. Data of these patients were included in the analysis. 
In another trial, 74% (220/300) of the patients were included under 
DC [1] and were asked consent as soon as possible. This was done 
only in survivors, suggesting that if patients died before regaining 
consciousness, data were used [10]. As overall 28-day mortality was 
high (58%), a substantial part of the data were probably analysed 
without consent. In another trial [4], diligent attempts to contact the 
relative were made and an independent physician was consulted 
before it was deemed necessary to waive consent. If attempts to 
contact relatives continued to be unsuccessful, or if the patient died 
before relatives could be contacted, the IRB was notified and data 
were used. Summarizing, in these studies [1, 2, 4], data were used 
if the patient died before DC was obtained, and reasonable efforts 
were made to obtain permission from a patient representative.
etHICAL ConsIDerAtIons
Guiding ethical principles for medical research are respect for pa-
tient autonomy, protection against discomfort, risk, harm and ex-
ploitation and the prospect of benefit. Taking our lactate-study as 
point of departure for analysis, some questions remain:
 
1. Why is DC necessary?
To optimally respect patient’s autonomy, seeking consent before 
study participation is preferable. Principle One of the Nuremberg 
Code states that the primary consideration in research is the sub-
ject’s voluntary consent, which is “absolutely essential” [11]. Un-
fortunately, in emergency ICU research this is often not possible, 
illustrated by the PAC-man trial in which only 2.6% of the patients 
could consent before starting the study [9]. Emergency research 
represents an exceptional situation, in which the mechanisms of the 
consent process may need to be modified, but the social contract 
between researcher and research subject must be respected in or-
der to provide a safeguard against unethical research.
Despite the importance of the subject’s voluntary consent or its vari-
ous surrogate procedures, the question remains whether arguments 
in favour of not using data, are outweighed by the following ar-
guments in favour of using data in such extraordinary case when 
patients die early and DC would have to be sought from bereaved 
proxies?
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2. Is proxy consent valid in emergency situations? 
Uncertainty exists whether a substituted judgement on what a patient 
would have decided would concur with the patient's preferences. Some 
have shown that most patients confirmed the judgement made earlier 
by the relatives [9]. However, surrogate decision-making for critical 
care research resulted in false-positive consent rates of 16-20% [12, 
13]; a recent review showed overall inaccuracy of 32% [14]. 
The validity of proxy consent may be further reduced in emergen-
cy situations. Overwhelming emotions may decrease validity. Most 
proxies seem to make decisions based on what they hope will hap-
pen (benefit of therapy), not taking in consideration what is a real 
prospect  (possible non-benefit and research-related burden) [15]. 
It is of ethical and fundamental concern that relatives cannot make 
balanced decisions in this period of uncertainty. If the risk exists that 
consent by relatives in emergency ICU situations reflects more a 
regime of bureaucracy (consent is required, we need a signature), 
rather than true ethical concern (by obtaining consent the relatives 
act in the patients interests) [16], then how can we value consent in 
the tragic situation in which the patient has died?
3. Do we harm the patients by using the obtained 
data? 
Can we estimate how many patients or relatives would refuse the 
use of data obtained in acute situations without consent? In two 
studies evaluating emergency therapies [17, 18], waiver of consent 
was used with subsequent written notification. Survival hospital-
discharge rates were 8% (43/538) and 17% (14/82). Only 0.4% 
(2/538) and 0% (0/82) were withdrawn at relatives request after 
written notification [19]. In the PAC-man trial 3.3% (6/181) of sur-
vivors refused consent [9]. In our lactate-study 2.7 % (3/111) of 
patients or relatives refused study participation after randomization. 
It seems that very few patients or relatives refuse consent for using 
already obtained data in emergency situations. 
Do we harm patient's interests by using data without consent? 
The data in our lactate-study, consisting of regular data as sur-
vival, consumption of health care resources, laboratory values and 
haemodynamics data, are patient-identifiable only by the principal 
investigator. Given privacy-respecting handling of data and thor-
ough confidentiality, patient’s interests are not harmed by using the 
data.   
4. Would we introduce selection bias by not using 
the data? 
Patients who die early are the most severely ill (100% mortality) and 
excluding them could reduce external validity, jeopardize the bal-
ance between study arms and influence the effect of the interven-
tion as this could be different in patients who die early compared 
with survivors or those who die later. The intention-to-treat principle, 
recommended in the ICH E9 [20], implies that the primary analysis 
should include all randomized subjects. Compliance with this prin-
ciple would necessitate complete follow-up of all subjects for study 
outcomes. Not using study data of patients who died early would 
thus hamper the intention-to-treat principle.
Although the Registry of the Canadian Stroke Network used a differ-
ent consent procedure than our study, it does show that important 
selection biases can be found if many patients died or left the hos-
pital before they could be approached for consent [21]. The in-hos-
pital mortality rate was much lower among enrolled patients (6.9%) 
than among those eligible for study participations but not enrolled 
(21.7%). Hence, study-patients were not representative anymore of 
typical stroke patients. Other studies showed that absolute require-
ments to obtain consent have led to selection biases in retrospective 
studies based on chart review [22, 23], and decreased enrolment in 
registries [24]. 
These concerns probably apply equally to the critical care/emer-
gency medicine context, but additional data in this area would be 
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useful. After completion of our lactate-study, we plan to compare 
study results including or excluding data from patients who died 
before DC could be obtained. By doing this, the hypothesis posed 
in this article will be tested, that not using these data will introduce 
selection bias, make randomization arms asymmetrical and jeop-
ardize trial results. 
5. Do future patients benefit from the obtained 
data?
Clinical research plays an important role in obtaining knowledge for 
improvement of therapy, patient safety and progress in medicine. 
Future patients will benefit from critical care research results of to-
day. If data, obtained in emergency ICU situations without consent, 
cannot be used, and selection bias is introduced, study results may 
be ruined and future patients be harmed. Degrading a study in this 
fashion also devalues the contribution made by subjects who do 
consent to take part in the study, which is an ethically undesirable 
consequence. While this premise cannot provide an argument for 
including data when research subjects expressly deny consent, it 
does make an ethically valid case for including data where such 
explicit denial of consent does not exist. 
Notwithstanding this discussion, it should not be forgotten that the 
society’s interests in medical progress may never overrule potential 
burden and risks for patients, as enshrined in the Nuremburg Code 
[26, 11].
6. What is the burden for the relatives?
 Health care providers have a prima facie duty to relieve and pre-
vent suffering (harm, burden) of patients, their relatives and society. 
Confronting relatives again with the event that their loved one died 
on the ICU can be seen as harm or burden. Indeed, concerning our 
lactate-study, the local Ethics Committee acknowledged this psy-
chological burden. If we can say that confronting bereaved relatives 
represents additional burden, which we have the duty to relieve or 
prevent, it seems morally correct to adopt policies that prevent seek-
ing DC from proxy’s after their relatives death. Extending the time 
period of seeking consent could theoretically reduce the burden. 
However, obtaining written consent a long time after the patient has 
died can be impractical (telephone consent is not allowed and it is 
questionable whether the agreeing relative will take effort to reply 
a request for written consent) and more importantly, actively ap-
proaching relatives for seeking consent in a “fatal medical research 
case” would still be a real burden for the relatives.
7. Is the individual’s (or proxy’s) decision about the 
privacy of their medical information binding?
The individual’s decision (whether made by the individual him/her-
self or his/her proxy) is not absolutely binding. In certain situations it 
is permissible to use personal information even though the individ-
ual has not allowed it. This point is supported by principles in ethics 
and law: (i) Article 8 of the European Convention on Human Rights 
permits personal information to be used without consent (even if 
the individual expressly objects) if the processing is necessary and 
proportionate for “the protection of health”. This is generally un-
derstood to include some medical research projects. Additionally 
(ii), the EU Data Protection Directive allows member states to adopt 
laws which allow personal data to be processed for scientific pur-
poses without consent provided sufficient safeguards apply and last 
(iii), the UK Data Protection Act 1998 permits such processing if it is 
necessary and proportionate for the goals of medical research. 
Although there is little case law, the courts would likely consider the 
following factors when deciding whether the twin principles of ne-
cessity and proportionality have been met include: the practicality of 
seeking consent (or proxy consent), the importance of answering the 
research question, alternative ways of answering this question, the 
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degree of anonymisation of the data, the practicality of discarding 
individuals’ data, the implications of discarding the data (selection 
bias) and the degree of distress caused to the individual or proxy by 
ignoring their wishes. 
8. Deferring consent: how long do circumstances 
continue to prevent the giving of consent?
In the lactate-trial, study procedures were allowed for as long cir-
cumstances continue to prevent the giving of consent [6]. The local 
Ethics Committee interprets such a circumstance as physical ab-
sence of the patient’s relative arguing that, as soon as relatives 
arrive, this circumstance is not valid anymore and hence, consent 
should immediately be sought. Given that seeking proxy consent 
in emergency conditions is questionably valid (see consideration 2) 
and it is a burden for the relatives to consent for their dead relative 
(see consideration 6), it could be seen in a way that in fact the cir-
cumstance continues that prevents the giving of consent.  
In order to prevent investigators’ abuse of this ongoing circum-
stance, a time limit for seeking consent could be suggested. In a 
conducted survey among investigators active in the field of traumat-
ic brain injury, opinions concerning the most appropriate time for 
requesting proxy DC, were investigated (figure 2). Peak preferences 
of time limits were “<24 hours” and “no limit”. Accumulating the 
percentages, 68% (12+8+29+19) of the respondents believed that 
DC should be asked within 72 hours after starting the study. 32% 
(1+26+5) felt that the time limit should be longer than 72 hours (or 
even that consent was not at all required) [16]. 
CoMPArIson WItH otHer stAtes In tHe 
eUroPeAn UnIon
The United Kingdom has recently introduced legislative and reg-
ulatory provision for emergency research. In principle, these pro-
visions allow for proxy and deferred consent, and are included 
in the Mental Capacity Act 2005 (http://www.opsi.gov.uk/acts/
acts2005/20050009.htm) and an amendment (http://www.opsi. 
gov.uk/si/si2006/20062984.htm) to the UK Clinical Trials regula-
tions. 
Italian implementation of the European Clinical Trial Directive 
2001/20/EC has enabled enrolment of incapacitated patients in 
clinical trials and DC is required according to the ethics commit-
tee’s approval [27].
In the Austrian law, allowing proxy consent in case of mental inca-
pacity, there is a special provision regarding “emergency” situations, 
in which inclusion of a patient can take place without proxy consent. 
The time period of the emergency is not considered as long as it 
takes to appoint a legal representative, but as long as the specific 
emergency is a medical emergency. Regains the patient the ability 
to consent, he/she is to inform without delay and to ask consent for 
further participation. Participation for such patients has to be with 
the prospect of a potential direct benefit, “which exceeds the risks”. 
Figure 2. Survey among investigators active in the field of traumatic brain injury. 
Within which time period should proxy deferred consent be obtained or informa-
tion provided? (n=77)
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Thus, the prospect of any kind of group benefit is not enough. If 
the presumed patient’s will is known and documented, it has to be 
respected. Additionally, the public on the research site has to be 
informed about the clinical trial (e.g. by notice on a notice-board at 
the hospital or on a web-site).
The issue of whether data from patients who have died can be used 
without formal authorisation from patients or representatives is ad-
dressed in neither the Dutch, British, Italian and Austrian legisla-
tion. In the UK researchers have generally relied on interpretation 
of the provisions of the Data Protection Act 1998 (http://ico-cms.
amaze.co.uk/DocumentUploads/use and disclosure of health data.
pdf) to legitimise such data use. The UK also allows the use of an 
independent physician’s consent in restricted circumstances, which 
would indeed be very useful when judging whether or not sufficient 
care has been taken to seek consent otherwise (i.e. prior to death), 
before using data without relatives’ agreement.  
syntHesIs
Dutch regulatory bodies have indicated that if the patient has died 
shortly after randomization, and consent could not yet be obtained, 
this forms no reason to abandon the requirement to obtain DC to 
use the data. 
It is our conviction that the obligation to obtain consent should be 
respected as thorough as possible. However, (i) the validity of proxy 
consent obtained during emergency situations can be ethically 
questioned; (ii) using data of patients who died and for whom DC 
was not yet obtained will not harm the patient or relatives (provided 
that appropriate confidentiality and privacy measures have been ap-
plied); (iii) not using data will probably introduce selection bias; 
(iv) using data will benefit future patients and society; (v) confront-
ing bereaved relatives to obtain consent is an additional burden 
and (vi) an individual’s decision about the privacy of their medical 
information is not absolutely binding. We therefore think that it is 
inappropriate to enforce a strict rule that DC must be obtained from 
bereaved relatives of deceased patients.
recommendations
In studies that use DC, data should be used if the patient dies before 
written (subject or proxy) consent can be sought. In order to prevent 
unauthorized use of this exception of the obligation to obtain con-
sent, we however recommend a time limit for the exception of 72 
hours (after start of study procedures). Only if a patient dies after 
this period and consent is not yet obtained, data should not be used. 
If national legislation (e.g. in the UK) allows the use of independent 
physician’s consent, consent to use the data should be sought in this 
way. If not, as a sign of respect for patient autonomy, we plea for 
a written notification send to the patients’ general practitioner and 
to relatives after the early mourning phase in cases where data are 
being used for study analyses despite the lack of DC [19]. Reports 
on all non-survivors without obtained consent should, in addition, 
be sent to the local Ethics Committees. 
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ABstrACt
Purpose: To illustrate the impact on the validity of trial results when 
excluding patients from a randomized controlled trial in whom no 
deferred consent could be obtained after randomization because 
study procedures had already been finished.
Methods: The unadjusted and adjusted primary outcome measures 
of a recent randomized controlled multicentre study in the field of 
intensive care medicine were compared, including (n=348) or ex-
cluding (n=289) patients with missing deferred consent. 
results: Thirty-nine patients (11%) died early before the patient or 
his/her proxy could be approached and consent be obtained. In an-
other 20 patients (6%), it was not possible to inform proxies and ask 
consent within the period of study procedures. A significant treat-
ment effect (p=0.006) in the adjusted analysis became non-sig-
nificant (p=0.35) when the patients with missing deferred consent 
were excluded.
Conclusions: The exclusion of patients without obtained deferred 
consent can reduce statistical power, introduce selection bias, 
make randomization asymmetrical, decrease external validity and 
can hereby jeopardize study results. This may have implications for 
emergency research in varying disciplines. 
IntroDUCtIon
Respect for individual autonomy, expressed in the concept of in-
formed consent, is the basic ethical principle in research with hu-
mans. Many critically ill patients are unable to give consent as a 
consequence of mental incapacity, and this can be further compli-
cated in emergency situations, in which treatment needs to be initi-
ated without delay. Proxies are not always available in the first hours 
of hospital or intensive care admission or are too overwhelmed to 
understand the provided information to give valid consent. Deferred 
consent is an acceptable substitute in these emergency circum-
stances. [1] However, clinicians and investigators may encounter 
an important practical and ethical problem after enrolling patients 
under deferred consent: should the researcher use the study data if 
study procedures have already been finished before it was possible 
to inform the patient or his/her proxy and ask consent? This includes 
the situation in which the patient has died early.
The intention-to-treat principle implies that the primary analysis 
should include all subjects. Compliance with this principle would 
necessitate complete follow-up of all subjects for study outcomes. 
As patients who die early are the most severely ill, excluding them 
could reduce external validity, jeopardize the balance between study 
arms and influence the effect of the intervention. [1, 2]
In an earlier discussion paper we argued that deferred proxy con-
sent is the preferable substitute for informed consent in emergency 
critical care research. In case of the situation when study proce-
dures are finished or the patient dies before consent can be ob-
tained, we recommend to use the study data that have already been 
obtained, provided sufficient privacy measures have been applied. 
Several arguments support this recommendation. First, using data 
of patients who died and for whom deferred consent was not yet 
obtained will not harm the patient or relatives. Second, confronting 
bereaved relatives to obtain consent after death of the patient is an 
additional burden. Third, using data will benefit future patients and 
society. Fourth, the Dutch
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Central Committee on Research involving Human Subjects (CCMO) 
stated that the research has ended with the death of the patient 
and relatives do not have the legal right to give consent for the use 
of medical data after the patient has died. Finally and most impor-
tantly, not using the data will probably jeopardize validity of study 
results [2] 
To support the latter argument, we compared the results of a recent 
randomized controlled multicentre study in the field of intensive 
care medicine [3], when including or excluding data from patients 
where study procedures were already finished before consent could 
be obtained. We hypothesize that not using these data will reduce 
internal and external validity. 
MetHoDs
In the example study, patients with hyperlactatemia on intensive 
care admission were randomly allocated to either the lactate group 
or the control group. In the lactate group, resuscitation therapy was 
guided by blood lactate levels with the objective to decrease lactate 
levels by 20% or more per two hours, during the first eight hours of 
intensive care stay. In the control group the treatment team had 
no knowledge of lactate levels (except for the admission value). 
Because of the emergency nature and severity of disease in the 
target population, patients were enrolled under deferred (proxy) 
consent: study procedures were temporarily allowed without consent 
and, as soon as possible, written consent from the patient or legal 
representative was obtained. In-hospital mortality was the primary 
outcome measure. This primary outcome was compared between 
the two randomization groups using the chi-square test and using 
predefined multivariate Cox’s proportional hazards analysis, strati-
fied by centre and sepsis group, where adjustment was made for the 
following co-variables: age, sex, baseline APACHE II and baseline 
SOFA-score [4]. We compared the primary outcome measures in 
the study population with or without patients where study proce-
dures were already finished before consent could be obtained. 
resULts
The study-population consisted of 348 patients; 39 patients (11%) 
died early before the patient or his/her proxy could be approached 
and consent be obtained. In another 20 patients (6%), it was not 
possible to inform proxies and ask consent within the period of study 
procedures (no family available, non-Dutch speaking family, trans-
fer to other hospital etc). Table 1 shows the baseline characteristics 
according to the obtained consent status. There were more patients 
with missing consent due to early death in the control group than 
in the lactate group (14.7% (26/177) vs. 7.6% (13/171), p=0.042). 
The number of patients in each group with missing consent due 
to other reasons (than early death) was equal (control group 6.8% 
(12/177) vs. lactate group 4.7% (8/171), p=0.492).
Variable Obtained consent 
(N=289)
Missing consent 
(N=59)
P-value
Age – yr 61 ±17 66 ±17 0.042
Male sex – n (%) 177 (61%) 44 (75%) 0.053
Median time from 
arrival at hospital to 
randomization – hours 
(interquartile range)
8 (1-78) 3 (1-78) 0.90
ICU admission within 
6 hours from hospital 
admission - n (%)
139 (48%) 38 (59%) 0.022
Median time from 
ICU admission to 
randomization – hours 
(interquartile range)
0.6 (0.2-1.3) 0.5 (0.2-0.8) 0.089
APACHE II score 22.3 ±8.7 27.5 ±8.7 <0.001
SOFA score 8.6 ±3.9 10.3 ±4.4 0.003
Diagnostic category – n (% of patients in the consent group)
      - Sepsis category: 113 (39%) 22 (37%) 0.020
            - Severe sepsis     - 58 (20%)     - 11 (19%)
            - Septic shock     - 55 (19%)     - 11 (19%)
Table 1. Baseline characteristics according to consent status.
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Table 2 shows the results of the unadjusted and adjusted primary 
outcome analyses. A significant treatment effect (p=0.006) in the ad-
justed analysis even became non-significant (p=0.35) when patients 
with missing deferred consent were excluded. In addition, when add-
ing the variable “missing consent” to the multivariable Cox’s propor-
tional hazards model the treatment effect of lactate-guided therapy 
was reduced from 0.006 to 0.063. When adding the variable “miss-
ing consent due to early death” the p-value was reduced to 0.210.
When calculating interaction, we could not demonstrate a signifi-
cant difference in the unadjusted treatment effect between those 
with and without missing consent.
DIsCUssIon
As illustrated by the data, excluding patients in whom no deferred 
consent can be obtained after randomization may result in invalid 
study results. In our study a significant adjusted treatment effect 
became non-significant when excluding patients with missing de-
ferred consent. This phenomenon can be ascribed to two different 
reasons. First, it is the effect of a lack of power due to the reduced 
sample size in combination with altered mortality rates. This can be 
      - Non-sepsis  
        category:
176 (61%) 37 (63%)
            - Neurologic     - 31 (11%)     - 6 (10%)
            - Cardiac arrest     - 32 (11%)     - 16 (27%)
            - Other non- 
              sepsis
    - 113 (39%)     - 15 (25%)
Hospital – n (% of patients in the consent group)
      - Hospital I 159 (55%) 37 (63%) 0.15
      - Hospital II 40 (14%) 12 (20%)
      - Hospital III 26 (9%) 3 (5%)
      - Hospital IV 64 (22%) 7 (12%)
Referring department – n (% of patients in the consent group)
      - Operation theatre  
        (acute surgery)
75 (26%) 18 (31%) 0.31
      - Operation theatre  
        (elective surgery)
39 (14%) 3 (5%)
      - Ward or  
        emergency  
        department
161 (56%) 36 (61%)
      - Other ICU 13 (5%) 2 (3%)
Treated with metformin 12 (4%) 3 (5%) 0.75
Treated with anti-
retroviral therapy
2 (1%) 0 (0%) 1.0
Median blood lactate level – mEq/l 
(interquartile range) 4.3 (3.5-5.8) 5.2 (3.8-8.0) 0.006
Central venous oxygen 
saturation - %
72 ±12 74 ±8 0.45
Values are means ±SD unless otherwise specified.
Control  
group
Lactate  
group
Relative risk 
(95%CI)
P Value
In-hospital mortality: unadjusted analysis - % (n)
All patients (n=348) 43.5%  
(77/177)
33.9%  
(58/171)
0.78  
(0.60-1.02)
0.067
Excluding early death 
(n=309)
33.8%  
(51/151)
28.5%  
(45/158)
0.84  
(0.60-1.18)
0.32
Excluding all missing 
deferred consent 
(n=289)*
33.1%  
(46/139)
28.7%  
(43/150)
0.87  
(0.61-1.22)
0.42
In-hospital mortality: adjusted analysis - hazard ratio (95% CI)
All patients (n=348)  0.61  
(0.43-0.87)
0.006
Excluding early death 
(n=309)
0.80  
(0.53-1.21)
0.28
Excluding all missing 
deferred consent 
(n=289)
0.81  
(0.53-1.25)
0.35
Table 2. Mortality with and without patients with missing deferred consent
* P-value for interaction between consent status (missing or obtained consent) and 
treatment effect (Breslow-Day test of homogeneity): 0.59
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illustrated when calculating the actual power in the two populations. 
Based on an unadjusted absolute mortality reduction from 43.5% to 
33.9% in the entire sample size of 348 patients, the calculated pow-
er was 45%. This was reduced to 12% when excluding all patients 
with missing deferred consent (sample size 289 patients, absolute 
mortality reduction from 33.1% to 28.7%). The second reason is 
the likely introduction of a selection bias. Furthermore, because 
patients with missing consent were more severely ill, this means that 
by excluding these patients, the study population will not be repre-
sentative anymore for the actual population defined by the in- and 
exclusion criteria.
More patients in the control group had missing consent due to early 
death than in the lactate group (14.7% (26/177) vs. 7.6% (13/171), 
p=0.042). Besides that more patients have died in the control group 
due to the randomization treatment effect, this difference could pos-
sibly be explained by a more systematic search for consent in the 
lactate group because of the open-label design of the study. If the 
latter were really true than this would have resulted in an additional 
bias if these patients were excluded from the analysis. 
In conclusion, the exclusion of patients with missing informed con-
sent, because study procedures have already been finished before 
it was possible to obtain consent, is outweighed by the risk that this 
reduces statistical power, introduces selection bias, makes randomi-
zation asymmetrical, decreases external validity and so jeopardizes 
study results. In addition, very few patients or relatives refuse con-
sent for the use of already obtained data in emergency situations 
[1, 3].
Therefore, not using data from patients in whom study procedures 
have been completed and deferred consent has not been obtained 
is unethical and, in addition, will be unjust to patients and proxies 
who have consented for using the data. These findings may have 
important implications for emergency research in disciplines vary-
ing from intensive care and emergency medicine to cardiology and 
(trauma) surgery.
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ABstrACt
Important ethical aspects apply to the process of obtaining con-
sent in emergency critical care research: the incapacity of almost 
all patients for giving informed consent and the emergency and 
life threatening nature of the conditions involved, resulting in short 
therapeutic time frames. We argue that deferred proxy consent is 
the preferable substitute for informed patient consent in emergency 
critical care research. However, researchers can face two problems 
when using this consent procedure. First, can proxies give a valid 
judgment for consent or refusal in the acute phase of the life threat-
ening illness of their relative and second, what should researchers 
do with already obtained data when study procedures are finished 
(e.g. because the patient has died) before proxies can be informed 
and consent be sought? We propose to approach the relatives with 
information about the trial and asking them for consent only if it is 
ethically valid to do so. The first psychological distress may prohibit 
a complete understanding of the information, which is necessary 
for a true and valid informed proxy consent. In addition, we recom-
mend to use the study data if study procedures are finished before 
proxies can be informed and consent be sought, provided sufficient 
privacy measures have been applied. 
IntroDUCtIon
The need for medical research programs involving critically ill pa-
tients is real and profound. However, involving this patient category 
in observational or interventional trials raises ethical, juridical and 
practical concerns. Clinical trials in emergency and critical care set-
tings frequently involve patients with acute catastrophic injuries or 
life threatening illnesses causing loss of decision-making capacity 
and, given the emergency nature of the conditions, facing (very) 
short therapeutic time frames. Examples are hemorrhagic shock, 
septic shock, circulatory arrest, subarachnoid hemorrhage, trauma 
and traumatic brain injury. 
All clinical trials are subject to the ethical and juridical principles of 
Good Clinical Practice and international and national regulations. 
The guiding ethical principles underlying clinical trials are respect 
for autonomy of the subject, protection against discomfort, harm, 
risk and exploitation and the prospect of potential benefit. 
Informed consent in emergency critical care research can, given the 
emergency nature and severity of the condition or due to pharma-
cological sedation, seldom be obtained from patients themselves. 
Delaying acute experimental treatment to obtain informed patient 
or proxy consent might jeopardize the trial results. Several solutions 
are in use for obtaining consent in emergency situations. Proxies (le-
gal representatives) or an independent physician can give consent 
before inclusion in research, or (patient or proxy) consent can be 
deferred for some time or consent can even be waived. The pros-
pect of benefit can even be complicated by the equipoise under-
pinning the statistical null hypothesis of pharmacological trials: the 
hope that an individual patient will benefit, being evenly certain as 
the chance of no benefit. 
In this article we will argue that using deferred proxy consent is the 
preferable substitute for informed patient consent in emergency crit-
ical care research. We will address two problems, which researchers 
can face when using deferred proxy consent. First, can proxies give 
a valid judgment for consent or refusal in the acute phase of the 
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life threatening illness of their relative and second, what should re-
searchers do with already obtained data when study procedures are 
finished (e.g. because the patient has died) before proxies can be 
informed and consent be sought? We propose some recommenda-
tions regarding these two dilemmas. 
tHe ConCePt oF Proxy Consent
Most ethical committees in European countries consider consent by 
legal representatives valid. The moral basis for such proxy consent is 
restricted to the substituted judgment about inclusion into the trial. 
Theoretically the proxy is supposed to act as the patient, if compe-
tent, would have decided. The question remains if the patient wants 
to be represented by relatives for inclusion in a trial. Roupie et al. [1] 
found that only 41% of 1089 patients would want their spouse/part-
ner to be their surrogate, whereas 28% wanted to be represented by 
the physician in charge of their care. Furthermore, many proxies do 
not seem to know what the patient’s wishes are [2]. For instance, 
Coppolino & Ackerson concluded that surrogate decision makers 
for critical care research resulted in false-positive consent rates in 
up to 20% [3]. In the study by Sulamsy et al. [4] agreement between 
patients and proxies varied between 57% and 81%, depending on 
whether previous discussions had taken place on similar situations. 
It is unlikely that such existential discussions occur frequently in the 
target population resulting in lack of evidence what their relative 
would have wanted in case of severe illness. 
tHe ConCePt oF DeFerreD (Proxy) Consent 
In eMergenCy CrItICAL CAre reseArCH 
Proxies are not always available in the first hours of hospital or in-
tensive care admission or are too overwhelmed to understand the 
provided information to give a valid consent. This prompted inves-
tigators and ethical committees to use deferred proxy consent and 
waiver of consent in emergency critical care research facing short 
therapeutic windows. With deferred (proxy) consent, patients are 
included into the research without prior consent. After inclusion, 
the patient (deferred patient consent) or his/her representatives (de-
ferred proxy consent) should be informed as soon as possible and 
subsequent consent should be requested. With waiver of consent, 
consent is waived at all. Emergency research without prior consent 
(deferred consent or waiver of consent) can morally be accepted on 
the principles of fairness, justice and beneficence. Furthermore, the 
requirement for all patients to give written informed (proxy) con-
sent before enrolment can result in a significant selection biases, 
such that research populations are not representative anymore of 
the typical patient [5]. A study searching for public views on emer-
gency exception to informed consent found that 49% of 530 people 
believed that enrolling patients without prior consent in an emer-
gency situation would be acceptable and 70% would not object to 
be entered into such a study without providing prospective informed 
consent [6]. 
The implementation of waiver or deferred consent strategies was 
successful in terms of enrolment rates and therapeutic windows: 
the adoption of waiver of consent in the National Acute Brain In-
jury Study- Hypothermia (NABIS-H) resulted in a higher enrolment 
and it reduced the time between injury and treatment [7]. In this 
study, relatives of only 11 out of 113 patients arrived within 6 hours 
of the injury. In the CRASH trial, mean time to randomization was 
significantly longer and patient recruitment higher in those hospitals 
where consent was required compared with those where it was not 
required (8). In a septic shock trial the investigators could not con-
tact the proxies within the inclusion time in 74% of the cases, and 
these were included under waiver of consent [9]. 
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DILeMMA 1.  
Are ProxIes CoMPetent enoUgH DUrIng 
tHe ACUte PHAse oF A sUDDen AnD 
UnexPeCteD eMergenCy sItUAtIon?
The emotional nature of an emergency situation has been shown to 
limit the reliability of proxy consent for clinical research [2,10,11]. 
In addition, only 48% of 79 representatives of European Brain Injury 
Consortium (EBIC) associated neuro-trauma centers in 19 Europe-
an countries felt that relatives could make a balanced decision in an 
emergency situation [12]. Also in our own experience the validity of 
informed consent and proxy consent given in an emergency situa-
tion is at least troubling. Therefore, under emergency circumstanc-
es, proxy consent does not always seem to secure proper patient/
subject protection.
The process of obtaining consent for inclusion into an emergency 
critical care trial contains three phases. First information about the 
trial is provided, second the investigator asks the proxies for con-
sent, and third the proxies give consent or refusal. However, when 
consent for clinical research is sought during an emergency situa-
tion, comprehension is generally less than optimal [13,14,15,16]. 
Patients enter an intensive care in physiological crisis, while their 
families enter the intensive care in a psychological crisis [17]. Ad-
mission to an intensive care triggers a variety of emotional and 
psychological responses in the relatives that often manifest in the 
form of distress, anxiety, anger, guilt and fear. Such responses can 
impede the ability of family members to exercise effective coping 
strategies [18]. In many cases relatives are so distressed or over-
whelmed in the first chaotic phase of admission of their loved one, 
that they cannot fully understand the information provided during 
the acute phase, at least their understanding is selective. They have 
a need for information about the diagnosis and prognosis [19], but 
most probably have no interest in the pro’s and cons of inclusion 
into a clinical trial. Uncertainty as to whether the patient will survive 
has a profound influence on the relative’s reactions, actions and 
strategies [20]. 
Decision making competence is based on factual understanding, 
evidencing a choice (consent or refusal) and reasoning and appreci-
ation of the situation. We argue that some family members in emo-
tional distress are temporarily incompetent in these three points. 
Hence, relatives of a patient who is in a life-threatening situation 
can be temporarily incompetent for valid proxy consent during the 
acute phase.
DILeMMA 2.  
WHAt IF stUDy ProCeDUres Are FInIsHeD 
BeFore ProxIes CAn Be InForMeD AnD 
Consent Be soUgHt? Use tHe DAtA or not?
Clinicians and investigators may encounter another important prac-
tical and ethical problem when enrolling patients in a study under 
deferred (proxy) consent: should the researcher use the study data 
if study procedures are already finished before it was possible to 
inform proxies and ask consent? This includes the situation in which 
the patient has died early.
- A recently finished clinical trial as an example
The clinical importance of this dilemma is illustrated by the enrol-
ment process of a recently completed Dutch multi-center randomized 
controlled trial (“early lactate-directed therapy in the ICU” - study: 
http://www.clinicaltrials.gov/ct/show/NCT00270673?order=1). In 
this clinical trial using deferred consent, which was approved by 
the local Ethics Committee referring to the Dutch revised “Medical 
Research in Human Subjects Act” [21], approximately 10% of the 
randomized patients died before consent could be sought [22,23], 
in comparison with an estimated overall study mortality rate of 40%. 
In another 5% of the enrolled patients, it was not possible to inform 
proxies and ask consent within the period of study procedures (in 
our example study this lasted 72 hours from randomization)
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- ethical considerations
The question is whether the arguments in favor of not using data are 
outweighed by the following arguments in favor of using data, which 
can be particularly important in the specific situation that a patient 
has died. First, not using these data will probably introduce selection 
bias, make randomization arms asymmetrical and jeopardize trial 
results. Moreover, the intention-to-treat principle implies that the 
primary analysis should include all randomized subjects [24]. Sec-
ond, the validity of proxy consent obtained from bereaved relatives 
can be ethically questioned. As already mentioned in dilemma 1, 
the risk exists that consent by relatives in emergency ICU situations 
reflects rather a regime of bureaucracy (consent is required, we 
need a signature), than true ethical concern (by obtaining consent 
the relatives act in the patients interests); how then can we value 
consent in the tragic situation in which the patient has died? Third, 
very few patients or relatives refuse consent for the use of already 
obtained data in emergency situations [22,25,26,27]. Furthermore, 
using data will not harm the patient or relatives, provided that ap-
propriate confidentiality and privacy measures have been applied. 
Fourth, jeopardizing studies by not using data might harm future 
patients and society. Degrading a study in this fashion also devalues 
the contribution made by subjects who do consent to take part in 
the study, which is an ethically undesirable consequence. While this 
premise probably cannot provide an argument for including data 
when research subjects expressly deny consent, it does make an 
ethically valid case for including data where such explicit denial of 
consent does not exist. Fifth, since confronting bereaved relatives 
represents additional burden, which health care providers have the 
duty to relieve or prevent, it seems morally correct to adopt policies 
that prevent seeking consent from proxy’s after their relatives have 
died. Sixth, the individual’s decision about the privacy of their medi-
cal information (whether made by the individual him/herself or his/
her proxy) is not absolutely binding if the processing is necessary 
and proportionate for “the protection of health” (Article 8 of the Eu-
ropean Convention on Human Rights), if sufficient safeguards apply 
(EU Data Protection Directive) or if it is necessary and proportionate 
for the goals of medical research (UK Data Protection Act 1998). 
- Back to our example
The Central Committee on research involving Human Subjects 
(CCMO, “the Dutch national Ethics Committee”) was asked for a 
judgment on the use of already obtained data of the patients who 
died before consent could be sought. The Committee stated that 
Figure 1. Proposed flow-chart for use of proxy deferred consent in emergency criti-
cal care research. We recommend this flow-chart in the circumstance 1) that the 
emergency nature of the disease prevents a priori obtaining of informed consent 
and 2) that patients are mentally incapacitated.
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this situation is comparable with the situation in which the research 
project has already been finished at the time that deferred consent 
can be sought. They judged that in such case relatives should be 
notified about the research project (in line with the responsibility of 
a good health care provider), but that seeking consent was not use-
ful anymore because of the lack of consequences. 
recommendations
We propose approaching the relatives with information about the 
trial and asking them for consent only if it is ethically valid to do 
so. The first psychological distress may prohibit a complete under-
standing of the information, which is necessary for true and val-
id informed proxy consent. In addition, we recommend using the 
study data if study procedures are finished (including the situation 
in which a patient has died) before proxies can be informed and 
consent be sought, provided sufficient privacy measures have been 
applied. Using these two recommendations, we have constructed a 
flow-chart for the conduct of emergency critical care research in an 
ethically valid and practically feasible way (figure 1).  
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Blood lactate has first been measured in human blood by the Ger-
man physician-chemist Johann Joseph Scherer in 1843. In chapter 
2, we describe his forgotten observations on a lethal case of ful-
minant septic shock due to puerperal fever in a young woman and 
describe the influence of his findings on further research on blood 
lactate measurement. Since then, more than 150 years have passed 
and still important unanswered questions remain regarding lactate 
monitoring.  To address these issues, we present in chapter 3 a sys-
tematic review, conducted using the format of a Health Technology 
Assessment. Following an explicit search and selection strategy, we 
reviewed a substantial amount of articles (>150) and concluded 
that blood lactate measurement in critically ill patients: 
I) Is accurate in terms of measurement technique but adequate 
understanding of the (an)aerobic etiology is required for its 
correct interpretation
II) Provides not only diagnostic but also important prognostic 
information 
III) Should be directly measured instead of estimated from other 
acid-base variables 
IV) Has an unknown effect on healthcare workers confidence
V) Can alter therapeutic decisions
VI) Could potentially improve patient outcome when combined 
with a treatment algorithm to optimize oxygen delivery, but 
this has only indirectly been shown
VII) Is likely to have similar benefits in critical care settings 
worldwide
VIII) Has an unknown cost-effectiveness. 
The International Network of Agencies for Health Technology As-
sessment describes a Health Technology Assessment as “the sys-
tematic evaluation of properties, effects, and/or impacts of health 
care technology. It may address the direct, intended consequences 
of technologies as well as their indirect, unintended consequences. 
Its main purpose is to inform technology-related policymaking in 
health care” [1]. Hence, by conducting this Health Technology As-
sessment, it not only allowed us to systematically review the litera-
ture on the clinical value of blood lactate measurement, but it ad-
ditionally provides a framework for future efforts on local or (inter) 
national policy decision-making on the use of lactate monitoring in 
critically ill patients [2].
One of the important findings of the Health Technology Assess-
ment, the consistency of the prognostic value of lactate, implies 
that its measurement certainly has a place in the risk-stratification 
of critically ill patients in the Intensive Care Unit or the Emergency 
Department. 
As early identification of critical illness is widely acknowledged as 
a vital step towards improving survival [3-5], we aimed at transfer-
ring this prognostic ability of lactate monitoring from the hospital 
to the pre-hospital setting. In Chapter 4 we present the results of a 
prospective observational pilot study (n=124), in which emergency 
medical services nurses measured pre-hospital blood lactate levels. 
We found that pre-hospital lactate levels were significantly associ-
ated with in-hospital mortality and that a level of 3.5 mmol/L was 
the best cut-off value to discriminate survivors from non-survivors. 
Importantly, the prognostic value was superior to that of heart rate 
and systolic blood pressure. In pre-hospital care, the process of risk-
estimation is particularly challenging because limitations of time, 
equipment, available skill set and environment render the objec-
tive diagnosis of haemodynamic shock difficult [6]. Our preliminary 
data therefore indicate a new avenue of research into the earliest 
possible treatment of haemodynamic shock [6]. Further studies are 
required to evaluate whether the use of blood lactate measurement 
in Emergency Medical Services has potential for triage decisions, 
earlier detection of occult shock and earlier start of goal-directed 
therapy in order to, ultimately, influence patient outcome.
Although blood lactate levels in ICU patients are generally associat-
ed with mortality, it was unknown whether lactate performs equally 
well in different diagnostic categories of the heterogeneous group of 
critically ill patients. In chapter 5 the results are shown of a prospec-
tive observational two-center study (n=394). We found that lac-
tate reduction during the first 24 hours of ICU stay was associated 
with improved outcome only in septic patients, but not in patients 
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with haemorrhage or other conditions generally associated with low 
oxygen-transport. We hypothesized that in this particular group of 
patients this could be due to irreversible damage already present at 
ICU admission. Potentially, for this reason, lactate-directed therapy 
might not be as beneficial in this particular group of patients, or 
should be started in an earlier phase in the emergency department. 
However, the study was limited in providing pathophysiological ra-
tionale as no data were collected on oxygen delivery and consump-
tion or on indices that suggest aerobic or anaerobic etiology (e.g. 
lactate to pyruvate ratio, liver function test, serum catecholamine 
concentration, or microcirculation imaging). 
In our search on why patients with hyperlactataemia have a worse 
outcome, we focused on the association between blood lactate lev-
els and multiple organ failure and more specifically, on how the 
individual failing organs relate to hyperlactataemia. We showed in 
a retrospective observational study (n=134), described in chapter 
6, that both the duration and level of hyperlactataemia were as-
sociated with the Sequential Organ Failure Assessment score. This 
association appeared stronger in the early phase of ICU stay than in 
the late phase. Of all individual SOFA organ components, respira-
tory and coagulation components, were most strongly associated 
with lactate. Further prospective research is warranted to elucidate 
why elevated lactate levels are related to adverse outcome and, 
most importantly, to study whether early blood lactate level-guided 
resuscitation can actually prevent organ dysfunction and, ultimately, 
improve patient survival. 
This brings us to the central part of the thesis, which is presented 
in chapter 7. In a two-year, multi-centre, open-label, randomized 
controlled trial conducted in four centres in the region of Rotter-
dam, 348 patients were randomly allocated to either lactate-guided 
monitoring (lactate group) or non-lactate guided monitoring (con-
trol group) during the first eight hours of ICU stay. In the lactate 
group, treatment was guided by lactate levels with the objective to 
decrease lactate by 20% or more per two hours whereas in the con-
trol group, the treatment team had no knowledge of lactate levels 
(except for the admission value) during the first eight hours. In the 
unadjusted primary outcome analysis we found a non-significant 
9.6% absolute mortality reduction (p=0.067), which was consist-
ent with a highly significant mortality reduction in the pre-defined 
multivariable analysis and with a decrease in important secondary 
outcome measures as organ failure, duration of mechanical ven-
tilation and length of ICU-stay. Two study results need particular 
attention. First, there was a discrepancy in significance between the 
unadjusted and adjusted primary outcome analysis. We hypothesize 
that the power of this study to show a treatment benefit on a di-
chotomous endpoint as mortality might have been insufficient. In 
our sample size calculation we targeted a 15% absolute in-hospital 
mortality difference based on the results of Rivers’ early goal-direct-
ed therapy study [7]. To be able to detect 10% absolute mortality 
reduction such as found in our study, approximately 800 patients 
would have been required. For a 5% difference, which would still be 
clinically relevant, around 3600 enrolled patients would have been 
needed. However, the statistical method of predefined co-variate 
adjustment allowed us to increase the power of the study without 
requiring increased sample size [8]. This technique makes treat-
ment effect estimation more individualized, reduces noise in the 
analysis and thereby improves the statistical power (i.e. the ability to 
identify a smaller treatment effect when it really exists). The second 
study finding that needs attention is the similar course of lactate 
levels in the two groups, despite that the treatment strategy in the 
experimental arm was particularly aimed at reducing lactate levels 
and that lactate levels in the control arm were not available to the 
treating doctors and nurses. This suggests that there was no causal 
relationship between the administered therapy (i.e. additional fluid 
resuscitation and vasodilator therapy) and hyperlactataemia in our 
study participants. Instead, lactate might be an epiphenomenon of 
severity of disease. By acting as a warning signal, clinicians might 
interpret hyperlactataemia or the lack of its subsequent reduction 
over time as a warning that their patients do not clinically improve 
or even deteriorate in the presence of stable hemodynamic parame-
ters. This could trigger intensified resuscitation or attention to other 
causes than inadequate tissue perfusion that could be associated 
with impaired lactate reduction (e.g. non-controlled septic focus). 
Unfortunately, the design of the study does not allow us to draw 
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definite conclusions on the mechanism behind the clinical outcome 
benefit found in this study.
Conducting this randomized controlled trial required great effort of 
the participating centers on a 24/7 basis. This resulted in steady pa-
tient recruitment leading to completion of the trial within two years. 
Other strengths of the study include the immediate start of the study 
treatment following ICU admission, the use of hospital mortality as 
the primary endpoint and its multi-centre design, as growing con-
cerns have been raised regarding adoption of single-center studies 
in clinical guidelines [9]. Additionally, the study findings are impor-
tant for clinical practice given that lactate levels are already com-
monly obtained in the critically ill, and thus, the proposed model 
for early goal-directed therapy could be implemented widely at little 
additional costs. The study is also a good example on the use of bi-
omarkers to tailor treatment to each individual ICU patient. Finally, 
the results extend the concept of River’s early-goal-directed therapy 
from the Emergency Department to the ICU and to other patient 
groups besides severe sepsis or septic shock.
On the other hand, some concerns remain when interpreting the 
study results. First, although unavoidable when investigating such a 
treatment protocol, the unblinded design imposes an inherent risk 
of bias. Second, the difference in terms of treatment intensity be-
tween the groups was smaller than in Rivers’ EGDT therapy study, 
possibly explaining the lack of difference in any of the physiological 
endpoints. Third, the treatment mechanism responsible for the re-
duced mortality remains to be further elucidated, as the difference 
in fluid resuscitation between the two groups was rather small and 
the efficacy of vasodilators therapy to improve poor microcirculatory 
perfusion remains open to discussion [10]. Additionally, as ScvO2 
monitoring was mandatory in the lactate group and facultative in 
the control group, we cannot exclude the possibility that this had 
an impact on the observed outcome difference. Finally, it is uncer-
tain whether the treatment components in general were beneficial 
(i.e. the fluids or vasodilators) or whether the lactate monitoring 
itself, where lactate acted as a individual biomarker of severe illness, 
was successful by tailoring ICU treatment to the patients’ needs. 
However, although there are clues of responsible mechanisms for 
the improved outcome in lactate-monitored patients, these are only 
suggestive and not conclusive. In order to unfold this, a new ran-
domized controlled trial should be designed, controlling for these 
specific mechanisms in a pre-specified way. 
In the last part of the thesis three studies are presented on ethical 
aspects of informed consent in emergency critical care research. 
The process of obtaining ethically valid informed consent for par-
ticipation in research is particularly challenging in intensive care 
patients. In chapter 8, we present the practical dilemma of using or 
not using data from patients who died early after start of the study 
without obtained deferred consent. Although it is our conviction that 
the obligation to obtain consent should be respected as thoroughly 
as possible, we identified a variety of arguments in favor of using the 
data without consent in these extraordinary circumstances: 
(a) not using data will probably introduce selection bias
(b) the validity of proxy consent obtained during emergency 
situations can be ethically questioned
(c)  using data of patients who died and for whom deferred 
consent was not yet obtained will not harm the patient or 
relatives (provided that appropriate confidentiality and privacy 
measures have been applied)
(d)  using data will probably benefit future patients and society
(e)  confronting bereaved relatives to obtain consent is an 
additional burden
(f)  an individual’s decision about the privacy of their medical 
information is not absolutely binding. 
To test the first and arguably most important hypothesis, that not 
using these data will introduce selection bias and hereby jeopardize 
study results, we present in chapter 9 the results of our randomized 
controlled multi-centre trial when including or excluding patients 
in who deferred consent could not be obtained. The level of sig-
nificance in the unadjusted primary outcome analysis was reduced 
from p=0.067 to p=0.42 when the patients with missing deferred 
consent were excluded. In the adjusted primary outcome analysis, a 
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significant treatment effect (p=0.006) even became non-significant 
(p=0.35). 
Based on the thorough consideration of chapter 8 and the trial data 
of chapter 9, we present a decision tree in chapter 10 for the con-
sent procedure of emergency critical care research in an ethically 
valid and practically feasible way. Herein, it is proposed to approach 
the relatives for consent only if it is ethically valid to do so. It is also 
proposed to use the data if study procedures are finished before 
proxies can be informed and consent be sought, provided sufficient 
privacy measures have been applied. 
Finally we return to the case presentation, which was described in 
the introduction section. Despite the haemodynamic stability for 
the first few hours, the resident should have diagnosed a severe dis-
turbance in the homeostasis of his patient already 30 minutes fol-
lowing admission at the moment when the first lactate level became 
available. This thesis provides support for early lactate monitoring 
and lactate-guided resuscitation in this patient. The intensivist could 
then perhaps have made a bigger impact on the outcome of this 
patient, who died several days following admission.
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Lactaat werd voor het eerst in humaan bloed aangetoond in 1843 
door de Duitse klinisch-chemicus Johann Joseph Scherer. In hoofd-
stuk 2 van dit proefschrift wordt zijn vergeten observatie beschreven 
van een dodelijk geval van kraamvrouwenkoorts bij een jonge vrouw 
en wordt de invloed hiervan op de geschiedenis van onderzoek naar 
lactaat monitoring toegelicht. Sinds die tijd zijn meer dan 150 jaar 
voorbijgegaan en nog steeds zijn er belangrijke onbeantwoorde vra-
gen omtrent het meten van lactaat. Om deze vragen te verhelderen, 
wordt in hoofdstuk 3 een systematisch overzicht gepresenteerd in 
de vorm van een zogenaamd Health Technology Assessment. Ge-
bruikmakend van een expliciete zoek- en selectiestrategie werden 
meer dan 150 wetenschappelijke artikelen beoordeeld. Op basis 
hiervan kunnen we concluderen dat:
I) Het serum lactaat gehalte betrouwbaar gemeten kan worden, 
maar dat voldoende kennis nodig is van de anaerobe en 
aerobe etiologie van lactaat voor een correcte interpretatie 
van de waarde.
II) Het lactaat gehalte niet alleen diagnostische maar ook 
belangrijke prognostische informatie oplevert.
III) Lactaat direct gemeten dient te worden, en niet geschat op 
basis van andere zuur-base variabelen.
IV) Het meten van lactaat een onbekend effect heeft op 
het ervaren van (on)zekerheid door gezondheidszorg 
medewerkers.
V) Lactaat de potentie heeft om therapeutische beslissingen te 
beïnvloeden.
VI) Het meten van lactaat mogelijk de prognose van een patiënt 
kan verbeteren wanneer dit gecombineerd wordt met een 
behandelingsprotocol waarbij zuurstofaanbod aan de 
weefsels geoptimaliseerd wordt. Dit is echter slechts indirect 
aangetoond in de wetenschappelijke literatuur.
VII) Het aannemelijk is dat lactaat monitoring wereldwijd dezelfde 
voordelen biedt aan ernstig zieke patiënten
VIII) De kosten-effectiviteit van het meten van lactaat onbekend is.
 
Het INAHTA (International Network of Agencies for Health Tech-
nology Assessment) beschrijft een Health Technology Assessment 
als een “systematische evaluatie van eigenschappen, effecten en/
of gevolgen van gezondheidszorg technologie. Het kan hierbij zo-
wel gaan om de directe, bedoelde consequenties van een techno-
logie, als om de indirecte, onbedoelde gevolgen. Het hoofddoel is 
informatie verstrekking ten behoeve van beleidsvorming in de ge-
zondheidszorg” [1]. Derhalve, door een dergelijk Health Technology 
Assessment uit te voeren, kon niet alleen de wetenschappelijke lite-
ratuur op een systematische wijze geanalyseerd worden, maar kon 
daarnaast ook een kader opgesteld worden voor toekomstige lokale 
of (inter)nationale beleidsvorming ten aanzien van het gebruik van 
lactaat monitoring bij ernstig zieke patiënten [2].
Een van de belangrijke bevindingen van dit Health Technology 
Assessment, de consistente prognostische waarde van lactaat, houdt 
in dat het meten van lactaat absoluut van waarde is bij de risico-
stratificatie van ernstig zieke patiënten op de intensive care of de 
spoedeisende hulp. Omdat vroege identificatie van ernstige ziekte 
algemeen geaccepteerd is als een essentiële stap in de verbetering 
van de overlevingskansen [3-5], hadden wij als doel gesteld om de 
prognostische mogelijkheden van lactaat te verplaatsen van het zie-
kenhuis naar de pre-hospitale fase. In hoofdstuk 4 worden de resul-
taten gepresenteerd van een prospectieve observationele pilot stu-
die (n=124), waarin ambulance verpleegkundigen het pre-hospitale 
bloed lactaat gehalte bepaalden. Het bleek dat het pre-hospitale 
lactaat gehalte significant geassocieerd was met ziekenhuissterfte 
en dat een waarde van 3.5 mmol/L de beste afkap waarde was om 
onderscheid te maken tussen patiënten die overleefden of overle-
den. Het is belangrijk dat de prognostische waarde superieur bleek 
aan die van de hartfrequentie en de systolische bloeddruk. In de 
pre-hospitale zorg wordt het proces van risico-inschatting extra be-
moeilijkt door het gebrek aan tijd, materiaal en ervaren personeel. 
Hierdoor is de objectieve diagnose van haemodynamische shock in 
deze fase problematisch [6]. Deze preliminaire data initiëren daar-
om een nieuwe mogelijkheid van onderzoek naar de eerst mogelijke 
behandeling van haemodynamische shock [6]. Er zijn meer studies 
nodig om te evalueren of het gebruik van lactaat in de ambulance 
zorg potentie heeft voor triage beslissingen, vroegere detectie van 
‘verborgen’ shock en voor vroegere start van doelgerichte haemo-
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dynamische therapie om, uiteindelijk, de prognose van patiënten te 
verbeteren. 
Ook al is het bloed lactaat gehalte bij IC patiënten in het algemeen 
geassocieerd met mortaliteit, het was vooralsnog onbekend of dit in 
dezelfde mate gold voor de verschillende patiënten categorieën van 
de heterogene groep ernstig zieke patiënten die op een IC opgeno-
men worden. In hoofdstuk 5 worden de resultaten getoond van een 
prospectief observationele studie uitgevoerd in twee ziekenhuizen 
(n=394). Het bleek dat de daling van het lactaatgehalte geduren-
de de eerste 24 uur van IC opname alleen bij septische patiënten, 
en niet bij patiënten met een bloeding (of een andere aandoening 
waarbij het zuurstofaanbod normaliter laag is), geassocieerd was 
met een verbeterde klinische uitkomst. Onze hypothese is dat dit 
in deze laatste groep patiënten veroorzaakt kan zijn door irrever-
sibele schade die al aanwezig was bij opname op de IC. Mogelijk 
zal hierdoor lactaat-gerichte haemodynamische therapie niet even 
effectief zijn in deze specifieke groep patiënten, of zou dit in een 
eerdere fase gestart moeten worden. De studie is echter beperkt in 
het geven van een pathofysiologische verklaring door het ontbreken 
van gegevens over zuurstoftransport en variabelen die een aerobe of 
anaerobe etiologie suggereren (bijvoorbeeld lactaat/pyruvaat ratio, 
lever functie testen, serum catecholamine concentratie of microcir-
culatie monitoring).
Bij het zoeken naar een verklaring voor de slechte prognose van pa-
tiënten met hyperlactatemie, hebben we gefocust op de associatie 
tussen lactaat en multi-orgaan falen en de rol die de verschillende 
orgaansystemen hierin spelen. Uit een retrospectieve observatio-
nele studie (n=134), beschreven in hoofdstuk 6, bleek dat zowel 
de duur als de hoogte van hyperlactatemie geassocieerd waren met 
de SOFA (Sequential Organ Failure Assessment) score. Deze asso-
ciatie was sterker in de vroege dan in de late fase van IC opname. 
Van alle individuele SOFA orgaan systemen waren de respiratoire 
en coagulatie componenten het sterkst geassocieerd met lactaat. 
Er is meer prospectief onderzoek nodig naar de slechte prognose 
van hyperlactatemie en, nog belangrijker, naar de vraag of haemo-
dynamische therapie, specifiek gericht op het verlagen van lactaat, 
ook daadwerkelijk kan leiden tot een reductie in orgaan falen en 
uiteindelijk mortaliteit.
Dit brengt ons bij het belangrijkste gedeelte van het proefschrift dat 
beschreven wordt in hoofdstuk 7. In een twee jaar durende, multi-
centrische, open-label, gerandomiseerd gecontroleerde studie, uit-
gevoerd in vier ziekenhuizen in de regio Rotterdam, werden 348 
patiënten willekeurig behandeld met behulp van lactaat-gerichte 
hemodynamische monitoring (lactaat groep) of met haemodyna-
mische monitoring zonder lactaat (controle groep) gedurende de 
eerste acht uur van de IC opname. In the lactaat groep was de be-
handeling gebaseerd op het lactaat gehalte met als doel een daling 
van lactaat van 20% of meer per twee uur, terwijl de behandelaars 
in de controle groep niet op de hoogte waren van de lactaat gehalte 
(behalve de waarde bij opname) gedurende de eerste acht uur. Het 
resultaat van de ongecorrigeerde primaire uitkomst analyse was een 
niet-significante absolute mortaliteit reductie van 9,6% (p=0.067). 
Daarbij werd een sterk significante daling in mortaliteit gevonden 
in de vooraf gedefinieerde multi-variabele analyse met tevens een 
daling in belangrijke secundaire eindpunten zoals orgaan falen, be-
ademingsduur en van de duur van IC opname. Twee studieresultaten 
behoeven speciale aandacht. Ten eerste was er een verschil in statis-
tische significantie tussen de ongecorrigeerde en de gecorrigeerde 
primaire uitkomst analyse. Onze hypothese is dat de ‘power’ van 
deze studie om een behandelingseffect op een dichotoom eindpunt 
als mortaliteit aan te tonen, onvoldoende groot geweest kan zijn. 
In de ‘sample size’ berekening werd uitgegaan van een 15% abso-
luut verschil in ziekenhuissterfte, gebaseerd op de resultaten van 
Rivers’ studie naar vroege doelgerichte therapie [7]. Om een 10% 
absolute sterfte reductie te kunnen detecteren, zoals gevonden in 
onze studie, zouden ongeveer 800 patiënten hebben moeten deel-
nemen. Voor een verschil van 5%, dat nog steeds klinisch relevant 
geweest zou zijn, zouden ongeveer 3600 patiënten nodig geweest 
zijn. Echter, door toepassing van de statistische methode van a priori 
gedefinieerde co-variate correctie kon de ‘power’ van de studie ver-
groot worden zonder werkelijke uitbreiding van de studiepopulatie 
[8]. Deze techniek zorgt voor een meer geïndividualiseerde schat-
ting van het behandelingseffect, reduceert ruis in de analyse en 
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verhoogt hierbij de statistische ‘power’ (d.w.z. de potentie om een 
kleiner behandelingseffect aan te tonen als dit er in werkelijkheid 
is). Het tweede studieresultaat dat aandacht verdient is het gelijke 
beloop in lactaatgehalte bij de beide randomisatie groepen, terwijl 
in de lactaatgroep de behandelingsstrategie specifiek gericht was 
op het verlagen van lactaat en in de controlegroep de behandelde 
dokters en verpleegkundigen juist niet op de hoogte waren van het 
lactaatgehalte. Dit suggereert dat er geen causaal verband was tus-
sen de gebruikte therapie (d.w.z. meer vloeistofresuscitatie en meer 
vasodilatatoren) en hyperlactatemie in onze studiepatiënten. In 
plaats daarvan zou lactaat kunnen fungeren als een epifenomeen 
van ernst van ziekte. Door de functie als waarschuwingsignaal kun-
nen clinici de aanwezigheid van hyperlactatemie (of het gebrek aan 
daling van lactaat gedurende een bepaalde tijd) beschouwen als 
een waarschuwing dat hun patiënt klinisch niet verbeterd of zelfs 
verslechterd terwijl de patiënt op dat moment nog haemodyna-
misch stabiel lijkt. Dit zou kunnen leiden tot vroegere, intensievere 
resuscitatie of tot aandacht voor andere oorzaken (dan inadequate 
weefsel perfusie) van een gestoorde daling van het lactaatgehalte 
(bijvoorbeeld een ongecontroleerd septisch focus). Helaas kan er 
door de opzet van de studie geen verklaring gegeven worden voor 
het verantwoordelijke mechanisme achter de aangetoonde verbete-
ring in klinische uitkomst.
De uitvoering van deze gerandomiseerde gecontroleerde studie 
vergde een grote inspanning van de participerende ziekenhuizen. 
Dit heeft geresulteerd in een voorspoedige patiënten rekrutering 
met afronding van de studie binnen twee jaar. Andere sterke kanten 
van de studie zijn onder andere de zeer snelle inclusie van patiënten 
direct na opname op de intensive care, het gebruik van ziekenhuis-
sterfte als primair eindpunt en de multi-centrische studieopzet, zeker 
aangezien toenemende zorgen geuit zijn ten aanzien van gebruik 
van één-centrum studies bij het opstellen van (inter)nationale richt-
lijnen [9]. Hiernaast zijn de studieresultaten belangrijk voor de klini-
sche praktijk omdat lactaat al vaak gemeten wordt bij ernstig zieke 
patiënten en hierdoor kan deze vorm van vroege doelgerichte the-
rapie gemakkelijk geïmplementeerd worden tegen lage bijkomende 
kosten. De studie is ook een goed voorbeeld van hoe het gebruik 
van biomarkers op de IC tot aanpassing van de behandeling aan de 
individuele patiënt kan leiden. Tenslotte verruimen onze resultaten 
het concept van Rivers’ doelgerichte therapie van de spoed eisende 
hulp naar de intensive care en naar andere patiëntencategorieën 
dan ernstige sepsis en septische shock. 
Aan de andere kant zijn er ook bepaalde beperkingen als men de 
studie resultaten interpreteert. Ten eerste, ook al is dit onoverkome-
lijk bij het onderzoeken van een dergelijke behandelingsprotocol, de 
ongeblindeerde studie opzet heeft een inherent risico op bias. Ten 
tweede was het verschil in behandelingsintensiteit tussen de twee 
randomisatie groepen kleiner dan bij Rivers’ studie, hetgeen mo-
gelijkerwijs verklaart waarom er geen verschil was in fysiologische 
eindpunten. Ten derde dient er verder onderzoek plaats te vinden 
naar het verantwoordelijke werkingsmechanisme achter de verlaag-
de mortaliteit, aangezien het verschil in vloeistofresuscitatie tussen 
de twee groepen vrij klein was en de effectiviteit van vasodilatatie 
therapie om de microcirculatoire perfusie te verbeteren nog ter dis-
cussie staat [10]. Aangezien meting van ScvO2 verplicht was in de 
lactaat groep en slechts facultatief in de controle groep, bestaat er 
daarnaast de mogelijkheid dat dit invloed gehad heeft op het geob-
serveerde verschil in klinische uitkomst. Tenslotte is het onzeker of 
de verschillende therapiecomponenten (bijvoorbeeld de vloeistof- of 
vasodilatatie toediening) effectief waren of dat het meten van lac-
taat op zichzelf, als biomarker van ernstige ziekte, succesvol was bij 
het aanpassen van de IC behandeling op de individuele behoefte 
van de patiënt. Echter dient opnieuw opgemerkt te worden dat, ook 
al zijn er aanwijzingen ten aanzien van verantwoordelijke mechanis-
men, deze enkel suggestief en niet conclusief kunnen zijn. Om deze 
te bevestigen dient een nieuwe gerandomiseerd gecontroleerde stu-
die opgezet te worden waarbij op een vooraf gespecificeerde wijze 
voor deze mechanismen gecontroleerd wordt.
In het laatste gedeelte van dit proefschrift worden drie studies be-
schreven over de ethische aspecten van toestemmingsprocedures 
bij spoedeisend onderzoek bij ernstig zieke patiënten. Het verkrijgen 
van ethisch valide geïnformeerde toestemming voor inclusie in een 
wetenschappelijk onderzoek is namelijk gecompliceerd bij intensive 
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care patiënten. In hoofdstuk 8 wordt het praktische dilemma be-
schreven van het al dan niet gebruiken van studiedata van patiën-
ten die kort na de start van een studie overleden zijn, maar waarbij 
nog geen geïnformeerde toestemming gevraagd kon worden. Ook 
al is het onze sterke overtuiging dat de verplichting om geïnformeer-
de toestemming te verkrijgen zo goed mogelijk gerespecteerd dient 
te worden, toch hebben we in deze buitengewone omstandigheden 
een aantal argumenten opgesteld voor het gebruik van data zonder 
toestemming:
(a)  Het niet gebruiken van de data zal waarschijnlijk leiden tot 
een selectie bias.
(b)  De validiteit van toestemming door naaste familieleden of 
wettelijke vertegenwoordigers (proxy consent), verkregen 
tijdens spoedeisende situaties, is ethisch gezien twijfelachtig. 
(c)  Het gebruik van data van patiënten die gestorven zijn en 
waarbij geen uitgestelde toestemming verkregen kon worden, 
zal de patiënt of zijn/haar familie niet schaden mits er 
voldoende privacy gewaarborgd wordt.
(d)  Het gebruik van data zal waarschijnlijk gunstig zijn voor 
toekomstige patiënten. 
(e)  Het benaderen van rouwende nabestaanden om achteraf 
toestemming te vragen is een additionele belasting voor deze 
nabestaanden.
(f)  Een individuele beslissing over het gebruik van medische 
informatie is niet ten alle tijden bindend.
Om de eerste en ogenschijnlijk belangrijkste hypothese te toetsen, 
dat het niet gebruiken van de data zal leiden tot een selectie bias 
en hiermee de validiteit van de studieresultaten schaadt, worden in 
hoofdstuk 9 de resultaten beschreven van de gerandomiseerd gecon-
troleerde lactaatstudie met en zonder inclusie van patiënten waarbij 
geen geïnformeerde toestemming gevraagd kon worden. Het niveau 
van statistische significantie van de ongecorrigeerde primaire uitkomst 
analyse werd verlaagd van p=0.067 to p=0.42 als de patiënten met 
ontbrekende geïnformeerde toestemming geëxcludeerd werden. Bij 
de gecorrigeerde primaire uitkomst analyse werd een significant be-
handelingseffect (p=0.006) zelfs niet-significant (p=0.35).
Gebaseerd op grondige beschouwing van de argumenten beschre-
ven in hoofdstuk 8 en de studie data van hoofdstuk 9, wordt in 
hoofdstuk 10 een beslisboom beschreven voor een ethisch valide 
en praktisch uitvoerbare toestemmingsprocedure bij spoedeisend 
onderzoek bij ernstig zieke patiënten. Hierin wordt voorgesteld om 
de vertegenwoordiger van de patiënt alleen te benaderen voor toe-
stemming als het ethisch valide is om dit op dat specifieke moment 
te doen. Er wordt ook aanbevolen om de studiedata te gebruiken 
als de studieprocedures beëindigd zijn alvorens de patiënt of zijn/
haar vertegenwoordiger geïnformeerd kon worden en om toestem-
ming gevraagd. Hierbij dienen wel voldoende privacy maatregelen 
genomen te worden. 
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‘...want zij die bijvoorbeeld een proefschrift schrijven, dat immers 
alleen bestemd is om aan het oordeel van enige professoren te wor-
den onderworpen, en die de strengste en meest deskundige critici 
niet vrezen, zijn, dunkt me, meer te beklagen dan te benijden, daar 
ze zich eindeloos aftobben. Ze voegen toe, veranderen, schrappen, 
herstellen weer, herzien, werken het weer geheel en al om, laten het 
graag anderen zien, houden het negen jaar in portefeuille en zijn 
nooit tevreden met het resultaat. De beloning, die ze er tenslotte 
voor krijgen - immers de lof van een enkeling - is wel heel duur be-
taald met al hun zwoegen, zweten en gebrek aan het zoetste, wat er 
bestaat: de slaap. Voeg hierbij nog dat dit alles gaat ten koste van 
hun gezondheid, dat ze daardoor humeurig, lelijk, bijziende of zelfs 
blind worden, tot armoede vervallen, bij ieder uit de gunst zijn, dat 
ze alle genoegens moeten verzaken, dat ze vóór hun tijd oud zijn, 
ontijdig sterven en wat dies meer zij..’
Dit citaat van Desiderius Erasmus uit Lof der Zotheid (1515) schetst 
het lot van een promovendus. Maar gelukkig stond ik er niet hele-
maal alleen voor. Graag wil ik daarom van de gelegenheid gebruik 
maken om een aantal personen te bedanken die een belangrijke rol 
gespeeld hebben bij de totstandkoming van dit proefschrift.
Prof.dr. J. Bakker, beste Jan, het is een voorrecht om als eerste pro-
movendus in het Erasmus MC bij je te mogen promoveren. Toen 
je in 2005 vroeg of ik interesse had in dit promotieonderzoek, wist 
ik intuïtief dat promoveren onder jouw leiding geen kleinschalige 
wetenschappelijke exercitie zou zijn. Met je heldere visie, ruime 
ervaring, netwerk en pragmatische persoonlijkheid heb je me alle 
ruimte en kansen geboden om van dit promotietraject een klinisch 
toepasbaar en maatschappelijk relevant project te maken. Hierbij 
heb je mij naast inhoudelijke wetenschappelijke verdieping ook veel 
bijgebracht op het terrein van organisatie, presentatie en manage-
ment. Hartelijk dank voor dit alles.
Mijn dank gaat uit naar de overige leden van de promotiecommissie. 
Prof.dr J.L.C.M. van Saase, Prof.dr. D. Tibboel, Prof.dr. A.B.J. Groe-
neveld en Prof.dr.  J.J.B. van Lanschot ben ik zeer erkentelijk voor 
de bereidwilligheid om zitting te nemen in deze commissie. Ik ben 
u allen veel dank verschuldigd voor uw expertise bij de boordeling 
van mijn proefschrift. Prof.dr. J.L. Vincent, Dr. A. Rhodes and Prof.
dr. B. Levy, I would like to express my gratitude for your willingness to 
travel all the way to Rotterdam. It’s a great honour that you, as inter-
national experts in the field of lactate monitoring and goal-directed 
therapy, are willing to participate in the defence of my thesis.
Dr. J. van Bommel, beste Jasper, ik wil je hartelijk danken voor je 
deskundige en enthousiaste inbreng als copromotor. Vanaf het mo-
ment dat onze wegen halverwege dit promotietraject samenkwa-
men, had ik het gevoel dat de promotie in een stroomversnelling 
terecht kwam. Je zorgde voor structuur, gaf snel en kundig com-
mentaar en was met name heerlijk pragmatisch. Ook moet ik be-
kennen dat de congressen er zeker niet saaier op werden.
Dr. E.J.O. Kompanje, beste Erwin, dank je wel voor je rol als co-
promotor. Wat begon als een medisch-ethische schrijfoefening is 
uitgegroeid tot een zeer wezenlijke verbreding van dit proefschrift. 
Al in de eerste weken gaf je me eerdergenoemd citaat van Deside-
rius Erasmus en sindsdien hebben we als kamergenoten niet alleen 
lief en leed gedeeld op het gebied van onderzoek maar ook op vele 
andere vlakken. Ik wil je hier zeer hartelijk voor bedanken. Ober, 2 
sepsis!
De patiënten die deelgenomen hebben aan de wetenschappelijke 
studies in de verschillende participerende ziekenhuizen ben ik zeer 
veel dank verschuldigd. 
Beste Els, dank je wel voor je praktische ondersteuning als secre-
taresse maar vooral ook voor je persoonlijkheid. Vanaf het begin 
hebben we een bepaalde klik gehad en ik heb dit altijd zeer gewaar-
deerd!  
Dear Alex, it was a pleasure to cooperate with you. Thank you for 
all your help involving the research projects (and of course for the 
Brazilian gifts when you returned from a holiday). I hope that you 
will successfully finish your PhD trajectory soon. All the best for you 
and Theresa.
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Jeanette Schoonderbeek, Steven Sleeswijk Visser en Johan van der 
Klooster wil ik graag bedanken voor hun enthousiasme waarmee ze 
de lactaatstudie in het Ikazia Ziekenhuis, RdGG Delft en Sint Fran-
ciscus Gasthuis tot een succes gemaakt hebben. Jeanette, onder 
jouw hoede maakte ik kennis met de intensive care als AGNIO in 
het Erasmus MC en ik was verheugd dat we onze prettige samen-
werking konden voort zetten bij je overgang naar het Ikazia. Ste-
ven, dank voor je inzet, voor de congressen en ik hoop dat je eigen 
wetenschappelijke onderzoek gaat slagen. Johan, ik was onder de 
indruk van de toewijding en snelheid waarmee je in het begin pati-
enten includeerde. 
Daarnaast wil ik graag de volgende personen van de LACTATE stu-
dy group danken voor hun bijdrage aan de succesvolle uitvoering 
van de lactaatstudie: Diederik Gommers, Ben van der Hoven, Willy 
Thijsse, Christine Groeninx Van Zoelen, Joachim Weigel, Patricia 
Gerritsen, Bart van den Berg, Jos Lenoble, Denis Reis Miranda, Jac-
queline Rischen, Bettina Dellen, Marianne Zijnen, Prof.dr. Can Ince, 
Cher Birsak, Hilde de Geus, Jelle Epker, Maaike Muller, Eva Klijn, 
Paul Mulder, Sten Willemsen, Matthieu Middelkoop, Iwan Meynaar, 
Lilian Dawson, Margot v Spreuwel, Peter Tangkau, Ed Salm†, Arie 
Rietveld, Peter de Feiter, Arjen Brouwers, Prof.dr. T. Stijnen, Prof.dr. 
J. Klein en Prof.dr. A.R.J. Girbes. Ook wil ik alle arts-assistenten en 
IC verpleegkundigen van de verschillende ziekenhuizen bedanken 
die geholpen hebben bij de inclusie van de studiepatiënten.
Zonder Wil Mol zou de lactaatstudie er niet geweest zijn. Met gren-
zeloos geduld en precisie screende je patiënten en vulde je CRF’s in. 
Dankzij jou was de administratie van de studie altijd piekfijn in orde. 
Dank je wel. Ook wil ik in dit kader graag Annemarie Brink (van je 
familie moet je het hebben!), Wilma in ’t Veld en Cynthia Beijers-
bergen hartelijk danken voor hun bijdrage. Jolanda Zandee, Wilma, 
Gerard Burggraaf, Maurice Ruijters, Niels Verburg, Remy Kleijn en 
Carolien Haazer ben ik ook zeer erkentelijk voor hun inspanningen 
voor de lactaatstudie in het Ikazia en RdGG Delft. 
Pieter Vergaert, hartelijk dank voor je enthousiaste ondersteuning 
vanuit Pulsion Medical Systems.
Selma Eikelenboom-Schieveld, Hans Rommes, Ferdinand Snellen, 
Roger Woodward, Christiane Druml, David Menon en Christian Wie-
dermann ben ik zeer erkentelijk voor hun bijdrage aan respectie-
velijk de ambulance studie, de lactaat prognose studie, de SOFA 
studie en de ethische consent studie.
Mijn collega arts-assistenten en medisch specialisten van Interne 
Specialismen in het Sint Franciscus Gasthuis wil ik bedanken voor 
het inspirerende en sfeervolle opleidingsklimaat. Ik heb het uiter-
mate goed naar mijn zin bij jullie.
Alle leden van Rusticus wil ik bedanken voor de fantastische studen-
tentijd in Mestreech. In mijn herinnering was die tijd nog mooier dan 
het in werkelijkheid al was. Het begon met de apen in een groen, 
groen, groen, groen, knollen- knollen land, via mijn 16e verjaardag 
in de Smid, het winnen van alle prijzen die Maastricht te verdelen 
had, tot meest recentelijk, de culinaire uitspattingen van SIO OSM: 
in één woord, van de zotte! 
Mijn paranimfen en soulmates, Raph en Roger, wil ik hierbij apart 
benoemen. Intelligentia, dank voor jullie vriendschap en voor jullie 
gedrevenheid bij de organisatie van deze dag. Ik ben vereerd dat 
jullie mij bijstaan tot hora est. Objection, your honor!
Ook wil ik hier Jasper bedanken, ander andere voor je wetenschap-
pelijke bespiegelingen die dit proefschrift mede gevormd hebben.
Lieve Joke, Frank, Liesbeth, Linde en Dirk. Deze dag is ook een 
mijlpaal voor jullie. Ik heb me tot op de dag van vandaag gesteund 
gevoeld door jullie en dat is me heel erg veel waard! Lieve Paul en 
Nel, ik voel me volledig deel uit maken van jullie gezin. Dank jullie 
wel voor de interesse en gezelligheid. 
Lieve Annick, dank je wel, voor alles, je bent mijn mooiste ge-
schenk. 
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